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Mild traumatic brain injury (MTBI) accounts for 80–90% of the nearly two million 
traumatic brain injuries (TBI) that occur each year. The psychological consequences of MTBI 
can be extensive and can persist well beyond the acute injury, profoundly impacting the lives of 
the individual, their families, and society. A substantial number of MTBI patients suffer 
depressive mood, fatigue, and poor sleep (i.e., behavioral symptoms) for weeks and months post-
injury. These symptoms reduce quality of life and delay the return to previous cognitive and 
functional status.  Behavioral symptoms of depressed mood, fatigue, and poor sleep commonly 
co-occur and thus may constitute a symptom cluster, defined as co-occurring symptoms which 
share a common influence on an outcome. Symptoms of depression, fatigue, and poor sleep may 
share a common inflammatory etiology, and may develop as a result of pro-inflammatory 
cytokine elevation that occurs post-injury and which may persist beyond the acute phase of 
injury. Inflammatory molecules from sites of injury or infection are known to signal the brain to 
engender inflammatory-related sickness behaviors, such as depressed mood, fatigue, and poor 
sleep. It is possible that these co-occurring symptoms synergize to negatively impact cognitive 
and functional recovery. Yet investigation of these behavioral symptoms as a cluster and their 
association with MTBI recovery is limited. 
Purpose:  The purpose of this project is to identify different behavioral profiles of  MTBI 




whether there are differences in cognitive and functional outcomes at six months post-MTBI 
among the identified behavioral cluster profiles, and to explore differences in the intensity of 
behavioral symptoms at six months post-MTBI based on SNP genotype. 
Research Design: This was a secondary data analysis of the database from the 
International Traumatic Brain Injury Initiative—TRACK-TBI pilot, which previously recruited 
TBI patients from two level I trauma centers. That study enrolled a total of 600 TBI patients; 340 
of which suffered MTBI and who will thus be considered for potential inclusion in the current 
study.  Participants in the original TRACK-TBI pilot study completed a battery of psychometric 
and health-related instruments and provided a blood sample for genetic analysis; these data were 
available to accomplish the aims of the present study.   
Sample and Setting: From the TRACK-TBI pilot database, we selected a convenience 
sample (n=340) of male and females (ages >18years) who suffered external force trauma to the 
head, and who had an MTBI with classification by emergency department arrival Glasgow Coma 
Scale (GCS) as follows: mild (GCS 13–15).  Only individuals who had completed follow-up at 
three months and six months were eligible. 
Statistical Analysis: Latent Class Analysis was used to identify subgroups of MTBI 
patients with behavioral symptom cluster, using items derived from the psychological battery 
completed by participants in the TRACK-TBI pilot study completed; the presence and intensity 
of behavioral symptom cluster was analyzed with respect to cognitive and functional recovery. 
An analysis of covariance was used to explore differences in the intensity of behavioral 
symptoms at six months post-MTBI based on SNP genotype. The outcomes of this study will 
build a foundation upon which to establish clinically based strategies to identify MTBI patients 
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INTRODUCTION AND BACKGROUND OF THE PROBLEM 
Nature of the Problem 
Traumatic brain injury (TBI) is a significantly growing public health, social, and 
economic concern, as it can result in adverse outcomes that persist for an extended period of 
time. Mild traumatic brain injury (MTBI) accounts for 80–90% of the nearly two million 
traumatic brain injuries (TBI) that occur each year (Carroll et al., 2004; Kristman et al., 2014; R. 
Ruff, 2005; R. M. Ruff, 2011). The psychological consequences of MTBI can be extensive and 
can persist well beyond the acute injury, profoundly impacting the lives of the individuals, their 
families, and society (Center for Disease Control and Prevention, 2003). Advances in the 
diagnosis and management of TBI continue to reduce mortality for those who have incurred 
traumatic injuries, resulting in an increasing number of trauma survivors (Kristman et al., 2014; 
R. Ruff, 2005). Yet, surviving MTBI profoundly impacts the lives of the individual, their 
families, and society (Center for Disease Control and Prevention, 2003). The consequences of 
MTBIs can be extensive and wide ranging, and include physical, emotional, and financial 
difficulties. These consequences may be enduring (Center for Disease Control and Prevention, 
2003). Traditionally the evaluation of the impact of TBIs has focused on survival, complications, 
and length of hospital stay. Few studies have evaluated the long-lasting psychological 




of life outcomes and escalate health care costs (Center for Disease Control and Prevention, 
2003). 
Research suggests that only 20–25% of all patients who suffer MTBI are hospitalized, 
and of these MTBI patients, 80 to 90% recover without residual psychological adverse outcomes. 
The remaining 10–20% (referred to as the “miserable minority”) (R. Ruff, 2005; R. M. Ruff et 
al., 2009); however, will suffer from long-term debilitating, unfavorable psychological outcomes 
and persistent physical, emotional, and cognitive symptoms (R. Ruff, 2005; R. M. Ruff et al., 
2009). This could affect them for weeks or months after the injury, and possibly hinder them 
from returning to previous functional status and daily activities (J. Kraus et al., 2005). Such 
adverse outcomes lead to extensive economic costs for the healthcare system (Carroll et al., 
2004; Cassidy et al., 2004; Kristman et al., 2014; R. Ruff, 2005). Nationally, MTBI costs nearly 
$17 billion each year (Center for Disease Control and Prevention, 2003).  
Several studies have described the possible adverse behavioral outcomes following MTBI 
(Ayalon, Borodkin, Dishon, Kanety, & Dagan, 2007; Bay & Donders, 2008; Bay, 2009; Beetar, 
Guilmette, & Sparadeo, 1996; Levin et al., 2005; Ponsford, 2005). In particular, a substantial 
number of MTBI patients suffer depressive mood, fatigue, and poor sleep (i.e., behavioral 
symptoms) for weeks and months post-injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-
Bonneau & Morin, 2012; Beetar et al., 1996; Chaput, Giguere, Chauny, Denis, & Lavigne, 2009; 
Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport, Kiss, & Feinstein, 2006). 
These symptoms not only reduce quality of life (Center for Disease Control and Prevention, 
2003), but also likely delay the return to previous cognitive and functional status (J. Kraus et al., 




thus may constitute a symptom cluster. Based on the oncology literature, a symptom cluster is 
when co-occurring symptoms share a common influence on an outcome (Fox & Lyon, 2007). 
Symptoms of depression, fatigue, and poor sleep may share a common inflammatory etiology, 
and may develop as a result of proinflammatory cytokine elevation (Kossmann, Hans, Imhof, 
Trentz, & Morganti-Kossmann, 1996; Shohami, Novikov, Bass, Yamin, & Gallily, 1994; S. H. 
Su et al., 2014; Woodcock & Morganti-Kossmann, 2013) that occurs post-injury and which may 
persist beyond the acute phase of injury. Inflammatory molecules from sites of injury or 
infection are known to signal the brain to engender inflammatory-related sickness behaviors, 
such as depressed mood, fatigue, and poor sleep (Dantzer, Wollman, Vitkovic, & Yirmiya, 1999; 
Dantzer, 2001; Dantzer & Kelley, 2007; Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008; 
Dantzer, 2009; Dantzer, O'Connor, Lawson, & Kelley, 2011; Kelley et al., 2003).  
Evidence confirms that MTBI patients exhibit elevations in pro-inflammatory cytokines 
(Kossmann et al., 1996; Shohami et al., 1994; S. H. Su et al., 2014; Woodcock & Morganti-
Kossmann, 2013), which may endure beyond the acute phase of injury. However, the 
pathogenesis of psychological long-term outcomes following MTBI is not fully understood. 
Low-grade systemic inflammation might contribute to the development of psychological long-
term outcomes in patients with MTBI. Studies that focused on the systemic inflammation 
following MTBI are limited. According to findings from studies using animal models, MTBI 
could activate systemic inflammatory processes. For example, research findings demonstrate that 
circulating levels of IL-6 is increased in experimental rodent models of MTBI (Holmin et al., 
1997; Shohami et al., 1994; S. H. Yang et al., 2013). Yet, it still remains unknown as to whether 




MTBI. Thus, it presents a fruitful area of research, in view of the fact that it is well established 
that systemic inflammatory processes activate the hypothalamic-pituitary-adrenal (HPA) axis 
(Murray, Buggey, Denes, & Allan, 2013) which may result in chronic stress, anxiety, and 
depression (Mustafa, 2013).  
Furthermore, peripheral pro-inflammatory cytokines are capable of signaling the brain to 
induce behavioral symptoms like fatigue, sleep disturbance, and depressive mood (i.e., sickness 
behavior). It is possible that cytokine-to-brain signaling may contribute to behavioral symptoms 
of trauma patients. For example, pro-inflammatory cytokines that access the brain initiate a 
cascade of brain-derived cytokines that increase in indoleamine 2,3-dioxy-genase (IDO) 
expression (Yamada, Akimoto, Kagawa, Guillemin, & Takikawa, 2009). Increased IDO, in turn, 
can lead to overproduction of kynurenic and quinolinic acids and to less production of serotonin. 
Lower serotonin is linked to the pathogenesis of depression, which is primarily interferon-
gamma-induced (Capuron & Miller, 2011; Haroon, Raison, & Miller, 2012; A. H. Miller, 
Maletic, & Raison, 2009).  
Although experiences of MTBI patients are described in literature, there is lack of 
evidence to guide health care providers to identify which MTBI patients are at greater risk for 
behavioral symptoms. Explication of the psychobiological mechanisms that underlie behavioral 
symptom expression in MTBI survivors is a critical first step that will improve risk assessment 
and ultimately lead to prevention and/or better management of trauma-associated behavioral 
symptoms. It is possible that these co-occurring symptoms synergize to negatively impact 
cognitive and functional recovery. Yet investigation of these behavioral symptoms as a cluster 




determine the extent to which these behavioral symptoms, independently or as a cluster, predict 
worse cognitive and functional outcomes post-MTBI. Further, it is possible that genetic variants 
may predispose to more persistent behavioral symptoms post-MTBI.  This proposal explores the 
relationship of these genetic variants to risk for depressive mood, fatigue, and poor sleep 
independently and as a cluster.  
Size and Importance of the Problem 
Behavioral Symptoms and MTBI 
MTBI patients can suffer from anxiety, fatigue, poor sleep, and depressive mood for 
weeks and months after injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & 
Morin, 2012; Beetar et al., 1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010; 
Ponsford et al., 2000; Rapoport et al., 2006).  
Ample research indicates that anxiety symptoms are prevalent in the aftermath of a mild 
TBI (Hiott & Labbate, 2002; Koponen et al., 2002; Ma et al., 2014; Mooney & Speed, 2001; 
Moore, Terryberry-Spohr, & Hope, 2006; Rao & Lyketsos, 2002; Rao et al., 2010; R. Ruff, 
2005; R. M. Ruff, 2011; Stulemeijer et al., 2006; Woodcock & Morganti-Kossmann, 2013). 
Anxiety in general has been reported at rates as high as 70% in patients with TBIs (Rao & 
Lyketsos, 2002).  
Likewise, fatigue is a frequent burdensome symptom post-TBI, and although the nature 
of fatigue may change with time, it can persist for years after the initial injury (Mollayeva et al., 
2014). The incidence of fatigue after TBI varies from 21% to73%, depending on patient 
characteristics (e.g., severity of injury, time since injury, etc.) and how fatigue is measured 




Kwasnica, 2005; Lidvall, Linderoth, & Norlin, 1974; Middleboe, Andersen, Birket-Smith, & 
Friis, 1992; Ponsford, Cameron, Fitzgerald, Grant, & Mikocka-Walus, 2011). Although fatigue is 
linked to poor recovery post-TBI, a recent systematic review concluded that the impact of fatigue 
on patient outcomes is unclear and more intensive investigation is essential (Mollayeva et al., 
2014). The prevalence and persistence of fatigue after TBI has the potential to impact activities 
of daily functioning, occupational and leisure activities, and thus quality of life (Cantor et al., 
2008; Ouellet, Savard, & Morin, 2004). Previous studies highlight the importance of fatigue after 
MTBI and the need for further investigation and identification of markers that could possibly 
identify MTBI patients who are at risk for more severe symptoms in order to implement 
interventions earlier for better quality of life in MTBI survivors. 
Additionally, the increased incidence of sleep disorders after TBI relative to the general 
population has been increasingly recognized (Castriotta et al., 2007; Watson, Dikmen, 
Machamer, Doherty, & Temkin, 2007). Sleep disturbance is a common complaint following TBI, 
and it is more common with MTBI (Beetar et al., 1996; Clinchot, Bogner, Mysiw, Fugate, & 
Corrigan, 1998; Fichtenberg, Millis, Mann, Zafonte, & Millard, 2000; Mahmood, Rapport, 
Hanks, & Fichtenberg, 2004). In recent reviews, 30–70% of TBI survivors reported sleep 
disturbances (Orff, Ayalon, & Drummond, 2009). Sleepiness may present as a separate symptom 
or along with other sleep disorders (e.g., sleep apnea, narcolepsy, post-traumatic hypersomnia, 
delayed sleep phase, insomnia, fatigue, alteration of sleep-wake schedule to movement disorders) 
(Castriotta et al., 2007; Orff et al., 2009; Watson et al., 2007). However, insomnia has been 
found to be more prevalent in mild TBI individuals (Ouellet et al., 2004). Most of the time the 




injury, consequently hindering the recovery process and return to pre-injury function (Orff et al., 
2009).  
Lastly, evidence reveals that MTBI patients with sleep disturbance are more likely to 
suffer depressive symptoms (Auxemery, 2012; Bay & Donders, 2008; Bay, 2009; Beaulieu-
Bonneau & Morin, 2012; Chaput et al., 2009; Guskiewicz et al., 2007; Kristman et al., 2014; 
Levin et al., 2005; Mooney & Speed, 2001; Ponsford et al., 2011; Rapoport, McCullagh, 
Streiner, & Feinstein, 2003; Rapoport et al., 2006). Depression is commonly reported after 
MTBI—with a prevalence of 15% in the first three months post-MTBI (Rapoport et al., 2003) 
and a prevalence of 18% new onset depressive symptoms up to a year after MTBI (Rao et al., 
2010)—and is highly correlated with poor recovery (Guskiewicz et al., 2007; Mooney & Speed, 
2001). There are only a few studies that investigated the relationship between MTBI and 
depression, as well as the risk factors related to the development of depression after MTBI 
(Levin et al., 2005; Rao et al., 2010).  
The results of these studies suggest that there are several possible predictive factors 
associated with MTBI, psychological adverse outcomes, and other biological factors that could 
be identified in future research. Using predictive parameters can help emergency department 
(ED) personnel to identify MTBI patients who are at higher risk before discharge from the ED; 
allowing the opportunity to make appropriate referrals and prevent suffering from debilitating 
symptoms. This is a clinically relevant and important area for research, as early identification 
with more knowledge about risk factors for MTBI behavioral symptoms soon after the injury can 
help initiate treatment early on, thus promoting optimal quality of life. 




recovery from MTBI for cognitive function (Guskiewicz et al., 2007; Mooney & Speed, 2001; 
Orff et al., 2009) and with the resumption of pre-injury lifestyle and responsibilities (Patterson & 
Holahan, 2012; Silver, McAllister, & Arciniegas, 2009).  
Although experiences of MTBI patients are described in literature, as summarized above, 
understanding the psychiatric morbidity following MTBI remains limited, even though these 
comorbidities are prevalent. Several studies have reported short- and long-term increased rates of 
comorbidities following TBI; most studies; however, combined mild and moderate to severe TBI 
in their analyses. Hence, it is difficult to draw conclusions regarding psychiatric outcomes 
following MTBI, as opposed to more severe forms of TBI.  
However, predictive power may be gained by evaluating clusters of symptoms that co-
occur and which may portend slower recovery. To date only six studies used cluster analysis to 
identify symptom profiles related to recovery (Bailie et al., 2016; Hellstrom et al., 2013; Hoffer 
et al., 2016; Snell, Surgenor, Hay-Smith, Williman, & Siegert, 2015; Velikonja, Warriner, & 
Brum, 2010). One study identified three clusters of psychological adaptation (high, medium, and 
low) which related to injury outcomes (Snell et al., 2015). A second study used cluster analysis 
to identify subgroups of MTBI patients based on a symptom intensity profile (Hellstrom et al., 
2013). Findings revealed that those with minor symptoms had a reduced risk for a positive CT or 
MRI findings, whereas the high-symptom-level group experienced difficulty returning to work 
and reported high levels of anxiety, depression and disability. Although both of these studies 
support this proposal, neither evaluated inflammation-related behavioral symptoms as a cluster 
predictive of cognitive recovery. Thus, there is a critical need to further develop prognostic 




who will thus most benefit from targeted therapy (McMahon et al., 2014). Explication of the 
cluster of behavioral symptoms (i.e., depressive mood, fatigue, and poor sleep) posited to 
underlie cognitive and functional recovery in MTBI survivors is a critical first step to improve 
risk assessment and to better manage post-MTBI outcomes (Lingsma et al., 2014).  
Genetic Variants and Behavioral Symptoms Post-MTBI 
Genetic variants may contribute to risk for clustering of behavioral symptoms (depressive 
mood, fatigue, and poor sleep) following MTBI. Yet most studies to date have not evaluated 
whether genetic variants predict a more intense and/or prolonged clustering of these behavioral 
symptoms. It is known that impairment of neuropsychological and cognitive functions are 
prevalent in MTBI patients with the APOE e4 allele (Isoniemi, Tenovuo, Portin, Himanen, & 
Kairisto, 2006; Liberman, Stewart, Wesnes, & Troncoso, 2002; Millar, Nicoll, Thornhill, 
Murray, & Teasdale, 2003; Potapov, Iusupova, Tendieva, Nikitin, & Nosikov, 2010; Sundstrom 
et al., 2004; Sundstrom et al., 2007; S. T. Yang et al., 2015) and although presence of the APOE4 
allele is not associated with the initial severity of brain injury post-TBI, it is correlated with 
greater risk of poorer outcomes at six months post-injury (Zhou et al., 2008). The negative 
influence of the e4 allele on memory, executive function, and fine motor control (Ariza et al., 
2006) has been highlighted in a meta-analysis (Zhou et al., 2008). In older (non-injured) adults, 
findings demonstrated a relationship between the APOE genotype and depressive symptoms 
(Rigaud et al., 2001; Yen et al., 2007) while other studies reported no such association (Cervilla, 
Prince, Joels, Russ, & Lovestone, 2004; Kessing & Jorgensen, 1999). With respect to fatigue, 
one study found that post-MTBI carriers of the APOE e4 allele had pronounced fatigue 




to poor sleep post-MTBI or to the clustering of behavioral symptoms (depression, fatigue, and  
poor sleep) following MTBI. Thus, there is a need to explore the linkage of the APOEe4 allele to 
vulnerability for more intense and enduring depressive symptoms, fatigue and poor sleep—
common behavioral symptoms which may share a similar inflammatory etiology in individuals 
following MTBI.  
Further, genetic association analyses suggest certain common single nucleotide 
polymorphisms (SNPs) may negatively influence recovery from MTBI (Feng et al., 2015; 
Lanctot et al., 2010; McAllister et al., 2005; McAllister et al., 2008; Pap et al., 2012; Roetker et 
al., 2012). It is possible that certain SNPs may predispose individuals to experience persistent 
behavioral symptom clusters after MTBI, further impeding recovery. McAllister et al. (2005; 
2008) found that rs1800497 allele status was associated with cognitive function post-mild to 
moderate TBI (McAllister et al., 2005; McAllister et al., 2008). Subsequently, others examined 
the influence of the (C/T) SNP rs1800497 on post-TBI outcome using data from two multicenter 
studies (the Citicoline Brain Injury Treatment trial and TRACK-TBI Pilot). Findings showed that 
the ANKK1 T/T genotype is related to poorer verbal learning performance at six months post-
TBI (Yue et al., 2015). Previous evidence also suggests that SNPs play a role in predisposing 
patients to depression (Feng et al., 2015; Pap et al., 2012; Roetker et al., 2012) and also may 
explain differential response to treatment (Lanctot et al., 2010). Since previous studies focused 
on TBI in general, it is thus the purpose of this project to explore which alleles SNPs are 
associated with more intense and/or persistent behavioral symptom cluster (depressive mood, 





Justification of the Importance 
 In light of the primary aim of this secondary analysis study research to determine  
the extent to which behavioral symptoms, independently or as a cluster, predict worse cognitive 
and functional outcomes post-MTBI, three important and innovative aspects of this project may be 
examined.  
The first is the use of symptom clusters analysis as a predictive tool for profiling 
subgroups enduring behavioral symptoms post-MTBI. As it also to a certain extent reveals 
symptom interrelationships (Aktas, Walsh, & Rybicki, 2010), this aspect primarily facilitates in 
exploring the influence of symptoms on each other, and aids in tailoring specific treatments 
accordingly. This conceptualization of symptom clusters is visualized as a shift of the paradigm 
of symptom management research, which addressed the reality of concurrent symptoms 
experienced in different populations and may lead to more promising research that will 
potentially generate knowledge needed for rapid improvement in symptom management. Thus, 
the paradigm shift would bridge the gap between research and bedside nursing by addressing 
symptoms (as a cluster), which is the most common reason that individuals seek healthcare 
(Dodd et al., 2001). This paradigm shift might improve the management of symptoms, ultimately 
reducing symptom burden (Aktas et al., 2010). Thus, profiling subgroups of MTBI patients will 
improve clinical practice, inform clinical practice guidelines, and ultimately provide patients 
with the most effective and innovative treatment modalities (Barsevick, Whitmer, Nail, Beck, & 
Dudley, 2006; Dodd et al., 2001; Kim & Abraham, 2008). In addition, when symptoms are not 




the knowledge regarding the symptom cluster experiences and cognitive and functional 
outcomes is crucial and can lead to innovative treatments.  
The second innovative aspect involve the chosen frameworks (the psycho-neuro-
immunology (PNI) framework and the Theory of Unpleasant Symptoms (TOUS) that guide this 
investigation. This integrative framework can lead to advancement in improving quality of life 
and cognitive and functional recovery post-MTBI. Specifically, the investigator will apply the 
field of genetics to explore a potential mechanism and to explain how genetic variants may 
predispose to more persistent behavioral symptoms post-MTBI. Understanding these 
physiological (genetic) factors may lead to effective symptom management approaches and/or 
tailored strategies. The PNI framework will guide the understanding of these relationships, where 
it is possible that these co-occurring symptoms synergize to negatively impact cognitive and 
functional recovery.  Furthermore, the TOUS (Lenz, Suppe, Gift, Pugh, & Milligan, 1995; Lenz, 
Pugh, Milligan, Gift, & Suppe, 1997) will guide the symptom-clustering aim, since it illustrates 
the importance of inclusion and consideration of the symptom experience as clusters. 
Incorporating the experience of symptoms “as clusters” (adapted from TOUS) would allow 
researchers to have a broader view of the symptom-related variables (e.g., genetic variants) that 
contribute to the symptoms clusters, as well as the symptoms-related recovery outcomes (e.g., 
cognitive and functional recovery). Overall, it is hoped that the innovative 3-dimensionally 
conceptualized frameworks will creatively illustrate the variations in MTBI patients with the 
enhanced understanding regarding symptom clusters and long-term recovery outcome. 
 Lastly, the third innovative aspect is the objective to explore the extent to which genetic 




genetic variants may predispose to more persistent behavioral symptoms post-MTBI. There is a 
compelling impetus for further exploration of genetic variants linked to inflammatory-related 
behavioral symptoms in individuals who suffer MTBI. Determining the extent to which genetic 
variants might contribute directly or indirectly to the symptoms (depression, fatigue, and  poor 
sleep) and might impact cognitive impairment in MTBI patients is innovative, as results may 
provide novel biomarkers to predict more intense and persistent symptoms as early as possible. 
This will provide a new and potentially important avenue for investigation into the biological 
basis for these behavioral symptoms. Understanding the role of these biomarkers (SNPs) in 
MTBI has potential to lead to predicting at discharge which MTBI patients are at risk for 
prolonged behavioral symptoms. The findings can guide the future development of personalized 
genetic-based approaches to help identify and treat trauma patients, in turn to promote quality of 
life and reduce symptom intensity and duration. 
In summary, the long-range objective of this research is to develop novel approaches to 
predict risk for behavioral symptoms in mild traumatic brain-injured (MTBI) patients at 
discharge from the ED. The outcomes of the proposed study will build a foundation to establish 
clinically based strategies to identify MTBI patients at risk and to target interventions to reduce 
behavioral symptoms and improve quality of life in trauma survivors and their families. Thus, 
there is strong rationale for this research in its potential to improve long-term outcomes for 
MTBI survivors who overcome their acute injury but who remain at risk for chronic and 
disabling behavioral symptom clusters.  
Central Hypothesis 




post-MTBI based on inflammation-related behavioral symptoms (depressive symptoms, fatigue, 
and poor sleep), independently or as a cluster; and there will be differences in behavioral 
symptoms at six months post-MTBI based on SNP phenotype. The evaluation of inflammation-
related behavioral symptom clusters post MTBI with respect to outcomes and genetic variants is 
an innovative approach that can result in novel predictive biomarkers for early risk assessment. 
Thus, there is strong rationale for the proposed research, which can improve long-term outcomes 
for MTBI survivors who overcome their acute injury but who remain at risk for chronic and 
disabling behavioral symptoms.   
Specific Aims and Hypotheses 
The following specific aims and hypotheses will be addressed:  
 Aim 1: Identify different behavioral profiles of MTBI patients based on the intensity of 
depressive mood, fatigue, and sleep quality.  
Hypothesis 1: There will be individual differences in the profiles of MTBI patients based 
on the intensity of depressive mood, fatigue, and poor sleep. 
 Aim 2: Determine whether there are differences in cognitive and functional outcomes at 
six months post-MTBI among the identified behavioral cluster profiles.               
Hypothesis 2: There will be differences in cognitive and functional outcomes at six 
months post-MTBI among the identified behavioral cluster profiles. 
 Aim 3: Explore differences in the intensity of behavioral symptoms at six months post-
MTBI based on SNP genotype.  
Hypothesis 3: There will be differences in behavioral symptoms at six months post-MTBI 





For a sizeable subgroup of MTBI patients, recovery is protracted, and prediction of who 
will experience protracted recovery is not well defined. Thus, there is a critical need to identify 
those at risk for a poorer outcome. Findings from this study will increase understanding of the 
role of depressive mood, fatigue, and poor sleep—as a symptom cluster—on cognitive and 
functional recovery. Additionally, enhanced knowledge from this secondary analysis will 
provide a foundation to guide future studies that evaluate the usefulness of these biomarkers 
(genetic variants), as predictors for the risk of more intense and enduring behavioral symptoms 
in MTBI patients. As well, the identified symptom clusters profiles as predictors for risk for 
more cognitive and functional outcomes at six months post-MTBI. Ultimately, this knowledge 
can be used to develop clinical strategies for earlier identification (i.e., at discharge) of MTBI 
patients who are at risk of such behavioral symptoms. This crucial knowledge will have a 
positive impact on the care of MTBI patients, as it will stimulate the development and 
implementation of specific symptom profiles to be used clinically to stratify risk for poor 
recovery and to identify those who may require earlier and more intense intervention to promote 





REVIEW OF THE LITERATURE 
MTBI: Introduction and Definition of MTBI 
Traumatic brain injury (TBI) is an acquired brain injury, which occurs when a sudden 
trauma produces damage to the brain. TBI can result when the head suddenly and violently 
strikes an object, or when an object penetrates the skull and enters brain tissue (National Institute 
of Neurological Disorders and Stroke, 2014). In the United States, TBI is a significantly growing 
public health, social, and economic concern. Of note, TBI can result in adverse outcomes, which 
may persist for an extended period of time. The annual incidence of TBI is estimated to be 
approximately 1.5–2 million, and of all TBIs—including mild traumatic brain injuries 
(MTBIs)—account for 80–90% (Carroll et al., 2004; Kristman et al., 2014; R. Ruff, 2005; R. M. 
Ruff, 2011). Research findings reveal that only 20–25% of all MTBI patients are hospitalized, 
and among these MTBI patients, 80–90% recover without residual psychological adverse 
outcomes. Yet, the remaining 10–20% (referred to as the “miserable minority”) will continue to 
suffer from long-term debilitating, unfavorable psychological outcomes. These symptoms could 
affect these individuals for weeks or months after the injury, and possibly hinder them from 
returning to previous functional status and daily activities (J. Kraus et al., 2005). Such long-term 
symptoms result in extensive economic costs for the healthcare system (Carroll et al., 2004; 
Cassidy et al., 2004; Kristman et al., 2014; R. Ruff, 2005), with costs approaching nearly $17 




It is important to highlight that past incidence data for MTBIs were primarily derived 
from patients evaluated in hospital emergency departments (ED). These ED-derived data 
underestimate TBI incidence because the majority of persons who sustain an MTBI either 
consult their primary care physician days after the injury or do not seek care at all (Langlois et 
al., 2003; Mellick, Gerhart, & Whiteneck, 2003). Consequently, the 1998 National Institute of 
Health (NIH) consensus statement concluded that MTBIs were under-diagnosed and the statistics 
likely underestimate the real extent of the problem (Rehabilitation of persons with traumatic 
brain injury.1998; Consensus conference. rehabilitation of persons with traumatic brain injury. 
NIH consensus development panel on rehabilitation of persons with traumatic brain injury.1999; 
Rose, 1999). 
For some individuals, suffering an MTBI can lead to persistent behavioral symptoms 
long after sustaining the injury. Several studies described the possible adverse behavioral 
outcomes following MTBI (Bay & Donders, 2008; Bay & Xie, 2009; Bay, 2009). Those studies 
report that a substantial number of MTBI patients suffer from fatigue, sleep disturbances, 
cognitive impairment, and depression for weeks and months following the initial injury (Ayalon 
et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al., 1996; Chaput et 
al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport et al., 2006). 
Yet, few studies have attempted to investigate predictive factors which can be used to identify 
who is at risk for developing intense behavioral symptoms following MTBI (R. M. Ruff et al., 
2009).  
Conclusions from a comprehensive review emphasized the need for future research to 




MTBI. These tools would have a powerful clinical advantage to target vulnerable MTBI patients 
and would be cost-effective (R. Ruff, 2005). Although MTBI is not life-threatening, suffering 
from poor outcomes interferes with the ability to return to work or the resumption of social 
activities for up to six months after injury (J. Kraus et al., 2005). Thus, reliable predictive 
measures are essential to identify patients at increased risk of developing poor psychological 
outcomes, and to implement follow-up strategies for MTBI patients at risk early on. 
Establishment of protocols in clinical practice that demand early assessment and follow-up 
treatments would possibly prevent and improve the psychological burden for MTBI patients 
(Lingsma et al., 2014) 
Although experiences of MTBI patients have been described in literature, understanding 
the psychiatric morbidity following MTBI remains limited, despite agreement that such 
comorbidities are common. Several studies have reported short- and long-term increased rates of 
comorbidities following TBI; most studies; however, combined mild and moderate to severe TBI 
in their analyses. Hence, it is difficult to draw conclusions regarding psychiatric outcomes 
following MTBI separately. Additionally, there is lack of evidence to guide health care providers 
to identify which MTBI patients are at greater risk for behavioral symptoms. Explication of the 
psychobiological mechanisms that underlie behavioral symptom expression in MTBI survivors is 
a critical first step that will improve risk assessment and ultimately lead to prevention and/or 
better management of trauma-associated behavioral symptoms.  
In comparison with moderate and severe brain injuries, MTBIs are often more 
challenging to diagnose. The lack of a universally agreed-upon definition of MTBI contributes to 




The World Health Organization (WHO) Task Force proposed an operational definition that 
differs from the definition developed by the MTBI Injury Committee of the Head Injury 
Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine 
(ACRM) (Carroll et al., 2004; Kristman et al., 2014). The definition proposed by WHO and the 
one used for this study is as follows:  
MTBI is an acute brain injury resulting from mechanical energy to the head from external 
physical forces. Operational criteria for clinical identification include: (1) 1 or more of 
the following: confusion or disorientation, LOC [Loss of Consciousness] for 30 minutes 
or less, posttraumatic amnesia for less than 24 hours, and/or other transient neurologic 
abnormalities such as focal signs, seizure, and intracranial lesion not requiring surgery; 
(2) GCS [Glasgow Coma Score] score of 13-15 after 30 minutes post-injury or later upon 
presentation for health care. (3) These manifestations of MTBI must not be due to drugs, 
alcohol, medications, caused by other injuries or treatment for other injuries (e.g., 
systemic injuries, facial injuries, or intubation), caused by other problems (e.g., psycho- 
logical trauma, language barrier, or coexisting medical conditions), or caused by 
penetrating craniocerebral injury. (Carroll et al., 2004), p. 115) 
 
The WHO Collaborating Centre for Neurotrauma Task Force conducted a comprehensive 
critical review of the literature to determine the best evidence on the epidemiology, diagnosis, 
prognosis, and treatment of MTB. That Task Force concluded that identification of prognostic 
factors is a priority for research. Exploratory studies have suggested a number of potential 
prognostic factors for recovery after MTBI (Carroll et al., 2004; Kristman et al., 2014). Yet, no 
definitive study has yet been published that establish prognostic factors to predict outcomes post-
MTBI.  
Theoretical Frameworks 
The psychoneuroimmunology (PNI) framework will be used to guide this investigation. 
In addition, the investigator will use the field of genetics to explore a potential mechanism to 




MTBI. Understanding these physiological (genetic) factors may lead to effective symptom 
management approaches and/or tailored strategies. Furthermore, the Theory of Unpleasant 
Symptoms (TOUS) (Lenz et al., 1995; Lenz et al., 1997) will guide the symptom-clustering aim, 
since it illustrates the importance of inclusion and consideration of the symptom experience as 
clusters. Incorporating the experience of symptoms “as clusters” (adapted from TOUS) would 
allow researchers to have a broader view of the symptom-related variables (e.g., genetic variants) 
that contribute to the symptoms clusters, as well as the symptoms-related recovery outcomes 
(e.g., cognitive and functional recovery). The PNI framework will guide the understanding of 
these relationships, where it is possible that these co-occurring symptoms synergize to negatively 
impact cognitive and functional recovery. Additionally, it is possible that genetic variants may 
predispose to more persistent behavioral symptoms post-MTBI; this also speaks to the mind and 
body connection. This suggests that this relationship is orchestrated by the unique mind and body 
connection.  
Psychoneuroimmunology Framework 
PNI is defined as the study of the interaction between behavioral, neural, endocrine 
(neuroendocrine), and immunological processes of adaptation (Ader, 1980). The interdisciplinary 
science of PNI examines an individual’s emotional responses on a multidimensional level to 
determine if valid relationships exist among emotions, immune function, and health (Robinson, 
Mathews, & Witek-Janusek, 2000). Interdisciplinary researchers discovered the biological link 
between the brain on one hand and the cells and tissues of the immune system on the other, 
which built the foundation for this field of science (Kemeny & Schedlowski, 2007).The basic 




involves coordinated interactions among the nervous, endocrine, and immune systems. The 
biological pathways that connect the brain to the cells and tissues of the immune system include 
direct innervations of lymphatic tissue by the central nervous system and a shared 
communication network in which cells of the nervous, endocrine, and immune systems use 
common molecules and receptors to jointly modulate one’s biology and one’s emotions and 
behavior. Moreover, an expanding body of evidence suggests that emotions play a role in the 
development and progression of disorders that involve immune processes (Kemeny & 
Schedlowski, 2007). 
Of particular relevance to this investigation is the concept of sickness behavior. Sickness 
behavior refers to the non-specific adaptive response of the innate immune system, which results 
in behaviors associated with sickness including lethargy, lack of interest in the environment, 
decreased appetite, and fatigue (Dantzer & Kelley, 2007). It is proposed that sickness behavior 
represents an expression of a central motivational state mediated by release of cytokines (Aubert, 
Kelley, & Dantzer, 1997; Dantzer & Kelley, 2007). In essence cytokine-induced sickness 
behavior refers to a motivational state that belongs to the realm of physiology, similar to other 
motivational states, such as fear or hunger (Dantzer & Kelley, 2007). Withdrawing from the 
environment to seek rest and care for the body is as normal in response to infectious agents as 
being able to shift to a state of increased arousal and readiness for action when confronted with a 
potential external threat. In theory, cytokines released in response to infection or inflammation 
alert the brain of any real or potential threats and initiate behaviors that are important for survival 




The result of a hyperactive pro-inflammatory state marked by excess production of pro-
inflammatory cytokines may contribute to the pathogenesis of various human diseases such as 
allergy, autoimmunity, obesity, depression and atherosclerosis (Sternberg, 2006). Some even 
refer to the ability of the immune system to alert or communicate information about the body to 
the brain as a “sixth sense” (Blalock & Smith, 2007). Sickness behavior is adaptive in that it 
forces an individual to rest and withdraw from activities so that physiological processes can 
effectively produce healing (Blalock & Smith, 2007; Kelley et al., 2003). However, sickness 
behavior is no longer adaptive if it goes beyond the organism’s resources and/or occurs out of 
proportion to the triggering factors that initiated the adaptive response. This is prevalent during a 
variety of chronic inflammatory diseases (Dantzer & Kelley, 2007). Pro-inflammatory cytokines 
released during infection, inflammation, injury and even psychological stress can signal the brain 
to initiate behavioral changes that facilitate adaptation to these threats.   
Cytokines signal the brain to induce sickness behaviors through neural, hormonal, and 
cellular pathways (Capuron & Miller, 2011). The purpose of the following section is to describe 
how cytokines access and signal the brain. Secondly, key evidence that supports the concept that 
cytokines signal the brain to induce sickness behaviors will be described. To accomplish this, 
two crucial models will be considered: Dantzer’s Motivational Model of Sickness Behavior and 
the Two-Hit Model of Cytokine-Induced-Depression.  
Cytokine signals access the brain. Cytokines are relatively large protein molecules, and 
as a result are prohibited from passing through the blood-brain barrier; however, the blood-brain 
barrier may be disrupted following TBI (Kumar & Loane, 2012). In view of the fact that 




(Capuron & Miller, 2011), there are specific mechanisms that differentially mediate cytokine 
effects on the central nervous system. The entry of peripheral cytokines into the brain initiates a 
cascade of signals, which become amplified within the context of the brain cytokine network. 
This network consists of cells within the brain (e.g., microglia and astrocytes) that are 
themselves capable of further cytokine secretion. The neural pathway of immune-to-brain 
signaling underlies the potent effects of peripheral proinflammatory cytokines on pathways 
involved in the pathophysiology of neuropsychiatric disorders, including the activation of the 
HPA axis and the alteration of the metabolism of key neurotransmitters, such as serotonin 
(Dantzer et al., 1999). 
Cytokines access and signal the brain through hormonal, neural and cellular pathways. 
Hormonal pathways refer to the activation of monocytes and macrophages, which release the 
proinflammatory cytokine and enter the brain through the choroid plexus and circumventricular 
organs of the blood-brain barrier. Once inside the brain, the activation of endothelial cells is 
responsible for the subsequent release of second messengers that act on specific brain targets 
(Capuron & Miller, 2011). Cytokines also signal the brain via neural pathways in which 
activated monocytes and macrophages stimulate primary afferent nerve fibers in the vagus nerve; 
this, in turn, results in the release of proinflammatory cytokines. This information reaches the 
brain by sensory afferents of the vagus nerve, which connect with specific brain regions through 
the activation of the nucleus of the tractus solitarius and postrema area (Capuron & Miller, 
2011). Lastly, D’Mello & Swain (2009) identified another new immune-to-central nervous 
system communication pathway in the setting of organ-centered peripheral inflammation. 




activated monocytes into the brain in mice with hepatic inflammation (D'Mello et al., 2009). This 
cellular pathway refers to the stimulation of microglia by pro-inflammatory cytokines to produce 
monocyte chemoattractant protein-1, which in turn is responsible for the recruitment of 
monocytes into the brain (D'Mello et al., 2009).  
Dantzer’s motivational model of sickness behavior. Dantzer’s theory of sickness as a 
motivational state is built upon Bolles’ definition of motivations as central states that reorganize 
perception and action (Bolles & Fanselow, 1980). Bolles (1974) emphasized that a motivational 
state enables the individual to detach perception from action, which results in a selective 
appropriate strategy depending on the encountered state. In order for the body to efficiently deal 
with an invading infectious organism, sickness takes precedence over other behavioral activities 
when the infected organism is at the death stage (Dantzer & Kelley, 2007). Bolles and Fanselow 
(1980) presented a fear motivation system, which by assumption activates a unique class of 
defensive behavior, such as freezing and flight from a frightening situation. This activation aims 
to defend the animal against predation of natural danger while reorganizing the perception of 
environmental events to facilitate the perception of danger and safety (Bolles & Fanselow, 
1980). The following examples illustrate the expression of sickness behavior as a motivational 
state. 
First, Neal Miller (1964) conducted the first series of experimental investigation that 
demonstrated a differential effect of bacterial endotoxin on behavior. Endotoxin administration 
decreased bar-pressing when the bar-pressing resulted in an appetitive stimulus like food or 
water, but endotoxin did not decrease bar-pressing when it resulted in the termination of an 




drum, an aversive stimulus (N. E. Miller, 1964). Interestingly, these results revealed that the 
consequence of the behavior, which does not necessarily decrease following exposure to 
sickness-inducing agents, influences the effect of the sickness-inducing agent.           
Second, Aubert, Goodall, and Dantzer (1995) compared the effects of cold and cytokines 
on spontaneous dietary self-selection of rats. First, they habituated rats to free access to 
carbohydrate, protein, and fat diets for 4 hours a day for 10 days. Then they randomly received 
physiological saline, IL-1 beta injection or lipopolysaccharide (LPS), or were exposed to cold (5 
degrees C). Results revealed that LPS- and IL-1 beta-treated rats ate less, but ingested relatively 
more carbohydrates and less protein, whereas relative fat intake remained unchanged. The rats 
exposed to cold slightly increased their food intake, but in a non-significant manner. They also 
increased their relative intake of fat but did not change their relative intake of carbohydrate and 
protein. These results reveal interesting pyrogenic and metabolic effects of cytokines, which 
provides a clear-cut example of behavioral reorganization in response to sickness (Aubert et al., 
1995). 
In a subsequent study, Aubert, Goodall, Dantzer, & Gheusi (1997) investigated the 
sensitivity to LPS injection in lactating mice. They found that nest-building significantly 
decreased in LPS-treated mothers compared with saline-treated animals at an ambient 
temperature of 22 degrees C. Furthermore, they found that LPS-treated mice exposed to cold 
temperature (6 degrees C) expressed not only pup-retrieving but also nest-building activity. 
Therefore, these activities are a result of a motivational state due to the cooler environment. 
These differential results indicate that the maternal behavioral expressions of LPS-induced 




components of maternal care under consideration). Apparently, sickness prevents mice from 
displaying motor activities (pup-retrieving or nest-building) and from evaluating the situation 
under consideration efficiently (Aubert et al., 1997). 
Finally, Aubert Kelley, & Dantzer (1997) compared the effects of LPS on food intake and 
food hoarding. Rats underwent tests under different motivational levels for food hoarding 
(receiving food supplement to maintain stable body weight or not receiving such a supplement). 
Interestingly, they found that LPS-injection significantly decreased total food intake in rats in 
general, whereas food-hoarding was less in LPS-treated rats compared to those who did not 
receive a supplement. The expression of a still salient secondary motivation in LPS-treated rats, 
which did not receive any food supplement, suggested the expression of an anticipatory feeding 
behavior along with a reduced immediate appetite. Their results demonstrated that LPS treatment 
disrupted food-hoarding in a minor way when rats received all of their food from hoarding, 
compared to rats that had supplemental food in their home cages (Aubert et al., 1997). LPS-
treated animals still appear able to adjust their defensive behavioral strategies with regard to their 
needs and capacities. These findings support the adaptive value of the behavioral changes 
displayed by LPS-treated animals (Aubert et al., 1997). 
In summary, the evidence described above confirms the hypothesis that sickness 
behaviors reflect the expression of motivational changes and reorganizations of behavioral 
priorities (Dantzer & Kelley, 2007). Additionally, Aubert, Kelley, & Dantzer (1997) confirmed 
that environmental conditions can be determinants of the behavioral change induced by illness or 
cytokines. In other words, when there are possible adverse effects of behavioral depression, 




Motivational aspect of sickness behavior. From the previous discussion of the historical 
origin of the motivational model, it was clear that sickness has motivational properties that 
reorganize the function of the organism at subjective, behavioral, and visceral levels in order to 
cope with the threat encountered (Dantzer, 2009). The motivational aspect of sickness behavior 
is a vital perspective in pathophysiology; it entails that the neural pathways underlie the 
expression of sickness behavior, activated by immune stimuli but could possibly receive 
activations from non-immune stimuli (Dantzer et al., 1999). 
Therefore, cytokines signal the brain by inducing sickness behavior as a result of 
expression of a motivational state triggered by activation of the peripheral innate immune system 
(Dantzer, 2009). As mentioned earlier it is an adaptive normal response to the exposure to a 
threat of a predator rather than being pathologic. In theory, cytokines released in response to 
infection or inflammation alert the brain to any real or potential threats and initiate behaviors that 
are important for survival (Frink et al., 2009). Some even refer to the ability of the immune 
system to alert or communicate with the brain as a “sixth sense” (Blalock & Smith, 2007). 
Sickness behavior is adaptive in that it forces an individual to rest and withdraw from activities 
so that physiological processes can more effectively produce healing (Blalock & Smith, 2007; 
Kelley et al., 2003).     
Pro-inflammatory cytokines released during infection, inflammation, injury and even 
psychological stress can signal the brain to initiate behavioral changes that facilitate adaptation 
to these threats. However, similar to other responses, sickness behavior can become anomalous 
or pathologic outside its original context and in the absence of inflammatory stimulus (Dantzer, 




The hyperactive pro-inflammatory state marked by persistent excess production of pro-
inflammatory cytokines like IL-1, IL-6 and TNF alpha and IFN gamma (Dantzer, 2009), which 
may also contribute to the pathogenesis of various human diseases in addition to sickness 
behaviors, such as allergy, autoimmunity, obesity, depression and atherosclerosis (Sternberg, 
2006).  
There is a predominance of pro-inflammatory cytokines over anti-inflammatory 
cytokines, which normally down-regulate the activation of the pro-inflammatory cytokines of the 
sickness response. This mismatch results in the exaggerated sickness response due to the 
peripheral immune system or direct activation of the brain cytokine system (Dantzer, 2009). 
The sensitization of the neuronal circuits is another facet. Activation of afferent nerve 
fibers by peripherally released cytokines represents the fast pathway of transmission of immune 
signals from the periphery to the brain. This neural pathway certainly sensitizes the brain target 
areas of inflammatory mediators to the action of brain-produced cytokines that relay and amplify 
the action of peripheral cytokines (Dantzer, 2001). 
The motivational competition between motivational states for behavioral output. 
Normally, hierarchal organization of motivational states is required for the expression of 
behaviors, along with continuous evaluation of the encountered internal context and external 
events occurrences (Dantzer, 2001). For example, if an individual is sick with the flu and 
experiences generalized muscle weakness, which cause them to stay in bed for the whole day, 
this individual is more likely to overcome this illness and will be better equipped to response to a 
threat.  




the competition of motivational states, in the sense that maternal behaviors are critical for the 
survival of the offspring. In the previously mentioned study by Aubert, Goodall, Dantzer, & 
Gheusi (1997), LPS-treated mice exposed to ambient temperature of 22 degrees C, compared to 
saline-treated mice, demonstrated pup-retrieving activity, but nest-building was significantly 
decreased.  However, LPS-treated mice exposed to ambient cold temperature, compared with 
saline-treated mice, demonstrated both pup-retrieving and nest-building activity. Interestingly, 
their results signify that the behavioral expression of LPS-induced sickness depends on the 
priority of the behavior under consideration (Aubert et al., 1997). In motivational terms, maternal 
behaviors compete with sickness, and maternal-motivated behavior takes superiority over 
sickness behavior. This observation provides a valuable example of the motivational competition 
between behaviors. 
The Two-Hit Model of Cytokine-Induced Depression 
Production of pro-inflammatory cytokines induces sickness behavior, which is 
terminated by endogenous anti-inflammatory molecules. Sustained production of pro-
inflammatory cytokines in the context of insufficient production of anti-inflammatory molecules 
causes depression in vulnerable individuals. Factors acquired or genetic can contribute to 
vulnerability. Vulnerability in the present context refers to an innate or acquired predisposition to 
develop a given pathology when causal factors are present. Dysfunction in genes controlling key 
proteins in cytokine production (e.g., IL-6) and serotoninergic neurotransmission (e.g., activity 
of the serotonin transporter) or serotonin receptor subtype are identified as vulnerability factors 
for cytokine-induced depression (M. R. Kraus et al., 2007). The association between IL-6 




response system in the pathophysiology of IFN-alpha-induced depression. In contrast, the effect 
of the 5-HTT-serotonin transporter gene was reported to be small and perhaps dependent on the 
status of the inflammatory response (Bull et al., 2009).  
There are several features that contribute to vulnerability and are considered markers of 
vulnerability. Firstly, psychological features can influence vulnerability to cytokine-induced 
depression. Patients who have high scores on depression scales at the start of cytokine treatment 
are more likely to develop depressive syndrome in response to immunotherapy than patients who 
have a low score at baseline (Capuron & Ravaud, 1999). Another example of psychological 
features is childhood adversity and maltreatment. Danese et al. (2007) conducted a cohort study 
and followed 1,000 individuals from birth to age 32. They found that patients with major 
depression and a documented history of childhood maltreatment showed higher levels of 
peripheral blood concentrations of high-sensitivity CRP compared with depressed patients 
without a history of childhood maltreatment (Danese et al., 2008) 
Secondly, physiological features can also influence vulnerability. For example, patients 
who respond to the first injection of IFN-α by an exaggerated pituitary-adrenal response are 
more likely to become depressed in response to repeated administration of IFN-α than patients 
who display a lower pituitary-adrenal response (Capuron et al., 2003; Capuron & Miller, 2011). 
Aging is accompanied by several changes in the immune system and reflect immuno-senescence 
and an altered susceptibility of disease. Thus, the elderly respond to stressful events with a larger 
fluctuation of immune function and a greater propensity for the development or progression of 
disease than young or middle-aged individuals (Irwin & Miller, 2007). Godbout et al. (2005) 




peripheral injection of lipopolysaccharide (LPS) in aged mice. Their data revealed that activation 
of the peripheral innate immune system leads to exacerbated neuro-inflammation in the aged 
mice compared with adult mice. The dysregulation link between the peripheral and central innate 
immune system is likely to be involved in the severe behavioral deficits that frequently occur in 
older adults with systemic infections.  
Another example is obesity, an inflammatory condition. O’Connor et al. (2005) tested the 
hypothesis that obesity affects the IL-1beta system, with functional consequences in the brain of 
obese mice. Their results indicate IL-1beta-mediated innate immunity is augmented in diabetic 
obese mice at the periphery and in the brain, and the mechanism is due to diabetes-associated 
loss of IL-1beta counter-regulation. Obesity and aging is correlated with chronic low-grade 
inflammation that leads to priming or sensitization of brain microglial cells (Perry, 2004). 
Superimposed on this low-grade inflammation status, a peripheral infectious episode leads to 
exaggerated synthesis of inflammatory cytokines and other mediators in the brain that has an 
impact on behavior and mood or exacerbates the progression of chronic neurodegenerative 
disease.  
Finally, immuno-compromised individuals, patients taking certain immune-altering 
medications, or drug abusers can be more vulnerable (Irwin & Miller, 2007). These groups may 
be more vulnerable as any alteration in the balance between pro-inflammatory and anti-
inflammatory cytokines (in the sense of a predominance of pro-inflammatory cytokines over 
anti-inflammatory cytokines), results in an exaggerated sickness response to activation of the 
peripheral immune system or direct activation of the brain cytokine system (Dantzer, 2009). 




response are more likely to become depressed in response to repeated administration of IFN-
alpha than patients who display a lower pituitary-adrenal response (Capuron et al., 2003) 
The third vulnerability factor is genetic predisposition to particular diseases (e.g., 
autoimmune diseases, diabetes or cancer etc.) (Irwin & Miller, 2007). Dysfunction in genes 
controlling key proteins in cytokine production and serotoninergic neurotransmission are 
identified as vulnerability factors for cytokine-induced depression (Bull et al., 2009; M. R. Kraus 
et al., 2007). Krauset et al. (2007) conducted a study to investigate the impact of functional gene 
variants of the cerebral serotonin (5-HT) signaling pathway previously implicated in depression 
risk in hepatitis C-infected outpatients treated with interferon alfa-2b. Their findings suggest an 
impact of allelic variation in 5-HT1A receptor expressions on the development of interferon 
alpha-induced depression during antiviral treatment of chronic hepatitis C. Prediction models of 
interferon-induced depressive symptoms based on HTR1A variation offer a perspective for an 
antidepressant-selective serotonin reuptake inhibitor prophylaxis in patients genetically at risk 
for interferon-induced depression (M. R. Kraus et al., 2007). 
In another study, Bull et al. (2009) determined if these polymorphisms were associated 
with the development of depression and fatigue during IFN-alpha and ribavirin treatment. 
Ninety-eight Caucasian patients who were receiving pegylated IFN-alpha and ribavirin treatment 
for chronic hepatitis C virus participated in this prospective cohort study. The association 
between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of 
the inflammatory response system in the pathophysiology of IFN-alpha-induced depression. In 
contrast, the effect of the 5-HTT genes was small and perhaps dependent on the status of the 




The interaction between psychosocial factors and other psychobiological vulnerability 
(e.g., depression) is characterized by alteration of immune function and increased susceptibility 
to, or progression of, disease (Irwin & Miller, 2007). Collectively, the above features may help 
while using markers for prediction of patients at risk for depressive symptoms and a guide in the 
development of interventions to prevent the occurrence of depression thus improving the quality 
of life.    
Cytokines and depression. Cytokine-to-brain signaling has been implicated in mood 
disorders, particularly depression that accompanies illness (Dantzer et al., 2008; Dantzer, 2009). 
Because of the close similarities between symptoms of sickness and clinical signs of depression, 
any of these conditions is likely a risk factor for the occurrence of major depressive disorders. 
Evidence for the possibility of a shift from sickness behavior to depression is available from two 
different sources: clinical research and experimental studies on animal models of depressive 
disorders (Dantzer, 2009). The growing body of evidence implicates pro-inflammatory cytokines 
in the etiology of depressive-like symptoms associated with chronic illness (Dantzer et al., 2008).  
In the research field of PNI, accumulated evidence demonstrates reciprocal 
communication pathways between nervous, endocrine, and immune systems (Schiepers, 
Wichers, & Maes, 2005). Findings in the field of PNI stimulated increased interest in the 
involvement of the immune system in psychiatric disorders (Capuron & Miller, 2011). Research 
suggests that these reciprocal connections between nervous and immune systems are essential to 
understand the underlying pathophysiology of depression. More so, pro-inflammatory cytokines, 
such as IL-6, play a significant role in developing depression and can mediate its psychological, 




depression indicates that external psychological stressors and internal organic inflammatory 
diseases or condition stressors induce inflammatory process (Maes et al., 1999; Maes et al., 
2009; Schiepers et al., 2005; Wichers & Maes, 2002). Additionally, it evident that psychological 
stress might induce an inflammatory response with increased production of pro-inflammatory 
cytokines (Maes et al., 1999; Maes et al., 2009; Schiepers et al., 2005; Steptoe, Hamer, & Chida, 
2007; Wichers & Maes, 2002). 
The conceptual model for the proposed investigation is grounded in the inflammatory 
theory of depression. Convergent findings from several lines of evidence reveal a robust 
association between depressive disorders and pro-inflammatory pathways, and some of this 
evidence is causal (Dantzer et al., 2008; A. H. Miller et al., 2009; Oxenkrug, 2013). Pro-
inflammatory cytokines access the brain through multiple mechanisms and initiate a cascade of 
reactions that lower serotonin levels and increase glutamatergic effects (Dantzer et al., 2008). 
Depression is characterized by deficient serotonergic neurotransmission and enhanced glutamate 
receptor N-methyl-d-aspartate activation. Pro-inflammatory cytokines activate indoleamine 2,3-
dioxygenase (IDO), which degrades tryptophan, a precursor to serotonin. In a pro-inflammatory 
environment, tryptophan is shunted toward production of kynurenine, via IDO, competing with 
the serotonin pathway. These pro-inflammatory cytokine-induced modifications promote the 
development of depressive symptoms. Within the microglia, kynurenine is metabolized to 
quinolinic acid, an agonist of glutamatergic NMDA receptors. This results in a serotonergic 
deficiency and glutamatergic overdrive in pro-inflammatory states that promotes the 





The Theory of Unpleasant Symptoms  
The Theory of Unpleasant Symptoms (TOUS) (Lenz et al., 1995; Lenz et al., 1997) is 
one of the guiding frameworks for this research. The original theory provides a model for the 
experience of, and relationships between, concurrent symptoms (Lenz et al., 1995). The theory 
was developed through collaboration among three researchers who initially were working with 
two concepts, dyspnea and fatigue. The investigators acknowledged shared characteristics 
between the dyspnea and fatigue that led to the ideas of developing an inclusive theory that 
addresses multiple unpleasant symptoms across clinical populations. The original theory 
included influencing factors—physiologic, psychological, and situational factors. The 
investigators emphasized that symptoms vary in several components—duration, intensity, 
quality, and distress. The experience of the symptoms ultimately produced an effect on a 
patient’s level of performance across the three domains of functional status, cognitive 
functioning, and physical performance (Lenz et al., 1995). After the development of the original 
theory, the authors recognized that further refinements in the theory were necessary in order to 
address the possibility of experiencing several symptoms at the same time. Furthermore, they 
acknowledged the need to include the possibility for the experience of several symptoms to have 
multiple effects (Lenz et al., 1995). A revision of the TOUS was published in 1997 (Lenz et al., 
1997). The revision reemphasized the three major concepts of the theory: the symptoms, the 
influencing factors which affect the symptom experience, and the performance of outcomes. The 
revised theory is useful in describing the possibility of interactions between the influencing 




factors and that there is a reciprocal relationship between the influencing factor and symptoms. 
The TOUS has been applied in research and practice. 
The TOUS has three major concepts: the symptoms, influencing factors, and performance 
of outcomes. First, symptoms in the updated version are conceptualized as a multidimensional 
experience, which can be conceptualized and measured separately or in combination with other 
symptoms (Lenz et al., 1997). The dimensions of the symptom experience are the following: (a) 
intensity which refers to strength or severity, (b) timing which refers to duration and frequency 
of occurrence, (c) level of distress perceived which refers to degree of discomfort, and (d) quality 
which refers to the patient’s description of what the symptom feels like. Lenz et al. (1997) stated 
that the dimensions are separable but related. Using these dimensions, each symptom can be 
conceptualized and measured separately or related to other symptoms. Quality is frequently the 
most difficult to discern because of individuals’ varying levels of ability to describe a symptom 
or their ability to pinpoint or differentiate one symptom from another (Lenz et al., 1997). The 
second concept is influencing factors. Three categories are identified that influence the 
symptoms: physiological, psychological, and situational factors. In the updated version of the 
theory, the authors acknowledged the need to consider several interrelated aspects within each 
factor, in addition to the relations between these factors and interactions that could influence the 
symptom experience in return (Lenz et al., 1997). The third concept is performance of outcomes 
or effects of the symptom experience. The authors conceptualized performance to include 
functional and cognitive activities. Functional performance was conceptualized generally to 
include physical activities, activities of daily living, social activities, and role performance such 




The main difference between the original and the revised model is that the original model 
represents a unidirectional influence moving from the influencing factors to the symptom 
experience to the performance or consequences. The revised model is more detailed and 
represents a bidirectional influence among all three of the major concepts of the model: 
symptoms, influencing factors, and performance of outcomes. Additionally, the revised model 
emphasizes the importance of the experience of multiple symptoms at the same time. It also 
advocates that one or more symptoms may aggravate effects on performance and provide a 
reciprocal influence on the influencing factors. Interaction occurs among symptoms, allowing for 
the multiplicity or additive nature of the symptom experience when more than one symptom is 
involved (Lenz et al., 1997).  
It was emphasized by the authors that the experience of unpleasant symptoms could 
change the physiological, psychological, and situational status of a person. Therefore, the major 
theoretical statements of the updated version of the theory are as follows:  (1) the performance of 
outcomes has a reciprocal relation to the symptom experience; (2) the decreased levels of 
performance can have a feedback loop of the influential factors, with a negative impact on 
physiological and psychological states and situational conditions; (3) the influential factors can 
display an interaction effect in their relation to the symptom experience; and (4) the symptom 
experience can have a moderating or mediating influence in the relationship between 
physiological or psychological status and performance (Lenz et al., 1997).  
The two main assumptions, as Lenz says, are the following: (1) There are commonalities 




individual subjective phenomena occurring in family and community contexts (Lenz et al., 
1997). 
The elements of the theory provide perspective for research in both the basic and the 
clinical science of nursing. The Theory of Unpleasant Symptoms was examined in published 
research in different populations, such as cancer patients (Chen & Tseng, 2005), pregnancy 
(Milligan, Flenniken, & Pugh, 1996), childbirth (Pugh & Milligan, 1993), dyspnea in patients 
with chronic obstructive pulmonary disease (Gift, 1990), and cardiac patients (Jurgens et al., 
2009). The theory has clearly demonstrated its usefulness in research to date. As the model 
continues to develop, it will serve as a framework quantitative research (Motl & McAuley, 2009; 
Rychnovsky, 2007; S. J. Woods, Kozachik, & Hall, 2010). The usefulness of the TOUS in 
practice has been demonstrated in a variety of clinical settings and various populations (Chen & 
Tseng, 2005; Gift, 1990; Gift, Jablonski, Stommel, & Given, 2004; Milligan et al., 1996; Pugh & 
Milligan, 1993).  
The TOUS presents a holistic, comprehensive and dynamic view of the unpleasant 
symptoms experience. Managing the care for patient experiencing unpleasant symptoms is part 
of the real world of nursing and what patients encounter on a day-to-day basis. This model offers  
increased insight into the reality of unpleasant symptom experiences, and hopefully provides 
direction to guide management strategies aimed unpleasant symptoms. There is congruence with 
other theories such as symptom management theory (Dodd et al., 2001) and research internal and 
external to nursing. This theory contributes to other disciplines such as psychology and can be 
readily applied in clinical settings guided by other disciplines. For example, in the psychology 




disease (AD) patients in an effort to evaluate the usefulness of the theory with AD patients and 
designing nursing interventions. The researchers reported that the theory is useful because it 
emphasizes the complexity and interaction of symptoms and the interrelationships among 
symptoms, influencing factors and symptom consequences/performance outcomes (Hutchinson 
& Wilson, 1998). The importance of the caregiver and the social and environmental context, 
which are the situational factors in the theory, were especially relevant in AD (Hutchinson & 
Wilson, 1998).  
Research has helped in the refinement of the original theory, and interactions among 
components and their interrelationships with other components were incorporated in the revised 
version of TOUS. The TOUS is an inclusive and interactive dynamic theory incorporating 
multiple concepts in one encompassing model. The theory is useful as it ranges from simple to 
complex depending on the number of unpleasant symptoms and variables a researcher decides to 
study. Additionally, the theory seems relevant to many cultural groups and it can be applied to 
many situations in different setting(Chen & Tseng, 2005; Gift, 1990; Gift et al., 2004; 
Hutchinson & Wilson, 1998; Jurgens et al., 2009; Milligan et al., 1996; Motl & McAuley, 2009; 
Pugh & Milligan, 1993; Rychnovsky, 2007; S. J. Woods et al., 2010). 
Most importantly, the inclusion of multiple influencing factors that influence the patients’ 
symptom experience makes the theory valuable because nurses can uniquely design interventions 
that are individualized for each patient’s characteristics and patterns of symptoms. One of the 
goals of nursing care is to accomplish better outcomes and increase patients’ satisfaction. With 
this theory, by individualizing the care, nurses can facilitate in accomplishing this goal. There are 




application in nursing is an essential tool that provides nurses with the framework for their 
clinical decision-making and ensures accountability by increasing transparency of their actions 
(Meleis, 2011). More specifically, one of the nursing accountabilities to society is to support the 
development of nursing theory and research to explain observations and guide nursing practice 
(American Nurses Association, 2010). Therefore, this TOUS could be useful guide to practice 
when assessing patients with unpleasant concurrent symptoms.  
Finally, the TOUS has many practice implications and can be used to identify preventive 
interventions or develop innovative treatments that could be applied across similar symptoms. 
However, more attention needs to be paid to symptom assessment and management where recent 
findings suggest potentially useful interventions. These interventions need to be addressed and 
examined. For example, these interventions can include prevention interventions after a 
traumatic injury aimed to prevent the symptom of stress. Another example is restorative 
interventions after the experience of the symptom of stress aimed to restore rather than alleviate 
stress. 
The concept of symptom clusters. The concept of symptom clusters has recently 
become an important concept in symptom related nursing research, especially in cancer 
(Donovan & Jacobsen, 2007; B. Given, Given, Azzouz, & Stommel, 2001; B. A. Given, Given, 
Sikorskii, & Hadar, 2007; C. W. Given, Given, Azzouz, Kozachik, & Stommel, 2001; Kirkova, 
Aktas, Walsh, Rybicki, & Davis, 2010; Kirkova, Walsh, Aktas, & Davis, 2010). The concept of 
symptom clusters was initially developed in psychology and psychiatry, and then developed to 
general medicine. It has been extensively utilized in these disciplines for many years now. 




though concurrent symptoms are frequently reported in clinical practice symptom management 
research, surprisingly, has not reflected this reality (Aktas et al., 2010; Barsevick et al., 2006; 
Dodd, Miaskowski, & Lee, 2004). According to Miaskowski, Dodd & Lee (2004), symptom 
clusters is the new frontier in symptom management research. Researchers suggest that specific 
symptom clusters have a cooperative effect on patient outcomes and prediction of morbidity 
(Aktas et al., 2010; Barsevick et al., 2006; Dodd et al., 2004). The purpose of this section is to 
explore the concept of symptom cluster by review of literature in three different disciplines: 
psychiatry and psychology, nursing, and general medicine.  
Symptom clusters in psychology and psychiatry literature. The pathophysiology of 
associated symptoms is reasonably well understood and causal relationships are established in 
many known diseases. On the other hand, it is well known that it is not easy to identify etiologies 
of most mental disorders. More often, an agreement on specific symptoms is recommended for a 
common etiology, which is then regarded as sufficient to recognize a psychological syndrome 
(Collen, 2008).  
It is evident in review of psychology and psychiatry literature that symptom clusters have 
long been the basis of disease diagnosis of psychological disorders. Several themes have been 
addressed in the literature review with regard to the concept of symptom cluster. These themes 
include empirical methods and factor analysis, the associative relationships among symptoms in 
a cluster, basic aspects, common etiology of psychological disorders and symptom construction 
expressed by symptom clusters, and clinical implication of the concept of symptom clusters 




In a recent study by Hybels, Blazer, Pieper, Landerman and Steffens (2009), the 
researchers explored the basic aspects of symptom presentation in older adults with major 
depression by identifying homogeneous clusters of individuals based on symptom profiles. It 
was a secondary data analysis using latent class cluster analysis. In another classic study by 
Asmundson, Frombach, McQuaid, Pedrelli, Lenox and Stein (2000), the researchers described 
symptom clusters as corresponding to basic aspects of posttraumatic stress disorder (PTSD). But 
the researchers questioned whether PTSD symptom clusters derived by experts were truly 
corresponding to the basic aspects of PTSD and then proceeded to verify this assumption 
statistically by using factor analysis (Asmundson et al., 2000). 
However, there has been controversy over the appropriate way to define symptom 
clusters for PTSD. Amdur and Liberzon (2001) tested the factor structure of the Impact of Event 
Scale (IES) in a sample of 195 male combat veterans with chronic PTSD by using confirmatory 
factor analysis. They found that the two-factor model including Intrusion and Avoidance 
deviated significantly from being a good fit. In spite of this, a four-factor model, including 
Intrusion and Effortful Avoidance subscales—as well as Sleep Disturbance and Emotional 
Numbing subscales—was significantly a better fit (Shevlin, Murphy, Dorahy, & Adamson, 2007; 
Shevlin, Dorahy, Adamson, & Murphy, 2007). They concluded that essential behavior became 
visible in the symptoms of a cluster. Conceptually, one can look at psychological disorder as a 
group of symptoms that may be constructed into precise symptom clusters, which distinguish 
characteristics of a specific disorder. Subsequently, these symptom clusters present the basis for 




Shevlin, Murphy, Dorahy, and Adamson (2007) conducted a study to describe the 
distribution of positive psychosis-like symptoms in the general population by means of latent 
class analysis. They used latent class analysis to identify homogeneous sub-types of psychosis-
like experiences. The latent class analysis showed that psychosis-like symptoms at the 
population level could be best explained by four groups that appeared to represent an underlying 
continuum (Shevlin et al., 2007). 
Shevlin, Dorahy, Adamson, & Murphy (2007) conducted another study that examined the 
types of borderline personality profiles, associated psychological disorders and stressful life-
events. They used data from the British Psychiatric Morbidity Survey to examine homogeneous 
subtypes of participants based on their responses to nine borderline personality disorder criteria 
(Shevlin et al., 2007). 
In psychology and psychiatry, symptom cluster is described using the associative 
relationships between symptoms. Amdur and Liberzon (2001) acknowledged the strong 
relationship between symptoms within a cluster. Other properties of symptom clusters include 
the nature or type of symptoms in a cluster and the number of symptoms in a cluster (Shevlin et 
al., 2007). 
The number of symptoms in a symptom cluster does not seem to be important. In a 
classic study, Rusch, Guastello and Mason (1992) attempted to delineate symptom clusters that 
may be considered most distinctive of patients diagnosed with borderline personality disorder 
(BPD). Medical records were examined to assess the extent to which each of the eight DSM-III-
R BPD criteria was present in 89 psychiatric in-patients diagnosed with BPD. Structural analysis 




It is also evident from the literature review that researchers are studying the etiology of 
psychological disorders and they are investigating symptom construction expressed by symptom 
clusters. For example, Dunn et al. (2002) determined clustering of depressive symptoms in a 
combined group of unipolar and patients with bipolar disorder using Principle Components 
Analysis of the Beck Depression Inventory. They also compared unipolar and bipolar. These 
symptom clusters were examined for interrelationships, and for relationships to regional cerebral 
metabolism for glucose measured by positron emission tomography. Different depressive 
symptom clusters may have different neural substrates in unipolar, but clusters and their 
substrates are convergent in bipolar (Dunn et al., 2002). These researchers have contributed 
essentially to the knowledge of brain regions involved in the expression of depressive symptoms. 
Symptom clusters in general medicine literature. In medicine, the concept of symptom 
cluster has been used to explore symptom categorization. Siegel, Myers and Dineen (1987) 
evaluated premenstrual symptoms in a group of women with severe premenstrual tension 
syndrome. They performed a factor analysis to establish the nature of symptom clusters in their 
selected sample. Similar to clinical observations reported earlier, their results revealed two 
distinct clusters of emotional and behavioral symptoms and two of physical symptoms.  
Symptom clusters would possibly help clinicians when looking at etiology of general 
medical disorders. For example, Cowey and Hardy (2006) defined metabolic syndrome as 
composed of cardiovascular risk factors including increased body mass index and waist 
circumference, blood pressure, plasma glucose, and triglycerides, as well as decreased high-
density lipoprotein cholesterol. The researchers noted that essence of the metabolic syndrome 




Nock, Li, Larkin, Patel and Redline (2009) described Syndrome Z which involves 
individual components of Syndrome X (the metabolic syndrome). They performed a factor 
analysis that revealed five syndrome components that included insulin resistance, obesity, 
hypertension, dyslipidemia, and sleep disturbance (Nock et al., 2009) 
Other researchers suggested that symptom clusters could be used to investigate the 
etiology in congestive heart failure patients (Martin & Pinkerton, 1983). They recommended that 
congestive heart failure in adults should be conceptualized as a clinical syndrome. They 
explained that patients with congestive heart failure exhibit clusters of symptoms that define sets 
of systemic congestion, pulmonary congestion and inadequate cardiac output. Some were found 
to have potentially correctable anatomic or metabolic defects, others had myocardial failure, 
while some had both as underlying causes of the syndrome.  
Eslick, Howell, Hammer and Talley (2004) conducted a study to determine how clusters 
of patients with symptoms compare to a clinical diagnosis in patients with irritable bowel 
syndrome and non-ulcer dyspepsia. They used a factor analysis and a k-means cluster analysis. 
The factor analysis identified nine symptom factors. These are diarrhea, constipation, 
dysmotility, dyspepsia or reflux, nausea and vomiting, bowel, meal-related pain, weight loss, and 
abdominal pain. The k-means cluster analysis identified seven distinct subject groups that 
included an undifferentiated group.  
Symptom cluster can also be used to plan treatment. In a study by Jurgens et al. (2009), 
the researchers identified the number, type, and combination of symptoms in hospitalized HF 
patients. They also identified the contribution of comorbid illness and age to symptom clusters. 




(1) acute volume overload cluster which includes shortness of breath, fatigue and poor sleep; 
(2) emotional cluster which includes depression, memory problems and worry; and  
(3) chronic volume overload clusters which includes swelling, increased need to rest and 
dyspnea on exertion. 
The knowledge of symptom clusters may improve the ability to recognize symptoms 
appropriately and make symptom-monitoring more meaningful for patients (Jurgens et al., 2009). 
This example demonstrates the clinical application of the concept of cluster in complicated 
illnesses.  
It has been shown through the literature review that factor analysis and cluster analysis 
identify different symptom clusters in different diseases, such as gastrointestinal (GI) syndromes 
(Eslick et al., 2004). Talley, Boyce and Jones (1998) conducted a study to determine whether 
distinct symptom groupings exist in the community of Sydney residents in Penrith, Australia. In 
total, 60% of the population reported four or more gastrointestinal symptoms. There was 
considerable overlap of irritable bowel syndrome (IBS) with dyspepsia and among the dyspepsia 
subgroups by application of the Rome criteria. Independently, 10 symptom groupings were 
identified by factor analysis.  
Another example is people with chronic hepatitis C infection. Quality of life has been 
shown to be poor among people living with chronic hepatitis C. However, it is not clear how this 
relates to the presence of symptoms and their severity. Lang et al. (2006) conducted a study to 
describe the typology of a broad array of symptoms that were attributed to hepatitis C viral 




neuropsychiatric basis which include mental tiredness, poor concentration, forgetfulness, 
depression, irritability, physical tiredness, and poor sleep. 
With regard to somatic diseases, researchers found clusters in chronic fibromyalgia 
patients. Recent evidence points to the likelihood of heterogeneity in the presentation and 
etiology of fibromyalgia (FM). In order to gain insight regarding this condition, a clear 
understanding of the symptomatology and consideration of potential FM subtypes is needed. 
Rutledge, Mouttapa and Wood (2009)conducted a study to determine whether clusters could be 
identified among 20 symptoms that participants in a prior online study identified and to elucidate 
the underlying structure of resultant clusters. Factor analysis was used on data from a study 
sponsored by the National Fibromyalgia Association. Results revealed that in this well-educated, 
primarily Caucasian sample, morning stiffness, fatigue, and not feeling rested in the morning 
were the symptoms with the highest severity scores.  
Another example of somatic diseases is in multiple sclerosis patients. Motl and McAuley 
(2009) examined the symptom cluster of fatigue, pain, and depression and its direct and indirect 
prediction of physical activity behavior in a sample of individuals with multiple sclerosis (MS). 
The data analysis indicated that fatigue, pain, and depression represented a symptom cluster. 
Additionally, the symptom cluster had a strong and negative predictive relationship with physical 
activity behavior.  
Recently, symptom clusters have been used in general medicine as a statistical method to 
describe the relationships between symptoms. For the purposes of this paper, statistical 
associations may be essential in defining symptom clusters. On the contrary, a small number of 




clusters. Hunter, Battersby and Whitehead (2008) provided a detailed analysis of the 
relationships between menopausal status and psychological and somatic symptoms. They used a 
principal components analysis to examine the relationships between symptoms.  
Kotagal et al. (1995) analyzed 91 psychomotor seizures from 31 patients, seizure-free at 
least one year after temporal lobectomy. The researchers explored fifty symptoms in every 
seizure and noted the time of onset and ending. They used statistical analysis to define symptom 
clusters and to identify the order of appearance of symptoms. They found that the eighteen most 
common symptoms they examined formed a tight cluster showing a high degree of correlation. 
They recommended that this high correlation is essential in defining symptom clusters.  
In another study, Kay et al. (1996) tried to assess the clustering of abdominal symptoms 
in a random population. Data from a cohort study of a 70-year-old Danish population were 
analyzed. They indicated that the defined level of significance of clusters was set at 1%. Their 
results revealed that in this 70-year-old population, abdominal symptoms occur in clusters 
comparable to clusters in younger populations.         
There is no evidence in the literature regarding statistical opinions and patients’ real 
symptom experience except for one example regarding asthma symptoms and coping. Kinsman 
et al. (1973) explored characteristics of subjective symptomatology of asthma within a group of 
100 asthma inpatients. Researchers suggested that complex patterning of subjective 
symptomatology is common in asthma. Symptom patterns described across each of their 
identified five symptom clusters may help to define coping styles related to the role of emotions 




Another evident aspect in the general medicine literature is the underlying dimension in 
defining symptom clusters. In factor analysis, the relationship between each symptom and factor 
is essential. Barrett et al. (2002)—in an attempt to develop a sensitive, reliable, responsive and 
easy-to-use instrument for assessing the severity and functional impact of the common cold 
using a factor analysis—identified four underlying symptom dimensions: cough, throat, nasal 
and fever aches. In another study, Alvir & Thys-Jacobs (1991) explored the effect of calcium 
therapy on peri-menstrual symptom clusters in a randomized, double blinded, crossover trial of 
calcium supplementation. Using a factor analysis, they identified four symptom clusters. Internal 
consistency was high for scales based on these factors which were negative affect, water 
retention, food, and pain. Correlations between the scores ranged from .35 to .69. Scores were 
low during the inter-menstrual phase and much higher during both luteal and menstrual phases. 
They also looked at dimensions of symptoms that were affected by calcium treatment. They 
found that calcium supplementation reduced negative affect, water retention, and pain during the 
luteal phase and pain during the menstrual phase. 
Another important aspect in defining symptom cluster is concurrence of symptoms within 
a cluster as a criterion in defining symptom. However, there is little evidence in the literature to 
support this essential aspect. Groppel, Kapitany and Baumgartner (2000) as well as Kotagal et al. 
(1995) defined seizure-related symptom clusters in their research as symptoms that occurred 
together. However, they didn’t address concurrence in relation to statistical methods; neither did 
they discuss the timing of coexisting occurrence for symptoms to form a cluster.  
Regarding the number of symptoms involved in a cluster, the existence of several 




restriction in the number of symptoms that can be involved in a cluster. For example, Alvir and 
Thys-Jacobs (1991) performed a factor analysis in order to investigate peri-menstrual symptoms. 
They identified two symptom clusters where each cluster contained two symptoms. The first 
cluster is food, which includes increased appetite and craving for sweets. The second cluster is 
pain, which includes abdominal cramps and back pain.  
Hammer et al. (2003) performed cluster analysis and factor analysis in order to 
investigate gastrointestinal symptoms in a subsample of patients with diabetes mellitus. The 
researchers identified only one cluster which included two symptoms; nausea and vomiting. 
Groppel et al. (2000) performed a cluster analysis of clinical seizure of psychogenic non-
epileptic seizures. They identified three clusters. Two of those clusters contained seven 
symptoms while the remaining one contained only one symptom clusters. Collectively, these 
results propose that there is no specific number of symptoms restricted in a cluster.  
Symptom clusters in nursing literature. In nursing literature, the concept of symptom 
clusters is a relatively new one. Several approaches to the concept of symptoms have been 
addressed, including symptom occurrence, symptom distress, and unpleasant symptoms. 
However, there is limited research and publications in literature about the use of the term 
“symptom clusters” and additionally there are changeable definitions.  
Some researchers borrowed this concept from general medicine, and the disciplines of 
psychology and psychiatry. Others used this term to explain several symptoms appearing 
together. Hall (1988) invented a very useful method of understanding and teaching about the 
multiplicity of symptoms in Alzheimer’s disease (AD). Each person with AD presents many 




symptoms and losses associated with various stages, Hall (1988) identified four symptom 
clusters that groups change associated with AD. These are intellectual losses, personality losses, 
planning losses, and progressively lowered stress threshold. Richards (1990) noted that each 
patient exhibits some symptoms from each category. Using this approach, Richards discussed 
that the goal for planning care is to compensate for the losses and to help the patient function 
better within their neurological capacity. Richards concluded that this approach is promising for 
practice and research as it is based on existing theories of stress and coping. 
Earlier works in the oncology nursing literature attempted to address concurrence of 
symptoms and associative relationships among symptoms presented in oncology patients (B. 
Given et al., 2001; B. A. Given et al., 2007; Lenz et al., 1997; Sarna, 1993; Sarna & Brecht, 
1997). 
However, although researchers in oncology nursing literature did not specifically relate 
their findings to the concept of symptom cluster, their contribution have formed the foundation 
for the newly promising concept of symptom clusters. Recently in the oncology nursing 
literature, there is a fair amount of research that relates oncology patients’ symptoms to the 
concept of symptom clusters (Armstrong, Cohen, Eriksen, & Hickey, 2004; Barsevick et al., 
2006; Cheung, Le, & Zimmermann, 2009; Donovan & Jacobsen, 2007; Fan, Hadi, & Chow, 
2007; Fox & Lyon, 2007; Gift, 2007; B. A. Given et al., 2007; Kim, McGuire, Tulman, & 
Barsevick, 2005; Kirkova et al., 2010; Lacasse & Beck, 2007; Liu et al., 2009; Maliski, Kwan, 
Elashoff, & Litwin, 2008; Miaskowski & Aouizerat, 2007).  
Following the previously addressed concept analysis, Armstrong et al. (2004) reviewed 




symptom clusters in the general oncology population compared to symptom research in the 
primary brain tumor population. They addressed symptoms as multidimensional experiences that 
include perceptions of frequency, intensity, distress, and meaning as symptoms occur and are 
expressed. They emphasized that a symptom can influence the occurrence and meaning of other 
symptoms. They found that symptoms occur in clusters in general oncology patients, and these 
clusters have been shown to influence functional status. The potential effect of tumor biology on 
symptom clusters is shown by the cluster of symptoms theorized to be associated with pro-
inflammatory cytokine production. Unfortunately, studies of symptom clusters have not been 
reported for patients with primary brain tumors. They recommended that application of the 
symptom cluster paradigm to guide research is needed.  
With regard to defining the symptom cluster, Dodd et al. (2001) conducted a study to 
determine the effect of the symptom cluster of pain, fatigue, and sleep insufficiency on 
functional status during three cycles of chemotherapy. They defined the concept of symptom 
cluster as follows: “When three or more concurrent symptoms are related to each other, they are 
called a symptom cluster. The symptoms within a cluster are not required to share the same 
etiology.” (Dodd et al., 2001, p. 465). They identified relationship and concurrence as the key 
attributes of a symptom cluster in cancer patients. However, they did not address the associative 
relationships or timing of symptoms occurring together (Dodd et al., 2001). 
With regard to underlying dimensions of symptoms in defining symptom clusters, Woods 
et al. (1999) identified the clusters of symptoms women experience during the premenstrual 
period and assessed the reliability of the symptom clusters as reported by women with three peri-




across menstrual cycle phases and by symptom patterns and estimated the stability of the 
symptom cluster rankings across three menstrual cycle phases. Using a factor analysis, they 
identified four symptom clusters representing the underlying dimensions of symptoms: turmoil, 
fluid retention, somatic symptoms, and arousal symptoms. With regard to the number of 
symptoms included in a cluster, it appears to be very diverse in nursing literature. Dodd et al. 
(2001) addresses the number of symptoms in the oncology population as a minimum of three 
symptoms in a cluster. 
With regard to shared etiology between symptom clusters, Dodd et al. (2001) noted that 
symptoms in a cluster are not required to share the same etiology. On the other hand, Gulick 
(1989), in an attempt to validate a multiple sclerosis-related symptom checklist, made an 
assumption that symptoms would cluster together according to neurological functional systems 
affected by multiple sclerosis. Using a factor analysis, the author tested this hypothesis and the 
results supported this hypothesis. Mitchell and Woods (1996) conducted a study to describe the 
type and stability of symptoms experienced by midlife women. They recommended that within 
the five different symptom clusters they identified, it is possible that the underlying etiology of 
each symptom cluster may be diverse.  
Link Between the Frameworks 
PNI, TOUS, and Genetics 
The primary aim of this research is to identify behavioral symptom clusters post-MTBI 
and to determine if there are differences in functional and cognitive outcomes based on symptom 
cluster. It is possible that these behavioral symptoms (depression, fatigue, and poor sleep) may 




cytokine elevation (Kossmann et al., 1996; Shohami et al., 1994; S. H. Su et al., 2014; 
Woodcock & Morganti-Kossmann, 2013) that occurs post-injury and which may persist beyond 
the acute phase of injury. Inflammatory molecules from sites of injury or infection are known to 
signal the brain to engender inflammatory-related sickness behaviors, such as depressed mood, 
fatigue, and poor sleep (Dantzer et al., 1999; Dantzer, 2001; Dantzer & Kelley, 2007; Dantzer et 
al., 2008; Dantzer, 2009; Dantzer et al., 2011; Kelley et al., 2003). This is congruent with the 
PNI framework, which seeks to understand the impact of environmental stimuli, especially 
psychosocial stimuli on behaviors, emotions, neuroendocrine stress responsivity, and immune 
functions (Mathews & Janusek, 2011).  
Furthermore, there is a compelling impetus for further exploration of genetic variants 
linked to inflammatory-related behavioral symptoms in individuals who suffer MTBI. 
Determining the extent to which genetic variants might contribute directly or indirectly to the 
symptoms of depression, fatigue, cognitive impairment, and poor sleep in MTBI patients is 
innovative, as results may provide novel biomarkers to predict more intense and persistent 
symptoms as early as possible. Thus, there is strong rationale for this research, which can 
improve long-term outcomes for MTBI survivors, who overcome their acute injury but who 
remain at risk for chronic and disabling behavioral symptom clusters. The addition of genetics 
adds another dimension to the PNI framework, since it is possible that genetic variants may 
predispose to more persistent behavioral symptoms post-MTBI. Above and beyond, the 
interconnectivity between the brain, emotions, behaviors, and immunity may in fact be guided 




Understanding these physiological (genetic) factors may lead to effective symptom 
management approaches and/or tailored strategies. Furthermore, the Theory of Unpleasant 
Symptoms (TOUS) (Lenz et al., 1995; Lenz et al., 1997) will guide the symptom-clustering aim, 
since it illustrates the importance of inclusion and consideration of the symptom experience as 
clusters. Incorporating the experience of symptom “as clusters” (adapted from TOUS) would 
allow researchers to have a broader view of the symptom-related variables (e.g., genetic variants) 
that contribute to the symptoms clusters, as well as the symptoms-related recovery outcomes 
(e.g., cognitive and functional recovery). The theory has positively influenced researchers’ 
viewpoint on many issues related to symptom management, which they are accounting for in 
their research (Barsevick et al., 2006; Barsevick, 2007; Dodd et al., 2001; Miaskowski, 
Aouizerat, Dodd, & Cooper, 2007). Additionally, the TOUS has been compared to the symptom 
management model published by Dodd et al. (2001). Although the symptom management model 
is focused more on the selection of symptom management strategies than on an explanation of 
the symptom experience, researchers have acknowledged the importance of this comparison.  
The “Perfect Fit” of the Chosen Frameworks  
Adding the TOUS framework as a third dimension to learn more about physiologic and 
psychological aspects and the experience of unpleasant symptoms “as clusters”, and blending it 
with the PNI and genetic framework, will contribute significantly to the nursing body of 
knowledge in understanding unpleasant symptoms and guiding management strategies. 
Specifically, The PNI framework will help clarify these relationships, where it is possible that 
these co-occurring symptoms synergize to negatively impact cognitive and functional recovery, 




post-MTBI. This is suggestive that these relationships are correlated to the unique mind and 
body connection and that the frameworks of PNI, genetics, and TOUS are all a perfect fit. The 
use for these frameworks in viewing the aim of this research “3-dimensionally” and their 
“perfect fit/blend” will guide the discovery and lead to remarkable advancement in the 
knowledge regarding improvement of quality of life and cognitive and functional recovery post-
MTBI. 
MTBI and Health Outcomes: Overview 
MTBI: Health Outcomes MTBI and Psychological Long-term Comorbidities 
Symptoms experienced. Although experiences of MTBI patients are described in 
literature, there is lack of evidence to guide health care providers to identify which MTBI 
patients are at greater risk for behavioral symptoms. Explication of the psychobiological 
mechanisms that underlie behavioral symptom expression in trauma survivors is a critical first 
step that will improve risk assessment and ultimately lead to prevention and/or better 
management of trauma-associated behavioral symptoms. In the following section, previous 
evidence describing behavioral symptoms experienced by MTBI after the injury will be 
addressed; specifically, anxiety, depression, fatigue, and sleep disturbance. Then, evidence of 
symptom cluster in MTBI patients and outcomes (cognitive impairments) will be addressed in 
the following section. 
MTBI and anxiety. Ample research indicates that anxiety symptoms are prevalent in the 
aftermath of a mild TBI (Hiott & Labbate, 2002; Koponen et al., 2002; Ma et al., 2014; Mooney 
& Speed, 2001; Moore et al., 2006; Rao & Lyketsos, 2002; Rao et al., 2010; R. Ruff, 2005; R. 




general is reported at rates as high as 70% in patients with TBIs (Rao & Lyketsos, 2002). 
Mooney & Speed (2001) classified 24% of their participants with mild TBIs as having developed 
an acquired anxiety disorder. The most commonly reported anxiety symptoms after MTBI 
include free-floating anxiety, fearfulness, intense worry, generalized uneasiness, social 
withdrawal, inter-personal sensitivity, and anxiety dreams (Rao & Lyketsos, 2002).   
Recently, Ma et al. (2014) conducted a study to determine the course of depression, 
anxiety, and sleep disturbance in patients with MTBI compared to healthy participants. They 
assessed patients at baseline after the injury and then at six weeks post-MTBI using the Beck 
Anxiety Inventory (BAI), the Beck Depression Inventory II (BDI), and the Pittsburgh Sleep 
Quality Index (PSQI). Their findings revealed that the average scores of the MTBI group were 
significantly higher than those of the control group only at baseline, and average scores all had 
improved and decreased significantly six weeks later. 
Interestingly, only the PSQI score improved to a level that was not significantly different 
from that of the control group. They concluded that MTBI causes depression and anxiety and 
diminished sleep quality. However, patients recovered six weeks post-MTBI, and sleep quality 
improves to a pre-MTBI level (Ma et al., 2014). The researchers identified that one of the major 
limitations of this study was that some of the patients were using medications before or after 
suffering MTBI that may have influenced their results; however, there was no mention of the 
type of medications the study participants were using. It is a noteworthy limitation and other 
researchers should account for pre- and post-injury medications. Regardless of the limitations, 
these results provide valuable information for understanding the development and recovery of 




research in this area in combination with biomarkers to better identify which patients are at more 
at risk for suffering anxiety and other symptoms, allowing early intervention. 
MTBI and fatigue. Fatigue is a prominent symptom following TBI, with self-report 
prevalence rates ranging from 43%–73% (Belmont et al., 2006). Fatigue can also endure as a 
predominant symptom several years after the TBI (Cantor et al., 2008; Ouellet et al., 2004). 
Fatigue after TBI has the potential to impact activities of daily functioning, occupational and 
leisure activities, and thus quality of life (Cantor et al., 2008; Ouellet et al., 2004). It has been 
emphasized that researchers need to conceptualize fatigue after TBI as a multidimensional 
symptom that includes components of physical, psychological, motivational, situational, and 
activity (Cantor et al., 2008; LaChapelle & Finlayson, 1998). Several factors are found to be 
highly correlated with post-TBI fatigue, including sleep disturbance, perceived stress, somatic 
symptoms, anxiety, and depression (Bay & Xie, 2009; Bushnik, Englander, & Wright, 2008; 
Ponsford et al., 2000). For example, Bushnik et al. (2008) conducted a prospective longitudinal 
study to quantify fatigue and associated factors during the first two years after TBI. Patients were 
assessed at three time points (6, 12, and 18-24 months after TBI). Self-reported fatigue improved 
during the first year, as did pain, sleep quality, cognitive independence, and involvement in 
productive activity. However, they found that further changes up to two years after TBI were not 
observed, but the subset of individuals who reported significant increases in fatigue over the first 
two years demonstrated poorer outcomes in regards to cognition, motor symptoms, and general 
functioning than those with decreased or stable fatigue (Bushnik et al., 2008) 
Systematic and comparative studies on fatigue after MTBI are limited. However, in an 




perceived stress, cortisol levels, and posttraumatic brain injury fatigue in outpatients. Seventy-
five injured persons with TBI and their relatives/significant others participated in this cross-
sectional study. Data collection including interviews and self-reported data from the Neuro-
functional Behavioral Inventory, the Perceived Stress Scale, the Profile of Mood States-Fatigue 
subscale, the McGill Pain Scale, as well as self-collection of salivary cortisol over a 12-hour 
period (N = 50). In their analysis, researchers regressed fatigue on perceived health, cognitive, 
somatic, and depressive symptoms, present level of pain, cortisol levels, and perceived chronic 
stress. Interestingly, they found that only perceived stress and somatic symptoms were 
significantly associated with post-TBI fatigue (p = .03; p = .05, respectively). Additionally, 
perceived chronic stress alone explained 37% of the variance in post-TBI fatigue. When somatic 
symptoms were included in the model, perceived chronic stress accounted for 50% of the 
variance in post-TBI fatigue. The Centers for Disease Control Acute Concussion guidelines has 
strongly suggested fatigue and stress management interventions that are beneficial in reducing 
these post-MTBI symptom (Bay & Xie, 2009; Stulemeijer et al., 2006). 
Subsequently, trauma comparison groups were examined to determine whether the 
persistence of fatigue was attributed to the brain injury. Stulemeijer et al. (2006) conducted the 
first study to determine the severity of fatigue six months after MTBI and its association to other 
outcomes. For example, these investigators tested whether injury indices, such as Glasgow Coma 
Scale scores, are related to higher levels of fatigue. In their study, they recruited a total of 299 
MTBI patients and 287 minor-injury patients with an ankle or wrist distortion (control group). 
They reported that 32% of MTBI patients and 12% of the control patients were severely fatigued. 




limitations in physical and social functioning, and fatigue-related problems like reduced activity. 
Furthermore, they reported that nausea and headache experienced in the ED were significantly 
related to higher levels of fatigue at six months (Stulemeijer et al., 2006). Their findings call for 
further investigation since higher levels of fatigue seems to be related to acute symptoms and 
mechanism of injury rather than injury severity indices. 
In a longitudinal prospective study researchers examined fatigue prevalence, severity, 
predictors, and covariates over six months post-MTBI. Post-MTBI fatigue was prevalent at one 
week (68%), at three months (38%), and at six months (34%) (Norrie et al., 2010). Interestingly, 
depression and earlier prevalence of fatigue were highly correlated with later fatigue (Norrie et 
al., 2010). Although fatigue was exacerbated by depression, it was not related to increased 
anxiety. Another noteworthy finding is that fatigue was categorized or labeled as “laziness” by 
family or friends in 30% of cases, which could reduce care-seeking behavior. Most importantly, 
their findings revealed that fatigue was a persistent post-concussion symptom that mainly 
resolved in the first three months, and highly recommended that the optimum intervention 
placement be at three months post-MTBI. Thus, assessing fatigue early on post-injury is valuable 
and there is more need for studies regarding the prevalence and mechanism of fatigue post-TBI 
(Norrie et al., 2010) 
Post-TBI fatigue appears to be persistent after mild-to-moderate TBI. For example, in 
those who were hospitalized and followed prospectively for symptom persistence and disability 
outcome, fatigue was present in 57% and persisted in 42% of the sample at one year (van der 
Naalt, van Zomeren, Sluiter, & Minderhoud, 1999). These studies highlight the importance of 




at risk for more severe symptoms. Such identification will permit the implementation of 
interventions earlier for better quality of life. 
MTBI and sleep disturbance. The increased incidence of sleep disorders after TBI 
relative to the general population has been increasingly recognized (Castriotta et al., 2007; 
Watson et al., 2007). Sleep disturbance is a common complaint following TBI, and it is more 
common with MTBI than severe or mild TBIs (Beetar et al., 1996; Clinchot et al., 1998; 
Fichtenberg et al., 2000; Mahmood et al., 2004). In recent reviews, 30–70% of TBI survivors 
reported sleep disturbances (Orff et al., 2009). Sleepiness may present as a separate symptom or 
along with other sleep disorder (e.g., sleep apnea, narcolepsy, or post-traumatic hypersomnia, 
delayed sleep phase, insomnia, fatigue, and alteration of sleep-wake schedule to movement 
disorders) (Castriotta et al., 2007; Orff et al., 2009; Watson et al., 2007). However, insomnia has 
been found to be more prevalent in mild TBI individuals (Ouellet et al., 2004). Most of the time 
the sleep disturbances are directly related to the TBI, enduring for months and/or years after the 
injury, consequently hindering the recovery process and return to pre-injury function (Orff et al., 
2009).  
In the previous section the importance of fatigue subsequent to traumatic brain injury was 
described. Although fatigue and poor sleep are related, the cause-effect relationship between 
MTBI-related sleep disturbance and MTBI-related fatigue remain unclear. Thus, it is important 
to include an assessment of sleep disturbance, along with fatigue, in this investigation of 
behavioral symptoms post-MTBI. In support of this, Beaulieu-Bonneau and Morin (2012) 
reported results of a prospective controlled study examining the correlation between sleepiness 




years post-head injury. These investigators assessed outcomes using polysomnography, 
maintenance of wakefulness test, Epworth Sleepiness Scale, Functional Outcomes of Sleep 
Questionnaire, Multidimensional Fatigue Inventory (MFI), Visual analogue scales (VAS), sleep 
diary, Insomnia Severity Index (ISI), Beck Depression Inventory (BDI-II), and State-Trait 
Anxiety Inventory (STAI-Trait). Their results revealed that the participants with TBI reported 
higher subjective fatigue as a more prominent symptom than sleepiness; the TBI participants also 
used compensatory strategies to reduce fatigue (e.g., napping and spending an increased amount 
of time in bed). This study is limited; however, due to the heterogeneity of the degree of brain 
trauma (i.e., moderate to severe) and the long time frame post-trauma of study participants 
(Beaulieu-Bonneau & Morin, 2012). Although this study excluded mild TBI patients, the 
findings have implications for research evaluating behavioral symptoms in this group.  
Orff et al. (2009) summarized the current literature and remaining issues regarding the 
significant prevalence and potential consequences of sleep disturbance following mild TBI. 
Fascinatingly, the majority of research indicates that MTBI is highly correlated with increased 
sleep disturbances when compared to severe TBI (Orff et al., 2009). In their review they 
highlight the limitation of research in the inability to explain the reason why MTBI is more 
commonly associated with sleep disturbances. They speculated that it could be attributed to the 
differences in the nature of the injury, where diffuse injuries and axonal shearing (common with 
MTBI) could lead to impaired global functioning and arousal, as opposed to the more acute and 
focal trauma injuries (severe TBI). Another issue is differences in treatment modalities with less 
severe injuries. Most of these patients are discharged at the ED, thus they may not be receiving 




of life in general (Orff et al., 2009). Further, Mahmood et al. (2004) hypothesized that severe 
TBI patients maybe be unaware of their deficits and underreported sleep issues, which is most 
likely the case in this population. On the other hand, MTBI patients may be inflating their sleep 
disturbances issues because of the difficulties of going back to their daily routine in the face of 
increased stress in the aftermath of their injuries, which although mild, could be worrisome 
(Mahmood et al., 2004). It is also speculated that differences in neurobiological mechanisms 
between mild and severe brain injuries may explain the greater incidence of sleep disturbance 
with MTBI (Mahmood et al., 2004).  
The above-mentioned studies emphasize the need for more research regarding sleep 
disturbance in those who suffered an MTBI. Sleep disturbance has many implications as it 
impedes the physical and cognitive recovery of TBI patients (Orff et al., 2009), hinders patients 
from the vitality of regaining lost functions, hampers patients from engaging in activities of daily 
living, and further reduces quality of life (Parcell, Ponsford, Rajaratnam, & Redman, 2006). In 
addition, MTBI patients with sleep disturbances are more likely to suffer from concomitant 
headaches, depressive symptoms, and irritability. Of note, patients with MTBI who experienced 
sleep disturbance also reported feeling depressed at ten days and six weeks after their injury 
(Chaput et al., 2009).  
Furthering the understanding of sleep disorders after MTBI is needed which will lead to 
earlier diagnosis and earlier treatments of sleep disorder to provide better care to the patients and 
to understand this less communicated and recognized symptom. Future research to elucidate the 
nature and extent of the relationship between MTBI and sleep disturbance is needed, especially 




as well as the specific consequences of sleep disturbance post- MTBI (e.g., impaired physical or 
cognitive recovery)(Orff et al., 2009).  
MTBI and depression. MTBI patients are at risk of depression (Auxemery, 2012; Bay & 
Donders, 2008; Bay, 2009; Beaulieu-Bonneau & Morin, 2012; Guskiewicz et al., 2007; Kristman 
et al., 2014; Levin et al., 2005; Mooney & Speed, 2001; Ponsford et al., 2011; Rapoport et al., 
2003; Rapoport et al., 2006)  and depression is  highly correlated with poor recovery 
(Guskiewicz et al., 2007; Mooney & Speed, 2001). Prevalence of depression is 15% in the first 
three months post-MTBI (Rapoport et al., 2003) and 18% up to a year after MTBI (Rao et al., 
2010). Few studies have investigated the relationship between MTBI and depression, as well as 
the risk factors related with the development of depression after MTBI (Levin et al., 2005; Rao et 
al., 2010). Of those studies, older age and abnormal computerized tomography (CT) scans are 
reported as risk factors for developing major depression in MTBI within three months of injury 
and could possibly predict the development of depression within the first three months post-TBI 
(Levin et al., 2005).  
These findings are similar to a longitudinal study that followed a sample of 43 MTBI 
patients for one year and found that increased age and presence of frontal subdural hemorrhage 
were the only two significant findings noted in the depressed group compared to the non-
depressed group (Rao et al., 2010). The results of these studies are suggestive that other 
biological factors could be identified as predictors in future research. Using predictive 
parameters can help ED personnel identify MTBI patients, who are at higher risk before 





In conclusion, although experiences of MTBI patients are described in literature, 
understanding the psychiatric morbidity following MTBI remains limited, even though these 
comorbidities are prevalent. Several studies have reported short- and long-term increased rates of 
comorbidities following TBI; most studies however, combined mild and moderate to severe TBI 
in their analyses. Hence, it is difficult to draw conclusions regarding psychiatric outcomes 
following MTBI separately. Additionally, there is lack of evidence to guide health care providers 
to identify which MTBI patients are at greater risk for behavioral symptoms clusters.   
MTBI: Symptom Clusters and Cognitive and Functional Outcomes 
Symptom clusters in MTBI population. In this literature review, we demonstrated that 
MTBI research has primarily focused on studying symptoms (single, paired, or all symptoms) 
experienced three, six, and twelve months or years post-injury. As mentioned earlier, MTBI 
patients can suffer from depressive mood, fatigue, and poor sleep for weeks and months after 
injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al., 
1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport 
et al., 2006). Prevalence of depression is 15% in the first three months post-MTBI (Rapoport et 
al., 2003) and 18% up to a year after MTBI. (Rao et al., 2010) Sleep disturbance is also a 
common complaint, (Beetar et al., 1996; Clinchot et al., 1998; Fichtenberg et al., 2000; 
Mahmood et al., 2004) and MTBI patients with sleep disturbance are more likely to suffer 
depressive symptoms (Chaput et al., 2009). Likewise, fatigue is a frequent burdensome symptom 
post-TBI, and although the nature of fatigue may change with time, it can persist for years after 
the initial injury (Mollayeva et al., 2014). The incidence of fatigue after TBI varies from 21% 




how fatigue is measured (Belmont et al., 2006; Borgaro et al., 2005; Lidvall et al., 1974; 
Middleboe et al., 1992; Ponsford et al., 2011). Although fatigue is linked to poor recovery post-
TBI, a recent systematic review concluded that the impact of fatigue on patient outcomes is 
unclear and more intensive investigation is essential (Mollayeva et al., 2014). Depression, 
fatigue, and poor sleep have been independently associated with impeded recovery from MTBI 
for cognitive function (Guskiewicz et al., 2007; Mooney & Speed, 2001; Orff et al., 2009) and 
the resumption of pre-injury lifestyle and responsibilities (Patterson & Holahan, 2012; Silver et 
al., 2009). However, predictive power may be gained by evaluating clusters of symptoms that co-
occur and which may portend slower recovery. Determining the existence of symptom clusters is 
vital in MTBI patients and will lead to further crucial investigation into the mechanisms that 
underlie these clusters that will advance the knowledge regarding cognitive and functional 
outcomes. Although there is ample of research in the literature about symptoms experienced 
post-MTBI, to date only six studies used cluster analysis to identify symptom profiles related to 
recovery (Goldstein, Allen, & Caponigro, 2010; Hellstrom et al., 2013; Hoffer et al., 2016; Snell 
et al., 2015; Velikonja et al., 2010). 
In one study, Snell et al. (2015) conducted a prospective observational study to examine 
associations between baseline demographic, clinical, psychological variables, and six-month 
follow-up outcome. They analyzed the data using a two-step approach to cluster analysis, which 
revealed three clusters of psychological adaptation (high, medium, and low) related to injury 
outcomes (Snell et al., 2015). The identified cluster-group membership was significantly 




early post-injury based on psychological factors, and that different group membership is 
correlated with different recovery outcomes and sequelae.  
A second study used cluster analysis to identify subgroups of MTBI patients based on a 
symptom intensity profile (Hellstrom et al., 2013). Findings revealed that those with minor 
symptoms had a reduced risk for a positive CT or MRI findings, whereas the high symptom level 
group experienced difficulty returning to work and reported high levels of anxiety, depression, 
and disability.  
In a recent study, researchers (Hoffer et al., 2016) compared MTBI patients to controls to 
examine the use of vestibular testing to diagnose MTBI. They identified five symptom clusters: 
(1) Post-Traumatic Headache/Migraine, (2) Nausea, (3) Emotional/Affective, (4) 
Fatigue/Malaise, and (5) Dizziness/Mild Cognitive Impairment. They highlighted the importance 
of considering other symptoms to critically provide prognostic value and treatment for best 
short-term outcomes or prevention of long-term complications (Hoffer et al., 2016). 
Goldstein, Allen, and Caponigro (2010) performed two cluster analyses using 
retrospective data from veterans with TBIs to explore whether subtypes emerged based on 
cognitive performance on test batteries. They found cluster membership was associated with 
education, age, and employment status, but not with neurological findings (e.g., lesion location) 
(Goldstein et al., 2010) 
In addition, Velikonja, Warriner, and Brum (2010) used the Personality Assessment 
Inventory (PAI) to detect emotional and behavioral profiles in acquired brain injury (ABI) 
patients (n=440). They analyzed their data by a three-step cluster analytic approach, and seven 




features and substance use; (2) high somatic and depressive symptoms; (3) high depression; (4) 
normal/no major concerns; (5) high substance use with antisocial personality features; (6) normal 
with possible minimization of concerns; and (7) multiple high symptoms with borderline 
personality features but no substance use.  
An interesting approach when taking the demographic information in combination would 
provide descriptive insight into the nature of post-injury affective and behavioral symptoms, 
which in turn could lead to establishing a more inclusive conceptualization of needs with 
specifically customized treatment modalities (Velikonja et al., 2010) 
Lastly, Bailie et al. (2016) explored the taxonomy of combat-related MTBI (n=1341 
military personnel) based on symptom patterns within two years of evaluation. Cluster analysis 
revealed four subtypes (primarily psychiatric PTSD group, a cognitive group, a mixed symptom 
group, and a good recovery group. Their results are indicative of the need for unique treatment 
resources and programs (Bailie et al., 2016).  
However, although each of these studies supports this proposal, neither evaluated 
inflammation-related behavioral symptom clusters as a potential predictor of cognitive recovery. 
Thus, there is a critical need to further develop prognostic models of MTBI to identify those at 
greater risk for poorer cognitive and functional recovery and who will most benefit from targeted 
therapy (McMahon et al., 2014). Explication of the cluster of behavioral symptoms (i.e., 
depressive mood, fatigue, and poor sleep) posited to underlie cognitive and functional recovery 
in MTBI survivors is a critical first step to improve risk assessment and to better manage post-




Symptom clusters and outcomes. Cognitive impairment is prevalent in the acute phase 
after MTBI, and these impairments include impaired verbal memory and slowed speed of 
language comprehension and information processing (De Monte, Geffen, May, & McFarland, 
2004), difficulties in attention, episodic memory, executive functions, working memory, 
information-processing speed, language functions, and visio-spatial processing that can last for 
months or even years (Kinnunen et al., 2011). MTBI patients with a decreased Glasgow Coma 
Scale score in the acute phase exhibit significantly decreased and disturbed cerebral perfusion in 
the frontal and occipital grey matter as seen on a normal non-contrast CT; moreover, these 
observations correlated with severity of injury and cognitive impairment (Metting et al., 2009).  
While these acute cognitive impairments are overwhelming, MTBI patients also have 
long-term cognitive impairments related to trauma-induced neuro-degeneration. These 
impairments include impairment of memory, changes in executive cognitive function affecting 
the accomplishment of tasks involving complex cognition, emotional instability causing deficient 
judgment and insight, impaired attention and concentration, struggles with speed of information 
processing (slowed), and sensorimotor impairments (Binder, Rohling, & Larrabee, 1997; 
Patterson & Holahan, 2012; Silver et al., 2009). In general, MTBI patients experience problems 
with attention and concentration to accomplish one goal for a given time, they are unable to 
efficiently shift attention to another goal, and/or they are unable to handle interruptions 
effectively (Binder et al., 1997).  
The long-term higher-level cognitive processes impairments following MTBI are more 
problematic to these patients than simpler cognitive tasks, such as keeping track of daily 




2009). The incidence of these long-term cognitive impairments following MTBI lead to a 
debilitating failure to resume their pre-injury lifestyle, such as returning to work, academic, 
and/or social life. In addition, MTBI patients can have adverse long-term psychiatric, neurologic, 
and psychosocial morbidities (Vanderploeg, Curtiss, Luis, & Salazar, 2007). For example, MTBI 
patients report poor psychosocial outcomes, including an increased self-reported disability, 
under-employment, low income, and marital problems (Vanderploeg et al., 2007). Usually, the 
expected recovery from cognitive impairments after MTBI varies from week to months. Yet, 10-
20% of MTBI patients will experience persistent cognitive impairments beyond the acute phase, 
which significantly disrupts their capacity to resume many pre-injury activities (Patterson & 
Holahan, 2012; Silver et al., 2009) 
At present, it still remains indistinguishable whether the long-term cognitive impairments 
correlate with pathophysiological factors of the injury itself, or if these impairments are a result 
of the influence of other psychological adverse outcomes such as fatigue, sleep, anxiety, and 
depression (Bigler, 2008; Wood, 2004).  
Historically, researchers attempted to theorize and explain the development of long-term 
cognitive impairment post-TBI. Some suggested that psychological distress post-MTBI 
influences the occurrence and maintenance of cognitive impairments experienced by MTBI 
(Ryan & Warden, 2003). Yet, the research related to the influence of symptoms on cognitive and 
functional outcomes in MTBI patients is limited. However, relevant to this proposal, Ramati et 
al. (2009) examined the association between psychiatric morbidity and cognitive functioning in 
86 electrical injury patients. They found that patients with multiple psychiatric morbidities 




compared to electrical injury patients with one or no post-injury psychiatric morbidities. Their 
results delineate the relationship between psychological symptoms and cognitive and functional 
recovery, and this worthy of investigation in the MTBI population. Others noted a relationship 
between level of depression and performance on cognitive tests. The incidences of depression 
were correlated with worse cognitive impairment and poor social functioning (Busch & Alpern, 
1998). In particular, worse prognosis of depression was highly associated with impaired mental 
flexibility and visuomotor tracking (Veiel, 1997). This is suggestive of the association between 
depression and TBI, and there is a need for more research to explore whether subgroups of 
patients with MTBI could be identified according to their symptom clusters to delineate those 
who are at risk poor cognitive and functional outcomes. 
On the other hand, it is well established that one of the causative factors linked to 
cognitive impairment following MTBI is neuro-inflammation. For example, the proinflammatory 
cytokine IL-1β is known to affect hippocampal-dependent memory tasks (Huang & Sheng, 
2010). Increased pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha are known to play a 
role in complex cognitive processes at the molecular and cellular level, as these cytokines reduce 
synaptic plasticity, affect neurogenesis and neuromodulation, and result in neurodegeneration 
(McAfoose & Baune, 2009; J. A. Smith, Das, Ray, & Banik, 2012). In other words, cognitive 
functions are at risk when disruption of cytokine levels exists. Most importantly, it is suggested 
that cytokine dysregulation could orchestrate the long-term development and pathogenesis of 
neuropsychiatric disorders such as major depression (McAfoose & Baune, 2009). When the 
microglia are activated post-injury, they release pro-inflammatory cytokines (e.g., IL-1, IL-6, 




neuroprotective, but chronic microglial activation may also be toxic and lead to 
neurodegeneration (J. A. Smith et al., 2012).  
Recent findings suggest that microglial activation and pro-inflammatory cytokines could 
be used as targets in the treatment of neuro-degeneration (J. A. Smith et al., 2012). Briones, 
Woods, and Rogozinska (2013) conducted a study to determine the effects of environmental 
enhancement (EE) (refers to conditions that provide increased social, cognitive, and physical 
stimulation) in attenuating the long-term consequences of MTBI subsequent to neuro-
inflammation, alterations in brain energy metabolism, and cognitive impairment. The study was 
conducted using rodents that were randomly assigned to receive either MTBI using the 
controlled cortical injury model or sham surgery. The animals were then randomized again to EE 
housing or standard laboratory housing. Cognitive and behavioral testing, and the levels of the 
pro-inflammatory cytokines IL-1β and TNF-α and the anti-inflammatory cytokine IL-10 were 
measured after 4 weeks of recovery in the brains tissue, specifically the ipsilateral region. The 
results revealed that EE correlated with decreased levels of the pro-inflammatory cytokines IL-
1β and TNF-α and enhanced levels of the anti-inflammatory cytokine IL-10 after MTBI. 
Additionally, EE alleviated MTBI-induced cognitive impairment. Thus, these findings 
demonstrate the potential of EE to attenuate the persistent neuro-inflammatory state, which 
occurs after MTBI.  
Primarily, it is crucial to advance the knowledge symptom clusters and cognitive and 
functional outcomes especially in this understudied MTBI population. Despite the evidence that 
supports the association between specific symptoms and cognitive impartment, the research on 




suggesting the need for more research regarding their associations. Thus, it is imperative to 
attempt to identify subgroups within the MTBI patients that may account for the differences in 
experiences, symptoms, and variation in cognitive and functional recovery outcomes following 
MTBI. This will address the gap in the literature and improve understanding of symptom-
clustering in MTBI patients and will aid in the development of rehabilitation programs that are 
tailored to specific profiles. 
It is hoped that the symptom cluster approach and analyzing the symptoms that are 
experienced concurrently will aid in profiling MTBI patients. The evolution of innovative 
cognitive and functional outcome initiatives and treatment modalities aimed to manage the 
consequences of MTBI, along with evidence from behavioral psychotherapy and cognitive 
remediation, could be applied to help improve cognitive function in MTBI (Tiersky et al., 2005). 
This highlights the need for more studies to identify predictive tools to identify patients who are 
at more risk for these persistent long-term cognitive impairments in order to intervene early on. 
Again, the devastation resulting from long-term impaired cognitive functioning could correlate to 
other adverse long-term outcomes. There is a need for the earlier assessment of cognitive and 
functional impairments for the purposes of identifying patients at risk for long-term outcomes. 
More broadly, there is a need for increasing the knowledge regarding the most prevalent 
impaired cognitive functions, understanding the recovery timeframe for these patients, and early 
interventions.  
MTBI and Biological Mechanisms 
MTBI and Genetic Variants (SNPs) 




(Bay & Donders, 2008; Bay & Xie, 2009; Bay, 2009). In particular, study findings reveal that 
patients suffer from fatigue, sleep disturbances, and depression for weeks and months following 
MTBI (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al., 
1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport 
et al., 2006). Yet, few studies have attempted to investigate predictive factors to identify the 
long-term development of symptoms following MTBI (R. M. Ruff et al., 2009). A 
comprehensive review emphasized the need for research to develop predictive tools to identify 
risk for poor outcomes post-MTBI (R. Ruff, 2005). Furthermore, as Lingsma et al. (2014) has 
pointed out, “explication of the psychobiological mechanisms that underlie behavioral symptoms 
in MTBI survivors is a critical first step to improve risk assessment, and ultimately prevent 
and/or better manage post-MTBI behavioral symptoms” (Lingsma et al., 2014). The 
pathogenesis of psychological long-term outcomes following MTBI is not fully understood.  
Genetic variants might contribute to the development of psychological long-term 
outcomes in patients with MTBI. Studies that focused on the relationship between behavioral 
outcomes and genetic variants following MTBI are limited and it still remains unknown as to 
whether the genetic variants could be used to predict adverse psychological outcomes post-
MTBI. Thus, it presents a fruitful area of research, in view of the fact that although experiences 
of MTBI patients are described in literature, there is lack of evidence to guide health care 
providers to identify which MTBI patients are at greater risk for behavioral symptoms. 
Explication of the psychobiological mechanisms that underlie behavioral symptom expression in 
MTBI survivors is a critical first step that will improve risk assessment and ultimately lead to 




that the recovery from MTBI is a nonlinear process and the time-frame for complete recovery, 
for some, may endure for months and years or never be achieved (R. M. Ruff, 2011). First there 
is a need to develop standardized behavioral measures linked to behavioral symptoms, which 
would greatly benefit MTBI patients by attending to those who are at risk for behavioral 
symptoms at their early stages of treatment. Furthermore, since it is shown in many studies that 
the behavioral outcomes seem to be independent of severity of injury, it is therefore useful to 
examine the role of other unique factors of MTBI, such as genetic variants which may contribute 
to the development or susceptibility of persistent behavioral symptoms clusters. Researchers 
have suggested and highlighted the need for the development of prognostic models of MTBI that 
will serve the symptomatic subgroups of MTBI patients that warrant elucidation (McMahon et 
al., 2014). 
Genetic variants and symptoms clusters. Genetic variants may contribute to risk for 
clustering of behavioral symptoms (depressive mood, fatigue, and poor sleep) following MTBI. 
Yet most studies to date have not evaluated whether genetic variants predict a more intense 
and/or prolonged clustering of these behavioral symptoms. Further, genetic association analyses 
suggest that certain common single nucleotide polymorphisms (SNPs) may negatively influence 
recovery from MTBI (Feng et al., 2015; Lanctot et al., 2010; McAllister et al., 2005; McAllister 
et al., 2008; Pap et al., 2012; Roetker et al., 2012). It is possible that certain SNPs may 
predispose individuals to experience persistent behavioral symptom clusters after MTBI, further 
impeding recovery. Identification of such associations will permit earlier intervention for those at 
risk for behavioral symptoms clusters. McAllister et al. (2005) found that rs1800497 allele status 




McAllister et al., 2008). Subsequently, others examined the influence of the (C/T) SNP 
rs1800497 on post-TBI outcome using data from two multicenter studies: the Citicoline Brain 
Injury Treatment trial and the TRACK-TBI Pilot. Findings showed that the ANKK1 T/T 
genotype is related to poorer verbal learning performance at six months post-TBI(Yue et al., 
2015). Previous evidence also suggests that SNPs play a role in predisposing patients to 
depression (Feng et al., 2015; Pap et al., 2012; Roetker et al., 2012) and also may explain 
differential response to treatment (Lanctot et al., 2010). The identification of these genetic 
variants may shed light on the mechanisms involved in treating non-response and lack of 
tolerance to treatment in TBI patients (Lanctot et al., 2010).  
Moreover, depression has been linked to inflammation and has been strongly associated 
with increased inflammatory cytokines (Haroon et al., 2012; A. H. Miller et al., 2009), and there 
is possibly interaction between SNPs and inflammatory cytokines (Lotrich, Albusaysi, & Ferrell, 
2013). Thus, patients with Val/Met polymorphisms rs6265 are at greater risk for inflammatory 
cytokine-associated depression, where Val66Met BDNF polymorphism (rs6265) and BDNF 
levels have been associated with depression (Lotrich et al., 2013)—notably, the distinct genetic 
variant APOE genotype (Feng et al., 2015) and polymorphism (e.g., rs6265) (Lotrich et al., 
2013), The variants rs1800479 (Roetker et al., 2012) and rs4680 (Nyman et al., 2011; Pap et al., 
2012; Vrijsen et al., 2014) may aid in predicting distinct sets of depression symptoms (Lotrich et 
al., 2013), greater treatment response and tolerability (Lanctot et al., 2010), and/or occurrence of 
intense adverse events (Lanctot et al., 2010) . SNPs, therefore, are viable targets for improving 




Additionally, SNP rs6311 is correlated with fatigue and reveals allele-specific binding of 
a transcription factor at that serotonergic system locus.(A. K. Smith et al., 2008). Meanwhile, 
SNP rs6311 can affect both transcription factor-binding and promoter methylation, and this 
along with stress response can influence the rate of HTR2A transcription in a genotype and 
methylation-dependent manner. This highlights the importance of molecular determinants of 
transcriptional regulation of major genes and the medical importance of integrating functional 
genomics (Falkenberg, Gurbaxani, Unger, & Rajeevan, 2011). Since previous studies focused on 
TBI in general, it is thus the purpose of this project to explore which SNPs are associated with 
more intense and/or persistent behavioral symptom cluster (depressive mood, fatigue, and poor 
sleep) post-MTBI, which may negatively influence recovery. Thus, there is a need to explore the 
linkage of the SNPs to vulnerability for more intense and enduring depressive symptoms—
fatigue and poor sleep—common behavioral symptoms which may share a similar inflammatory 
etiology in individuals following MTBI.  
In conclusion, several SNPs have been proposed in earlier studies, yet there is a need for 
replication or validation that the SNPs may be useful in the clinical setting. Genetic variants 
underlying behavioral symptoms clusters might eventually aid in predicting prognoses and 
responses to treatment. Therefore, investigation of these biomarker genetic variants (SNPs) may 
provide a valuable means to predict persistent and lingering behavioral symptoms in MTBI 
patients. This investigation is significant because it will fundamentally advance knowledge of 
behavioral symptoms in the subgroup of MTBI patients, as well as the genetic variants and their 





Clinical Implications and Future Directions 
Clinical Implications  
One of the important contributions of the symptom clusters analysis is that in addition to 
profiling subgroups, it also to a certain extent reveals symptom interrelationships (Aktas et al., 
2010). This notion primarily facilitates in exploring the influence of symptoms on each other, 
and aids in tailoring specific treatments accordingly. Historically, clinicians and researchers 
acknowledged the multiple, concurrent symptom-experience reality and highlighted the literature 
gap posited by the single-symptom focus of the majority symptom-management research, which 
led to the development of the concept of symptom clusters (Barsevick et al., 2006; Dodd et al., 
2001). This conceptualization of symptom clusters is visualized as a paradigm shift in the 
symptom management research, which addresses the reality of the concurrent symptoms 
experiences in different populations and is supposed to lead to more promising research that will 
potentially generate knowledge needed for rapid improvement in symptom management. The 
shift helped bridge the gap between research and bedside nursing by addressing symptoms (as a 
cluster), which is the most common reason that individuals seek healthcare (Larson et al., 1994).  
Furthermore, advancing the knowledge regarding symptom interrelationships within a 
cluster might overall help manage symptoms, ultimately leading to reducing symptom burden 
(Aktas et al., 2010). A more recent study demonstrated that military MTBI patients with a self-
reported history of an MTBI who completed multidisciplinary treatment reported a reduction in 
both persistent post-concussive and PTSD symptoms (Janak et al., 2015). Thus, it is hoped that 




practice guidelines, and ultimately provide patients with the most effective and innovative 
treatment modalities (Barsevick et al., 2006; Dodd et al., 2001; Kim & Abraham, 2008).  
Additionally, enhanced understanding of cluster symptoms related to the development of 
specific cognitive profiles of MTBI patients would allow for the development of future 
rehabilitation programs that target specific cognitive deficits. Furthermore, clinicians will 
identify patients at risk for poor cognitive and functional outcomes based on post-MTBI 
symptoms experiences/presentations (perhaps symptom clusters), which will allow tailoring 
earlier interventions to better serve this population promoting better quality of life. 
Moreover, the above-mentioned paradigm shift will potentially help in identifying 
underlying mechanisms such that treating the mechanism may relieve or prevent several different 
symptoms. Specifically, this may lead to new discoveries at the molecular level of genetics-
epigenetic and inflammation-cytokines:  
Implications for Genetics and Epigenetics  
Epigenetic modifications have revitalized the interest in the interaction between the 
environment and the genome. Results from numerous studies demonstrate that the environment 
influences epigenetic modification. However, a key feature that distinguishes epigenetic 
modifications from genetic changes is their reversible nature that provides opportunities for 
identification of a multitude of preventive and/or therapeutic interventions for a disease across 
the lifespan. It also ascertains the fact that our genes are not our destiny (Stein, 2012). Further 
knowledge and understanding regarding epigenetic modifications may help in identifying 
susceptibility for certain diseases through categorization of molecular mechanisms that are 




changes in methylation caused by factors such as diet, chemicals in the environment, and 
relational experiences during early development, including the quality of caregiver-infant 
interactions (Hochberg et al., 2011).  
The development of interventions will aid in adjusting the influence of the environment 
upon the genome while reversing and/or preventing epigenetic modifications in order to improve 
health and quality of life. There are several behavioral, nutritional, and pharmacological 
strategies that may target adverse epigenetic marks with the potential for reducing the risk of 
diseases over the human lifespan.   
First of all, behavioral therapies could be exploited to alleviate stress and other adverse 
environmental factors that may potentially lead to epigenetic modification. For example, exercise 
can result in weight loss and help provide resistance to stress-induced chromatin remodeling 
within the brain. It has been shown that rats that were exposed to greater physical activity prior 
to stress exposure exhibit resistance to stress-induced chromatin remodeling within the dentate 
gyrus (Bilang-Bleuel et al., 2005). These findings demonstrate that stress-related learning results 
in hippocampal chromatin remodeling, which may facilitate behavioral adaptation to 
environmental changes. This presents an opportunity for the exploration of other behavioral 
lifestyle changes that could aid in the prevention or restoration of epigenetic modification 
(Mathews and Janusek, 2011).  
Recently, Yehuda et al. (2013) examined the association between methylation of the GR 
and FKBP5 genes, downstream neuroendocrine measures, cortisol, and NPY, and before-and-
after prolonged exposure psychotherapy in combat veterans with PTSD (n = 8). The purpose was 




and FKBP51 genes would predict or correlate with treatment outcome (prolonged exposure 
psychotherapy) in these patients. Blood samples were analyzed for methylation at three-time 
points (pre-treatment, 12 weeks post-treatment and 3-month post-treatment follow-up). In 
addition, glucocorticoid receptor (GR) activity (i.e., plasma and 24-hr. urinary cortisol, plasma 
ACTH, lymphocyte lysozyme IC50-DEX, and plasma neuropeptide-Y) was assessed. Findings 
revealed that the methylation of the GR gene (NR3C1) exon 1F promoter at pre-treatment 
predicted treatment outcome. On the other hand, methylation of the FKBP5 gene (FKBP51) exon 
1 promoter region decreased in association with treatment, but was not predictive of treatment 
outcomes. These results denote that specific genes can be correlated with prognosis and 
symptom state. Although these preliminary results require replication and validation, they 
support research indicating that some glucocorticoid related genes are subject to environmental 
regulation throughout lifespan, and also that psychotherapy treatment may alter epigenetic state 
through environmental regulation. This is the first longitudinal study of an epigenetic alteration 
in association with behavioral treatment outcomes. This study represents an important initial step 
in establishing relevant molecular markers for PTSD therapies (Yehuda et al., 2013), and perhaps 
injury-related traumatic events that results in MTBI. 
It is widely known that epigenetic modification is reversible. This makes modulation of 
epigenetic states a potential therapeutic option for cancer and other diseases (Corpet & 
Almouzni, 2007). A number of agents that alter patterns of DNA mythelation are being tested in 
clinical trials (Egger, Liang, Aparicio, & Jones, 2004) along with ongoing research for agents 
that can inhibit methyltranferases directly to target other epigenetic regulators (Corpet & 




therapies that have shown positive anti-tumorigenic effects for some malignancies. These 
epigenetic therapies could include several inhibitors of enzymes controlling epigenetic 
modifications through DNA methyltransferases and histone deacetylases (Egger et al., 2004). 
Finally, the development of more specific agents capable of targeting discrete brain regions is 
another area that needs more research (Mathews & Janusek, 2011). 
Implications for Cytokine Brain-Signaling   
Several symptoms (e.g., pain, sleep disruption, and fatigue) can result from the persistent 
release of cytokine as a response to inflammation; thus, specific treatments aimed to block the 
cytokine production would have a direct effect on symptoms relief. Furthermore, the model of 
cytokine-induced depression provides valuable insights into the relationship between cytokines 
and depression (Dantzer, 2009). Clinicians may explore the implications of sickness behavior 
related to depression and specific disease-related symptoms. Nurses would benefit from 
awareness and understanding of the relationship between pro-inflammatory cytokine and 
sickness behaviors. Enhanced knowledge in this arena will aid nurses in assessing and 
identifying vulnerable patients at risk for these sickness behavior symptoms. Additionally, nurses 
can participate in educating patients to promote quality of life.  
There are several interventions that can interrupt the cytokine brain-signaling pathway, 
such as pharmacological and non-pharmacological interventions. First, for pharmacological 
interventions, there is a crucial need for the discovery and the development of novel 
antidepressant drugs that target the brain immune system or its secondary consequences of 
activating IDO or the enzymes responsible for degradation of kynurenine. These neural circuits 




function that may link cytokine-evoked changes in synaptic plasticity to translatable measures of 
specific behavioral impairments observed in depressed patients (Piser, 2010). For example, the 
administration of insulin-like Growth Factor-I into the lateral ventricles of the brain inhibits 
sickness behavior induced by a central injection of LPS (Dantzer, Gheusi, Johnson, & Kelley, 
1999). Furthermore, evidence shows that central administration of IGF-I decreases depressive-
like behavior and brain cytokine expression in mice (Park, Dantzer, Kelley, & McCusker, 2011). 
The anti-depressant activity of IGF-I may have clinical implications for psychiatric conditions 
with or without the presence of inflammatory diseases (Park et al., 2011). Park et al. (2011) 
conducted a study to investigate the extent to which central IGF-I would impair the development 
of depressive-like behavior by tempering the neuro-inflammatory processes within the brain. 
Additionally, they examined the extent it would do so by inducing expression of the brain-
derived neurotropic factor while decreasing pro-inflammatory cytokine expression in the brain. 
Their results revealed that the central IGF-I significantly impaired development of depressive-
like behavior in LPS-challenged mice by an anti-inflammatory response in the brain, which in 
turn decreases the expression of inflammatory proteins in naïve and LPS-challenged mice. In 
other words, these findings showed how IGF-I down-regulates glial activation and induces 
expression of an endogenous growth factor that shares anti-depressant activity. This is the first 
study which evaluated IGF-I for anti-depressive actions within the brain, which forms the basis 
for future studies defining the mechanism for IGF-I’s anti-depressant activity in humans (Park et 
al., 2011). 
Another example is the use of anti-cytokine therapies for depressed mood. In a large 




psoriasis showed significant improvement in depressive symptoms independent of symptoms 
related to the disease etiology (Tyring et al., 2006). Furthermore, in a small double-blind 
placebo-controlled trial, a COX-2 inhibitor administered to healthy patients with major 
depression increased the antidepressant efficacy of the norepinephrine reuptake inhibitor (Muller 
et al., 2006). These implications emphasize the importance and significance of targeting 
signaling pathways of cytokines to enhance antidepressant activity. Additionally, chemokines, 
such as MCP-1, which can attract monocytes to multiple tissue sites including the brain, enable 
inflammatory responses (D'Mello et al., 2009). These is another class of targets that have unique 
applicability to behavioral disorders associated with increased inflammation (Capuron & Miller, 
2011). Finally, the cytosolic enzyme indoleamine 2, 3-dioxygenase (IDO) can be manipulated to 
treat a range of chronic inflammatory diseases. There are studies of IDO inhibitors to improve T 
cell activity in inflammatory states and cancer, thus indicating broad interest in the development 
of pharmacologic agents that target IDO (Johnson, Baban, & Mellor, 2009). These are some 
examples of the development of pharmacological interventions relevant to immuno-biology and 
neurobiology, which emphasize the need for implication, and support opportunities for 
collaborative effort between disciplines to advance the understanding of the mind-body 
connection (Capuron & Miller, 2011) 
For non-pharmacological interventions, the immuno-modulatory and anti-inflammatory 
effects of specific nutritional factors help prevent or modulate neuropsychiatric symptomatology 
in chronic low-grade inflammation using nutritional interventions. For example, polyunsaturated 
fatty acids are essential nutrients and essential components of neuronal and glial cell membranes 




cytokine production. For example, n-3 fatty acids are anti-inflammatory, while n-6 fatty acids are 
precursors of prostaglandins. Inappropriate amounts of dietary n-6 and n-3 fatty acids can lead to 
neuro-inflammation because of their abundance in the brain. However, future investigations need 
to account for the two key enzymes in the metabolism of polyunsaturated fatty acids such as 
phospholipase A2 (PLA2) and cyclooxygenase 2 (COX2). These enzymes have significantly 
crucial roles in cytokine-induced depression. Elucidation of the genetic variations in the COX2 
and PLA2 genes increase the risk of IFN-alpha-induced depression, possibly by affecting the 
levels of docosahexaenoic and eicosapentaenoic acid (K. P. Su et al., 2010). 
Additionally, the abovementioned vulnerability features may help in using cytokines as 
markers for prediction of patients at risk for depressive symptoms, as well as a guide in the 
development of interventions to prevent the occurrence of depression and improve life. For 
example, since obesity is correlated with low-grade inflammation status (Perry, 2004), weight 
loss intervention will benefit obese vulnerable patient accordingly. Finally, it is well established 
that stress predisposes laboratory animals and humans to activate the inflammatory response (A. 
H. Miller et al., 2009). Behavioral interventions focused on stress management, as well as coping 
strategies that adjust sympathetic and parasympathetic tone (e.g., meditation, behavioral 
cognitive therapies, and yoga), should also be implemented and considered for further research. 
In conclusion, advancing the knowledge regarding the interrelationships among 
symptoms and addressing their influence on cognitive and functional outcome will pose 
important implications for clinical practice through development of specific innovative-





Future Directions and Research 
The evidence described in this paper reveals the increasing knowledge regarding the 
body-to-brain communication, but there is a need to increase such evidence in human paradigms 
for translation to clinical practice. Furthermore, the neurobiological mechanisms underlying the 
behavioral effects of pro-inflammatory cytokines have not been investigated in a manner that 
correlates a given behavioral effect of a cytokine to a specific action in a well-defined area in the 
brain. For this reason, micro-pharmacology experiments that target inflammatory mediators in 
specific brain areas must be implemented to define the cause-effect relationships (Dantzer et al., 
2008). The identification of the intracellular association between inflammation and depression 
will provide valuable targets for the development of new antidepressant drugs if the activation of 
brain pro-inflammatory cytokine signaling is proven to represent the final common pathway for 
the various conditions that lead to depression (Dantzer et al., 2008). 
Investigation of the responses of acute circulating inflammatory markers is a fruitful area 
which may provide insight into the role of psycho-neuro-immunological processes in patients. 
Additionally, standardization of appropriate markers of inflammation and a systematic approach 
for investigation of the risk factors will improve outcomes and quality life. Furthermore, it is 
possible to develop clinical trials aimed at blocking cytokine production or action, attenuating 
the production of second messengers, or deactivating glial cells which produce excessive 
quantities of pro-inflammatory cytokines. More research is needed in this area to enhance its 
innovative potential and avoid the duplication of efforts likely to occur because of the diversity 
of pathological conditions that lead to non-specific clinical signs of sickness behavior (Dantzer 




Taken together, future studies are warranted to illuminate the precise effects of certain 
cytokines and explore targets for interventions and therapies. For example, the potential targeting 
of inflammatory pathways for depression treatment, such treatments can provide valuable 
starting points for the identification of vulnerable subgroups of depressed patients who may be 
most appropriate for immune-targeted therapies. For example, the potential targeting of 
inflammatory pathways for depression treatment can provide valuable starting points for the 
identification of vulnerable subgroups of depressed patients who may be most appropriate for 
immune-targeted therapies. Finally, findings from warranted studies can lead to the development 
of feasible effective interventions aimed at identifying patients at risk for sickness behaviors, 
preventing or decreasing the negative effects of cytokine-induced inflammatory responses to 
improve outcomes of quality of life. 
Environmental exposures have been shown to affect the activity of the methylation 
machinery, and would also lead to behavioral and mental pathologies. Future studies should 
address and explore the specific mechanisms responsible for the observed epigenetic drift of MZ 
twins. Such studies can provide key insights into the impact of environment-gene interaction on 
behavior and vulnerability to diseases over the human lifespan. In conclusion, it is likely that 
epigenetic patterns affect and/or contribute to the relationship between the environment and 
human health (Mathews & Janusek, 2011). The good news is that evidence shows that epigenetic 
modifications are reversible; the supportive evidence addressed earlier opens a window for a 
variety of novel epigenetic-based interventions that could be implemented at periods of 




More specific to symptom clusters paradigm shift, in order to address gaps in the 
literature, identification and comparison of symptom clusters within the MTBI population is 
warranted with the consideration of profiling subgroups and identifying those who are at risk for 
intense behavioral symptom clusters while accounting for influencing factors causing symptom 
clusters and assessing symptom intensity overtime. It has been long emphasized that longitudinal 
research regarding post-discharge cognitive impairment in MTBI patients is needed, as it is 
possible that persistent intense behavioral symptoms sustain cognitive and functional outcomes 
in the absence of long-term structural damage (Bernstein, 1999). These studies will help inform 
the development of the most appropriate and treatment approaches for MTBI patients with 
persistent intense symptoms and poor cognitive and functional outcomes. Following the aims of 
the TRACK-TBI initiative, it is hoped through this current secondary analysis that we will help 
in identifying if symptom clusters account for variability in cognitive and functional outcomes 
post-MTBI.  
The aforementioned clinical implications are suggestive of the need for more future 
prospective studies of symptom management designed to identify components of specific 
innovative therapeutic interventions that will be collaborative and multidisciplinary and will 
specifically contribute to symptom reduction and improvement of cognitive and functional 
outcomes. Then, future research will call for further investigation of the prevalence of cognitive 
impairments after the reduction or elimination of symptoms. 
The evidence reveals the increasing knowledge regarding genetic-to-brain 
communication, but again there is a need to increase such evidence in human paradigms for 




sustain injury, like MTBI. Further, preliminary evidence also suggests that specific pre-existing 
genetic variants may predispose certain individuals to more persistent behavioral symptoms post-
injury. Determining the extent to which genetic variants contribute to the symptomatology of 
depression, fatigue, and poor sleep in MTBI patients can lead to novel biomarkers to predict 
behavioral symptoms as early as possible. The identification of these genetic variants may shed 
light on and aid development of viable targets in predicting distinct sets of behavioral symptoms, 
and eventually help in genetic-targeted intervention tailored for greater treatment response and 
tolerability, and improvement of resiliency against developing inflammatory cytokine-associated 
behavioral symptoms. 
Collectively, the compelling evidence provides impetus for further exploration in the 
genetic and PNI paradigm. The possibility that symptom clusters might participate directly or 
indirectly in the symptomatology of cognitive impairment in trauma patients is fascinating and 
worth further investigation. This is especially so due to the lack of evidence about predicting 
symptom clusters in MTBI patients. Investigation of genetic variants might provide valuable 
information for the prediction of symptom clusters as early as possible in MTBI patients. As 







Review of the Study Purpose, Research Questions, Aims, and Hypotheses 
In summary, the long-range objective of this research is to develop novel approaches to 
predict risk for behavioral symptoms in mild traumatic brain-injured (MTBI) patients at 
discharge from the emergency department (ED). The outcomes of the proposed study will build a 
foundation to establish clinically based strategies to identify MTBI patients at risk and to target 
interventions to reduce behavioral symptoms and improve quality of life in trauma survivors and 
their families. Thus, there is strong rationale for this research in its potential to improve long-
term outcomes for MTBI survivors who overcome their acute injury but who remain at risk for 
chronic and disabling behavioral symptom clusters.  
The central hypothesis is the following: There will be differences in cognitive and 
functional outcomes in patients at six months post-MTBI based on inflammation-related 
behavioral symptoms (depressive symptoms, fatigue, and poor sleep), independently or as a 
cluster; and there will be differences in behavioral symptoms at six months post-MTBI based on 
SNP phenotype. The evaluation of inflammation-related behavioral symptom clusters post MTBI 
with respect to outcomes and genetic variants is an innovative approach that can result in novel 
predictive biomarkers for early risk assessment. Thus, there is strong rationale for the proposed 
research, which can improve long-term outcomes for MTBI survivors who overcome their acute 




Specific Aims and Hypotheses 
Aim 1: Identify different behavioral profiles of MTBI patients based on the intensity of 
depressive mood, fatigue, and sleep quality. Hypothesis 1: There will be individual differences in 
the profiles of MTBI patients based on the intensity of depressive mood, fatigue, and poor sleep. 
Aim 2: Determine whether there are differences in cognitive and functional outcomes at 
six months post-MTBI among the identified behavioral cluster profiles.        
Hypothesis 2:  There will be differences in cognitive and functional outcomes at six 
months post-MTBI among the identified behavioral cluster profiles. 
Aim 3: Explore differences in the intensity of behavioral symptoms at six months post-
MTBI based on SNP genotype.  
Hypothesis 3: There will be differences in behavioral symptoms at six months post-MTBI 
based on SNP genotype. 
Research Design and Methods 
Research Design 
  This investigation was a secondary data analysis of the database from the International 
Traumatic Brain Injury Initiative (TRACK-TBI), which previously recruited TBI patients from 
two level I trauma centers. Transforming Research and Clinical Knowledge in TBI (TRACK-
TBI) study (NCT01565551) is a prospective cohort study of all TBI patients presenting to one of 
two level I trauma centers with in-house neurosurgical coverage(Dams-O'Connor et al., 2013; 
McMahon et al., 2014; Yue et al., 2013). Institutional review board approval was obtained for 
this study from the participating institutions. For the secondary data analysis, approval was 




Participants in the original TRACK-TBI study completed a battery of psychometric and 
health-related instruments and provided a blood sample for genetic analysis; these data were 
available to accomplish the aims of the present study. Latent cluster analysis was used to 
evaluate the differences in functional and cognitive outcomes at six months post-MTBI with 
respect to behavioral symptom cluster (depressive mood, fatigue, and poor sleep.  
Sample and Setting 
 From the TRACK-TBI database, a convenience sample (n=304) of male and females (ages 
>18years to 85 years) who suffered external force trauma to the head, and who had an MTBI 
with classification by emergency department arrival Glasgow Coma Scale (GCS) is as follows: 
mild (GCS 13–15, TRACK-pilot has 83 % mild) was selected. Only individuals who completed 
the three- and six-month follow-ups were eligible.  
Sample size. That primary study enrolled a total of 600 TBI patients; 340 of which 
suffered MTBI and who were thus considered for potential inclusion in the current study. Six 
hundred TBI patients were enrolled in the TRACK- TBI Pilot study. However, of these, 68 cases 
were excluded because of Glasgow Coma Scale < 13 upon arrival to the ED; 17 cases were 
excluded because of a reported LOC > 30 minute; 13 cases were excluded because of reported 
PTA > 24 hours; and 76 cases were excluded because of assault as mechanism of injury and 
reported injuries inflicted by other persons or resulted from domestic violence. Then 31 cases 
were excluded because of serious psychiatric disorders that interfere with outcome assessment. A 
sample of N=340 who suffered MTBI and who met the inclusion criteria were considered for 
potential inclusion in the current study. However, 139 MTBI patients had missing data and 




Also, of the sample that met the inclusion criteria (n=340), 187 MTBI patients had missing data 
and uncompleted biological data, and so the final sample for Aim 3 consisted of 153 patients.  
Sample Characteristics 
 Sample. A convenience sample of male and females (ages >18 years) who suffered 
external force trauma to the head, an MTBI with classification by emergency department arrival 
GCS as follows: mild (GCS 13–15, TRACK-pilot has 83 % mild), and who have completed the 
three- and six-month follow-ups.  
 Sample inclusion criteria. Concussion/MTBI patients who suffered minor injuries who 
were alert, oriented, read, write and speak English. All races are included. Mechanisms of injury 
to be included are the following: motor vehicle accident, motorcycle/bicycle accident, pedestrian 
struck by vehicle, struck by/against object, falls, and other accidental causes of injury. 
 Exclusion criteria. Patients who had history of sleep apnea, cognitive impairment, and/or 
serious psychiatric and neurologic disorders that interfere with outcome assessment were 
excluded. Individuals who suffered assault as mechanism of injury in which other persons 
inflicted the injury or if the injury resulted from domestic violence were excluded. Covariates 
(age, race, education, gender, demographics, and injury/health history) were controlled 
statistically. 
Data Collection & Management 
The Study Procedure and Recruitment  
 The Transforming Research and Clinical Knowledge for Traumatic Brain Injury (TRACK-
TBI) is a series of two large-scale prospective multicenter observational trials for improving TBI 




(ClinicalTrials.gov Identifier: NCT01565551, 2010–13) consisted of three centers and collected 
data from 600 TBI patients from April, 2010 until December, 2013 with a primary completion of 
data collection on August, 2012. This secondary data analysis used only data derived from the 
pilot study.  
 The TRACK-TBI project applies the official NIH/NINDS TBI Common Data Elements 
(TBI- CDEs) and standardized collection protocols for bio-specimens (Diaz-Arrastia et al., 
2014), imaging (Yue et al., 2013; Yuh et al., 2013; Yuh et al., 2014), and neurocognitive and 
neuropsychiatric outcome metrics (Dams-O'Connor et al., 2013). These processes have been 
expanded upon in the current TRACK-TBI study (ClinicalTrials.gov Identifier: NCT02119182, 
ongoing 2014–18) funded for 11 centers with goals of an estimated enrollment of 3000 TBI-
patients from February 2014 until August 2018 (estimated study completion date). 
 The TRACK-TBI pilot study was conducted by UCSF/SFGH. Patients were asked to 
participate in the study if they suffered a traumatic brain injury (TBI) within the preceding 24 
hours and had had a CT scan completed at San Francisco General Hospital as part of their 
clinical care. The main study procedures took place at SFGH and the UCSF China Basin 
Imaging Center. Upon enrolment, medical information regarding the injury was obtained from 
SFGH medical record and general history were obtained from the patient as well. SFGH medical 
record, including your CT scan were reviewed. The study consisted of five components and the 
entire study required approximately five hours over the course of six months: 
(1) Component 1 (Case Report Forms) takes approximately 30 minutes after enrollment. 
(2) Component 2 (blood draw) will take 10 – 15 minutes after enrollment. 




(4) Component 4 (three-month follow-up phone call) takes up to 30 minutes included 
functional and neuropsychological questionnaires. 
(5) Component 5 (six-month follow-up phone call or meeting here at San Francisco General 
Hospital) takes approximately 2–3 hours and included behavioral symptoms and 
cognitive impairments questionnaires. 
Study Variables Instrumentations with Psychometric Evidence 
For this secondary data analysis, genetic variants (i.e., SNPs) and symptoms cluster of 
behavioral symptoms (i.e., fatigue, depression and sleep) were the main independent variables. 
The dependent variables are the functional outcomes, cognitive outcome (i.e., nonverbal 
processing speed, mental, and verbal learning), and quality of life outcomes. Also, behavioral 
symptoms included were the following: Post-Traumatic Stress Disease (PTSD), somatization, 
depression, and anxiety. In addition, this study controlled for the following confounding 
variables: history of depression and anxiety. These variables were clearly and explicitly linked to 
the framework and aims of the study.  
In this section, conceptual and operational definitions will be addressed for each variable 
along with corresponding measurement instruments, which are utilized in quantitative research 
for the purposes of quantifying phenomenon to resolve research questions and inquiries. 
Researchers acknowledge that inappropriate measures can lead to inaccurate data (DeVellis, 
2012). As such, evaluation of measurements is essential. Although it might be time consuming, 
evaluation helps to prevent problems and errors that could result from the selection and use of 




Therefore, the purpose of this section is to review the measurements used in this research. Table 
1 lists study variables, and Table 2 list instruments and time points (refer to Appendix B). 
Biological Measures 
Serum Sample Collection and Biomarker Measurement 
 The blood samples for DNA genotyping analysis for TRACK-TBI Pilot patients were 
collected within 24 hours of injury, processed and stored in a -80°C freezer within two hours of 
collection, as previously described (Manley et al., 2010). Specimen acquisition is previously 
described (Yue et al., 2013), detailed protocols for collection, processing, and shipping of blood 
bio specimen, developed for the TRACK-TBI pilot are available on the NINDS TBI-CDE 
website (TBI Standards–NINDS Common Data Elements, 2016). The TBI-CDE bio specimens 
protocol was used effectively to collect, process, and store blood bio specimens for proteomic 
and genetic analyses (Manley et al., 2010). 
In brief, blood samples for DNA genotyping analysis were collected via peripheral 
venipuncture or existing peripheral venous indwelling catheters within 24 h of injury. Samples 
were collected in BD Vacutainer K2-EDTA vacutainer tubes, and subsequently aliquoted and 
frozen in cryotubes at −80 °C within 2 h of collection in accordance with recommendations from 
the NIH-CDE Biomarkers Working Group (Manley et al., 2010). DNA was extracted then the 
Single nucleotide polymorphisms (SNPs) (rs1800497 (ANKK1) rs1799971 (OPRM1), rs279836 
(GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT) was genotyped 
(please refer to Table 3). SNPs are variations at a single position in a DNA sequence among 
individuals and patients were categorized by genotype, and each SNP was categorized into the 




 SNP rs1800497 (ANKK1) categorized into 3 groups (A1/A1, A1/A2, and A2/A2). 
 SNP rs1799971 (OPRM1) categorized into 3 groups (A/A, A/G, and G/G). 
 SNP rs279836 (GABRA2) categorized into 3 groups (A/A, A/T, and T/T). 
 SNP rs279845 (GABRA2) categorized into 3 groups (A/A, A/T, and T/T). 
 SNP rs279871 (GABRA2) categorized into 3 groups (C/C, C/T, and T/T). 
 SNP rs4680 (COMT) categorized into 3 groups (Met/Met, Met/Val, and Val/Val). 
Functional Outcomes 
Glasgow Outcomes Scale—Extended (GOS-E). Global functional outcome and 
functional dependence was assessed using the GOSE (Jennett, Snoek, Bond, & Brooks, 1981; 
Shukla, Devi, & Agrawal, 2011; Wilson, Pettigrew, & Teasdale, 1998). GOSE is used with 
patients 18 years and older, and includes eight questions with subparts. Research assistants 
trained to uniformly assess the GOS-E administered the GOSE at three and six months post-
MTBI through structured phone-interview with each participant, employed to measure the 
impact of the TBI on the patient’s level of functioning. The GOSE is a multi-dimensional scale 
(depression, anxiety, and somatization subscales), which assesses various aspects of functional 
outcome. Specifically, it measures patient’s consciousness; independence; ability to return to 
work and/or previous lifestyle including social and leisure activities, social relationships, and 
other sequelae of TBI (Wilson et al., 1998). A major strength of the GOSE as opposed to other 
functional outcomes measures is that it includes activity or participation components that 
importantly illustrate patient recovery and aids in measuring functional outcome and burden of 
illness (Nichol et al., 2011) It is a revision of the original Glasgow Outcome Scale (GOS), which 




The GOSE is considered the ‘‘gold standard’’ for assessing patient outcomes after TBI (Shukla 
et al., 2011). Another acknowledged strength of the GOSE is that it attempts to deal with the 
potential confounding effects of pre-existing factors in post-TBI patients (Nichol et al., 2011). 
 Several limitations of the GOS led to the development of the extended version; such as the 
perceived allocation bias in the higher functional end of the scale, and the ‘open ended’ and 
unstructured format of the interviews (Wilson et al., 1998). These limitations speculate the 
insensitivity of the GOS, which was addressed in GOSE by separating each of the three higher 
function categories into two (Jennett et al., 1981). The GOSE (extended version of the GOS) 
provides eight, rather than five, categories of outcome: (1) Dead, (2) Vegetative State, (3) Lower 
Severe Disability, (4) Upper Severe Disability, (5) Lower Moderate Disability, (6) Upper 
Moderate Disability, (7) Lower Good Recovery, and (8) Upper Good Recovery (Nichol et al., 
2011). Structured interviews are provided to facilitate ratings patient outcome and the 
assignment of an ordinal score of 1 to 8. The severely disabled category is indicative of ability to 
follow commands yet cannot live independently, while a moderately disabled category indicates 
the ability to live independently with reduced work capacity. Lastly, a good recovery category is 
indicative of ability to return to work to full functional capacity (Jennett et al., 1981). Overall, 
the scores are either favorable (Lower Moderate Disability, Upper Moderate Disability, Lower 
Good Recovery, Upper Good Recovery) or unfavorable (Dead, Vegetative State, Lower Severe 
Disability, Upper Severe Disability) outcomes. Thus, the Upper Good Recovery (GOS-E score 
of 8) indicates return to pre-injury baseline with no residual effects of the TBI. In general, a 
given score of 7 or more as (good recovery) is indicative of return to full functional status at 




Distinctively, the GOSE differentiates between specific aspects of functional disabilities 
within mild-to-moderate, rather than mild-to-severe TBI and it is most commonly utilized post-
MTBI global functional outcomes measure (Levin, O'Donnell, & Grossman, 1979) and there is 
an extensive literature demonstrating its reliability and validity (Nichol et al., 2011). The GOSE 
is a reliable measure with added practical usefulness advantage of the ability to be administered 
through structured phone-interview, with an interrater reliability that ranges from 0.85 to 0.89 
(Pettigrew, Wilson, & Teasdale, 2003; Wilson et al., 1998), specifically shows a good reliability 
in patients with TBI (Wilson, Pettigrew, & Teasdale, 2000). The criterion validity of the GOSE 
demonstrated that it is better and more sensitive to change than the GOS (Levin et al., 2001; 
Wilson et al., 1998). The GOSE has been shown to be associated with other functional outcome 
measures: initial injury severity, the Disability Rating Scale, and self-reported measures of health 
outcomes (Wilson et al., 2000) 
Researchers identified limitations of the functional outcome measures including the 
following: insensitivity to function outcomes, limited domains of functional assessments, 
insufficient operational definitions, lack of evaluation for unconscious patients, and the inability 
to incorporate categories of morbidity and mortality (Nichol et al., 2011; Shukla et al., 2011). 
However, the GOSE has been valued by researchers as fulfilling all criteria for a reliable and 
valid outcome scale, and is regarded in combination with neuropsychological tests as a near 
comprehensive and inclusive outcome post-TBI (Shukla et al., 2011).                       
Cognitive Outcome 
California verbal learning trial–II. The California Verbal Learning Test, Second 




A., 2000), is a verbal learning and memory task which consists of the following: five learning 
trials, an interference trial, an immediate recall trial, and a post-20 min recall trial. The CVLT-II 
Trials 1–5 Standard Score (CVLT-TSS) is normed for age and sex, and provides a global index 
of verbal learning ability (Delis D. C. et al., 2000). It was used in this current study as one of the 
measures for cognitive impairment; specifically, verbal learning at the six-month follow-up. It 
measures both recall and recognition memory (Delis et al., 2000).  
The CVLT-II consists of a word list task of 16 words that are randomly presented, each 
of which belongs to one of four categories, including animals, vegetables, ways of traveling, and 
furniture, and the participants are asked to recall them across a series of trials. The words were 
selected after careful study of their frequency of use across multiple demographic variables 
(Delis D. C. et al., 2000). The participants are instructed to recall them in any order and as many 
as they can. There are a series of recall trials, followed by a 20-minute delay, at which point 
more recall trials are given, in addition to a yes/no recognition component. Following another 
delay of 10 minutes, a forced choice recognition component of 16 items is given (Delis D. C. et 
al., 2000). The CVLT-II is known for higher reported consistency on between-norm sets 
(Stallings, Boake, & Sherer, 1995). The forced-choice an item is useful for detecting 
malingering, thereby helping to reduce false results. In addition to recall and recognition scores, 
CVLT–II measures encoding strategies, learning rates, error types, and other process data (Delis 
D. C. et al., 2000).  
 The recent revision of the CVLT led to improved psychometric properties (Delis D. C. et 
al., 2000; Stallings et al., 1995). The new items provide more comprehensive and inclusive 




flexibility when the Standard or Alternate Forms impractical. A Short Form can be used with 
limited exam time is limited, less detailed test information needed, fatigued patients, and/or 
severe memory or cognitive impairments. The Short Form consists of nine words in three 
categories and is administered in only 15 minutes with two delay periods of 15 minutes. 
Additionally, an alternate form can be utilized when re-testing to prevents falsely inflated scores. 
The Standard and Alternate Forms can be administered in 30 minutes, with an additional 30-
minute delay (Delis D. C. et al., 2000). 
When comparing CVLT-II Trials 1-5 Free Recall results to the norms, researchers 
provide normative data from large samples of 285 outpatients in a mixed neurologic sample with 
low executive functioning (M=34.86, SD= 16.66), medium executive functioning (M= 43.10 
SD=17.26), and high executive functioning (M= 45.02, SD=22.72) (Hill, Alosco, Bauer, & 
Tremont, 2012). 
Wechsler Adult Intelligence Scale IV (WAIS IV). The Wechsler Adult Intelligence 
Scale Processing Speed Index (WAIS IV-PSI; consists of Digit Symbol Coding and Symbol 
Search subtests) (Wechsler, 2008). WAIS-IV PSI is a test of nonverbal processing speed with 
additional contribution from working memory (Kennedy, Clement, & Curtiss, 2003; 
Lichtenberger & Kaufman, 2013; Wechsler, 2008) comprised of two nonverbal tasks (Digit 
Symbol Coding and Symbol Search subtests of the WAIS IV) which involves both visual 
attention and motor speed (Wechsler, 2008). Briefly, it measures the amount of time it takes to 
process a set amount of information, or vice versa. It is considered one of the most clinically 
culturally, racially, and ethnically sensitive cognitive measures to neurological conditions, and is 




Wechsler, 2008). The Wechsler Adult Intelligence Scale is known to have an extensive 
normative data and excellent psychometric properties (Wechsler, 2008). Researchers 
investigated the extent to which working memory, motor speed and perceptual processing speed 
influence WAIS-III-PSI scores in a sample of 68 TBI outpatients of varying severity. In 
hierarchical multiple regression analyses, findings confirmed that the WAIS-III PSI scores of 
TBI patients reflect perceptual processing speed, with an additional component attributable to 
working memory (Kennedy et al., 2003). The composite score which is used in this study refers 
to a scale that ranged from 50 to 150 to resemble a certain percentile (0.1st to 99.9th percentile) 
of performance across different age groups. For example, the 25th percentile represented a score 
of ∼90, the 50th percentile represented a score of 100, and the 75th percentile represented a score 
of ∼110 (Wechsler, 2008). However, previous research with TBI patients revealed that it mainly 
reflects cognitive impairment in perceptual processing speed with a minimal attribution to 
working memory and slight contribution from motor speed (Kennedy et al., 2003). In this 
secondary data analysis, the WAIS-PSI was used to measure one of the cognitive outcomes—
specifically, nonverbal processing speed at the six-month follow-up post-MTBI. When 
comparing WAIS-IV Processing Speed Index Composite Score results to the norms, researchers 
provide normative data for a clinical sample that scored lowest and highest on WAIS-IV 
Processing Speed Index: The means that the lowest scores included autistic disorders (M=75.1), 
traumatic brain injury (M=80.5), major depressive disorder (M=95.8), ADHD (M=94), 
intellectually gifted (M=112.4), and probable Alzheimer’s dementia-mild (M=76.6). The highest 




and reading disorder (M=94.5). WAIS-IV Processing Speed Index score between the range of 90 
and 109 are considered average (Wechsler, 2008). 
Trail-Making Test and B (TMT). In general, The TMT measures attention, speed, and 
mental flexibility (Reitan, 1958). The TMT consists of two parts, A and B, and takes about 5 
minutes to be completed, as it measures the number of seconds needed for the patient to 
complete the tasks (Reitan, 1958). These tests are used to measure neuro-cognitive performance, 
where TMT-A assesses visual processing, and TMT-B assesses mental flexibility and processing 
speed (Reitan, 1958). In this secondary data analysis, the difference score between the TMT-B 
and TMT-A—TMT B-A—was used to measure one of the cognitive outcomes; specifically, 
mental flexibility at the six-month follow-up. TMT B-A represents a purer index of executive 
control and mental flexibility separate from visual processing and motor speed (Sanchez-Cubillo 
et al., 2009). The lower the score, the higher and more improved the performance will be 
concluded. 
On both components A and B, patients are instructed to complete the task quickly and 
accurately (Reitan & Wolfson, 2004). The TMT is known for its sensitivity to cognitive 
impairment post-TBI, and it is also used extensively for its good reliability with demographically 
adjusted normative data available for a wide age range (Tombaugh, 2004). Normative data for 
the TMT A and B are presented for 911 community-dwelling individuals aged 18-89 years. 
Researchers found that the performance on the TMT decreased with increasing age and lower 
levels of education. Based on these results, the norms were stratified for both age (11 groups) 
and education (2 levels). These current norms represent a more comprehensive set of norms than 




precisely the degree to which scores on the TMT reflect impaired performance for varying ages 
and education (Tombaugh, 2004).  
For comparing TMT B-A results to the norms, with the notion that the lower score 
correlates with better performance, researchers provide normative data from large samples of 
patients with traumatic brain injury (TBI) (n=90; M=102.1, SD=80.1), and healthy controls as 
well (n=223; M=36.4, SD=35) (Perianez et al., 2007). More specifically, the groups are the 
following:  the young group 16–24 (M= 24.99, SD=23), middle-aged 25–54/education 0-12 
years (M= 38.46, SD=27.1), middle aged 25–54/education 13+ (M=27.69, SD= 15.52), and the 
elderly group 55–88 (M=56.58, SD= 38; Perianez et al, 2007). Statistical properties of the 
demographic and TMT variables for each normative group of patients with TBI were the 
following: education: 0–11 years M=135.24, SD= 106.5, education: 12+ years M=81.95, SD= 58 
(Perianez et al., 2007). 
Behavioral Symptoms 
Post-Traumatic Stress Disease (PTSD). PTSD will be measured using the PTSD 
Checklist–Civilian Version (PCL-C). The PCL is a standardized self-reported rating scale for 
PTSD, comprising 20 items that correspond to the key symptoms of PTSD. Two versions of the 
PCL exist: (1) PCL-M is specific to PTSD caused by military experiences, and (2) PCL-C is 
applied generally to any traumatic event and asks about symptoms in relation to generic 
“stressful experiences” and can be used with any population. The PCL is self-administered and 
patients indicate how much they have been bothered by a symptom over the past month/week 




It was administered at the six-month follow-up, as the PCL can be easily modified to fit specific 
time frames or events (Kaloupek et al., 2010).  
As for the PCL-C psychometric properties, a good test-retest reliability was reported after 
one week using computerized PCL-C total scores with a civilian community population with 
slightly lower reliability found using mixed administration (computer vs. paper administration) 
(Campbell et al., 1999). Researchers reported average PCL- C scores for the computerized 
administration with only 1.5 points difference. For validity, internal consistency was reported in 
14 studies investigating psychometric properties in a variety of samples (e.g., military samples, 
patients with severe mental illness, patients with HIV, women with substance use disorders, 
women treated for breast cancer, patients with recent limb loss, female undergraduates, and 
community adults), and these studies reported total score values above .75 (Wilkins, Lang, & 
Norman, 2011). The PTSD Checklist Civilian Version (PCL-C) is a widely used self-
administered screening tool for identification of patients who need further evaluation for PTSD 
(Kaloupek et al., 2010).  
 Brief Symptoms Inventory-18 items (BSI-18). The BSI-18 is a screening tool to assess 
the level of psychological distress after TBI (Meachen, Hanks, Millis, & Rapport, 2008). The 
BSI-18 a short form of the Symptom Checklist-90-R and consists of three subscales 
(somatization, depression, and anxiety) as well as a Global Severity Index. Each subscale 
contains six questions that rate the level of distress over the past seven days using a 4-point 
Likert-scale, ranging from “not at all” to “extremely often” (Meachen et al., 2008). The overall 
reliability of the GSI is high, with a kappa of 0.89 and a retest reliability kappa of approximately 




validated psychosocial and functional tests in TBI patients (Meachen et al., 2008). The BSI-18 is 
commonly used as a measure of psychological distress post TBI, and is known for its 
comprehensive psychometric characteristics (Derogatis, 2000; Meachen et al., 2008).  
 Post-concussion symptoms. Post-concussion symptoms will be measured using the 
Rivermead Post-Concussion Symptoms Questionnaire (RPQ) (King, Crawford, Wenden, Moss, 
& Wade, 1995). The RPQ consists of 16 items and patients are asked to rate the degree of 
experienced symptoms for the last 24 hours compared to symptoms prior to head injury. Items 
include symptoms such as headaches, dizziness, nausea, noise sensitivity, sleep disturbance, 
fatigue, irritability, depression, frustration, poor memory, poor concentration, taking longer to 
think, blurred vision, light sensitivity, double vision, and restlessness. It is a 5-point Likert scale 
that ranges from 0 to 4, ranging from “not experienced at all” to “ a severe problem.” The total 
RPQ score is the sum of all of the 16 symptom items. Possible total scores range from 0 (no 
change in symptoms since the injury) to 64 (most severe problems symptoms) (King et al., 
1995). RPQ has demonstrated validity and reliability in studies using classical test theory (King 
et al., 1995). A well-established internal consistency of 0.71 was reported in MTBI patients 
(Lannsjo, Borg, Bjorklund, Af Geijerstam, & Lundgren-Nilsson, 2011). The test is divided into 
the RPQ-3 and the RPQ-13, with the RPQ-3 items assessing headaches, nausea and/or vomiting, 
and dizziness that are considered to be early concussion symptoms (headaches, dizziness, and 
nausea/vomiting) typically experienced as short term outcomes post MTBI. The RPQ-13 items 
assess cognitive, mood, sleep, and other psychological symptoms (i.e., hyperacusis, sleep 
disturbances, fatigue, irritability, depressed mood, frustration, forgetfulness, poor concentration, 




(Eyres, Carey, Gilworth, Neumann, & Tennant, 2005; King et al., 1995). The separate scores for 
analysis method is known for good test-retest reliability and construct validity. The RPQ-13 is 
considered as a long-term outcome post-MTBI (Eyres et al., 2005; Potter, Leigh, Wade, & 
Fleminger, 2006; Sveen, Bautz-Holter, Sandvik, Alvsaker, & Roe, 2010), thus used in this 
secondary data analysis. It is widely known for its psychometric characteristics and capability of 
detecting clinical changes in patients post MTBI.  
Quality of Life Outcome: 
Satisfaction With Life Scale (SWLS). The Satisfaction with Life Scale (SWLS) was 
developed as a measure of the judgmental component of subjective well-being (SWB) (Diener, 
Emmons, Larsen, & Griffin, 1985). The SWLS is a series of five statements that assess current 
patient life satisfaction. Patients rank each question from 1 (“strongly disagree”) to 7 (“strongly 
agree”) (Diener et al., 1985). The total score ranges from a maximum very high score between 
30–35 indicating “highly satisfied,” high score 25–29, “slightly below average in life 
satisfaction” score between 15–19, “dissatisfied’ score between 10–14, and “extremely 
dissatisfied” score between 5–9 (Diener et al., 1985). In this secondary analysis, we used the 
SWLS as the aqality of life outcome measure.  
 The average score for economically developed nations ranges between 20–24, indicating 
general satisfaction, but with desire for improvement in certain aspects of life (Diener et al., 
1985). A cut-off value of 19 or below was used to indicate significant dissatisfaction. The SWLS 
is considered to have good reliability and validity and is believed to be an accurate measure of 
subjective wellbeing (Diener et al., 1985; Pavot, Diener, Colvin, & Sandvik, 1991). As for 




and alpha coefficients have continually exceeded .80 (Pavot et al., 1991) also in the Diener and 
colleagues examined a two-month test-retest correlation coefficients for 76 students and it was 
reported at .82. Interestingly, the SWLS is known for sensitivity to differences and consistency 
between different populations with expected different qualities of life, such as psychiatric 
patients and male prison inmates, as well as different life directions and major life-events 
changes, and in patients receiving psychotherapy (Diener et al., 1985; Pavot et al., 1991). 
When comparing SWLS results to the norms, the reported mean of for TBI patients (n = 
95, six months to five years after inpatient rehabilitation; mean age = 32.4 years) was 19 
(SD=7.6), and time post-injury was significantly associated with higher SWLS total score 
(Corrigan, Smith-Knapp, & Granger, 1998). Undergraduates at the University of Illinois who 
were enrolled in psychology classes (n = 176) had a mean score of 23.5 (SD= 6.43) (Diener et 
al., 1985). In a Turkish sample cross-sectional assessment of the SWLS, university students (n = 
547) had a mean of 21.91 (SD= 6.18), correctional officers (n = 166) had a mean of 15.68 
(SD=6.97), and elderly adults (n=123) had a mean age = 68.18 (5.10) years. In the elderly 
population, 2 reported their health as “very poor,” 10 as “poor,” 51 as “average,” 46 as “well,” 
and 14 as “very well,” with a mean of 23.82 (SD=7.44) (Durak, Senol-Durak, & Gencoz, 2010).  
Additional Variables  
Covariates. This study controlled for the following confounding variables: health 
history, pre-injury functional status, and a history of behavioral symptoms (i.e., history of 






Statistical Analysis  
The independent variables to be evaluated for this study include genetic variants (i.e., 
SNPs), and symptoms cluster of behavioral symptoms (i.e., fatigue, depression and sleep). 
Dependent variables will include functional outcomes (i.e., Glasgow Outcome Scale Extended 
(GOSE)), cognitive out-come (i.e., nonverbal processing speed assessed by Wechsler Adult 
Intelligence Scale-IV (WAIS-IV), mental flexibility assessed by the difference score between the 
Trial Making Test (TMT) B and TMT A (TMT B-A). The main independent variables in this 
study will be verbal learning assessed by California Verbal Learning Test-II (CVLT-II), and 
quality of life outcomes assessed by the Satisfaction with Life Scale (SWLS). In addition, this 
study will control for the following confounding variables through a history of behavioral 
symptoms: history of depression, anxiety, and sleep disturbance. These variables are clearly and 
explicitly linked to the framework and aims of the study.   
 Preliminary analysis will assess variable distribution, residuals for normality, linearity, 
homoscedasticity, homogeneity, and multicollinearity. Data transformations to correct for non-
normal distribution will be completed as needed. Descriptive statistics will summarize the 
sample’s general health histories, injury type, severity, and demographics. Analysis will be 
performed using the SPSS Grad Pack Mac Version 20 (SPSS, 2011). First, the assumption of 
normality and homogeneity of variances and outliers will be assessed for all outcome measures. 
Normality will be assessed by examining histogram plots and z scores, while homogeneity of 
variances will be assessed by Levene's test. All variables will be checked for skewness and 




transformations will be necessary. 
 For the first aim, Latent Class Analysis (LCA) will be used to identify profiles of MTBI 
patients based on the intensity of behavioral symptom, using items derived from the Rivermead 
Post-Concussion Questionnaire that was administered at six-months follow-up. These assess 
presence and intensity of depressive mood, fatigue, and poor sleep, and are to be completed by 
participants in the TRACK-TBI study.  
 LCA analysis will be conducted using Mplus 7.4 (Muthén & Muthén, 1998-2011) for 
running the LCA. The analysis was performed by fitting a two-class model, and gradually 
increasing the number of classes one at a time for model comparison, setting a random starting 
value arbitrarily from 500 to 100. Several criteria were used to guide the decision on the number 
of classes in mixture modeling, including the Akaike Information Criterion (AIC), the Bayesian 
Information Criterion (BIC) (Schwarz, 1978), the sample-size-adjusted aBIC, the Vuong-Lo-
Mendell-Rubin (VLMR) test (requested using TECH 11 in Mplus), and the bootstrapped 
parametric likelihood ratio test (LRT; requested using TECH 14 in Mplus). Both tests compared 
the model of the currently chosen number of classes (K) to a model of K−1 classes. For AIC, 
BIC, and aBIC, lower observed values indicate better model fit. In case of entropy, values closer 
to 1.00 suggest better fit. In addition, a nonsignificant p value for the BLMR LR test indicates 
that the model with the K-1 class is preferred to the model with K classes. The final classes were 
determined by small AIC, BIC, and aBIC values comparing each class (K) with each of the K-1 
classes, as well as nonsignificant BLMR LR and strong entropy values. 
 For the second aim, analysis of variance (ANOVA) and analysis of covariance (ANCOVA) 




differences among the predicted classes and outcome variables (functional, cognitive, and quality 
of life) at six-months follow-up. The extent to which membership in an identified cluster predicts 
functional, cognitive, and quality of life outcomes at six-months post-MTBI was explored. We 
will  assess the association between predicted classes and the three main outcomes: Functional 
outcomes assessed by Glasgow Outcome Scale Extended (GOSE), cognitive outcome and 
nonverbal processing speed assessed by Wechsler Adult Intelligence Scale-IV (WAIS-IV; 
Coding Subset Total Raw Score, Symbol Search Subset), mental flexibility assessed by the 
difference score between the Trial Making Test (TMT) B and TMT A (TMT B-A), verbal 
learning assessed by the California Verbal Learning Test-II (CVLT-II), and quality of life 
outcomes assessed by the Satisfaction with Life Scale (SWLS).  
 For the third exploratory aim, an Analysis of Covariance (ANCOVA) was performed to 
explore the extent to which SNPs predict risk for more intense behavioural symptoms 
(somatisation, anxiety, depression, PTSD, and post-concussive syndrome) at six months post-
MTB. We assessed the association between SNPs genotype and three main measures: (1) BSI-18 
(the BSI-18 is a brief screen of psychological distress with a Global Severity Index (GSI), and 
three clinical subscales: BSI-somatisation, BSI-anxiety, and BSI-depression); (2) PTSD-PCL (3 
subscales; hyper-vigilance, avoidance, Re-experiencing); and (3) the Rivermead Post Concussion 
Symptoms Questionnaire 13 (RPQ-13). For all follow-up posthoc tests, the Hochberg’s GT2 was 
used to correct for the unequal sample size (Field, 2009). 
 The outcomes of this study will build a foundation upon which to establish clinically based 
strategies to identify MTBI patients at risk for protracted recovery and to identify those who may 





Protection of Human Subjects 
The TRACK-TBI pilot study is an example of Multi-Dimensional Data Sharing, where 
multicenter patients’ data and protected health information (PHI) are collected under informed 
consent into a central, custom-designed storehouse (QuesGen Systems, Inc., Burlingame, CA). 
In order to protect the privacy of patient enrolled in the study, each patient is assigned a globally 
unique identifier (Sorani et al., 2015). The permission for access ranged from ‘no-PHI’, to ‘local 
PHI only’, to ‘full-access’. For the purpose of this secondary data analysis, a completed and 
approved research collaboration proposal was submitted to the TRACK TBI executive 
committee, which was reviewed and accepted. Then, the Data Use Agreement between the 
Regents of the University of California, on behalf of its San Francisco campus (“UCSF”) and 
Loyola University of Chicago was acknowledged and signed by the data user’s research team 
members who will access and/or analyze data. Access to TRACK-TBI and access to clinical data 
is provided to the data user for the purpose of collaboration in TBI research and will be used only 
as described in research proposal agreed upon by the TRACK-TBI executive committee and is 
data access was effective as of March, 18, 2016.  
Additionally, an approval form from the Loyola University Medical Center (LUMC) 
institutional review boards (IRB) for conducting this secondary data analysis study was obtained. 
Federally sponsored studies are subject to strict guidelines for evaluation and before undertaking 
any study; researchers need to submit their research plans to the IRB, and must also go through a 




Beck, 2008). The duty of the IRB is to ensure that the proposed plans meet the federal 
requirements for ethical research (Polit & Beck, 2008).  
This is a no-benefit project; however, there are several anticipated benefits to MTBI 
populations in the future. It is hoped that results from this study will help in identifying MTBI 
patients who are at risk of fatigue, depression, cognitive impairment, and poor sleep at discharge 
and as early as possible. Findings may stimulate the development and implementation of programs 
for early interventions with these trauma patients to prevent these symptoms and to promote better 
quality of life. 
Study Limitations 
Overall secondary data analysis has been a widespread method in promoting the 
proficiency of the health research initiative; however, there are some advantages and 
disadvantages of analyzing existing secondary data (Cheng & Phillips, 2014). The major 
disadvantage is that the available data were not collected to address the particular research 
question or to test the particular hypothesis (Cheng & Phillips, 2014). However, overall the 
purpose of the analysis is to follow the TRACK-TBI initiative to improve long-term outcomes of 
TBI patients in general. Therefore, though a limitation of this study, it is not uncommon that 
valuable confounding variables were not available for the analysis (Cheng & Phillips, 2014). 
First, the threat from confounding variables is one of the most important threats the 
investigator needs to account for. The confounding variables, as described earlier, will be 
controlled for.  
Second, another threat to internal validity was the missing data. Third, selection bias, 




one of the weakest sampling techniques and available subjects might be atypical of the 
population of interest with regard to critical variables. Selection bias is the most problematic and 
frequently occurring threat to internal validity of studies not using an experimental design (Polit 
& Beck, 2008). Fourth, the threat of history refers to the occurrence of external events that take 
place concurrently with the independent variable that can affect the dependent variable (Polit & 
Beck, 2008). A case in point is when something happens to the patient between follow-up points 
or even before enrollment that causes depression, fatigue, or poor sleep; for example, events 
such as death in the family or loss of job. Preinjury stress has been hypothesized to play a role in 
long-term maintenance of symptoms (van Veldhoven et al., 2011). For example, using the Life 
Events Scale could have assessed major life events. In fact, there is support for this notion, 
where research shows that incidence of stressful life events was a significant predictor of 
anxiety, depression, and mental health in MTBI patients. Thus, the experience of stressful events 
prior to the injury may predispose those with MTBI to suffer from lingering poor long-term 
outcomes. Assessment of stressful life events during acute stages post-MTBI is essential (van 
Veldhoven et al., 2011). Since this is a secondary data analysis, the researcher was limited and 
might not be able to overcome some of the threat. 
Lastly, the threat to instrumentation is a minor threat in the use of self- report 
questionnaires as the measure for symptoms. There were no measures for each behavioral 
symptom (i.e., anxiety, depression, fatigue, poor sleep); they were either subscales from BSI- 
GSI (i.e., BSI-Depression, BSI-anxiety, BSI- Somatization), or for the cluster analysis, the items 
that address these factors were taken from the Rivermead Post-Concussion Questionnaire that 




Generalizability is identified as a threat to external validity. According to Polit and Beck 
(2008), generalizability is the criterion used in quantitative research to assess the extent to which 
the findings can be applied to other groups and setting. The population is a sample of MTBI 
patients with a range of ethnic diversity. Despite the study limitations, this study may not be 
generalizable to all MTBI patients. However, it could provide information that will help MTBI 
patients in the future by advancing the ability of clinicians to predict those who are at greater risk 
for more intense and/or prolonged depressive symptoms, fatigue, poor sleep, cognitive 
impairment, and anxiety.  
Another threat to external validity is the relatively small size. The TRACK-TBI pilot 
phase consisted of three centers and collected data on 599 patients (only 340 MTBI patients; 
with only 201 eligible for the study due to missing data). With regard to generalizability of the 
current findings, the results are not generalizable beyond the institutions where data was 
collected and cannot be generalizable to all MTBI patients.  
 However, despite these limitations, ultimately, the knowledge acquired can be used to 
develop and implement improved risk assessment protocols for behavioral symptoms and to 
target prevention programs to those most vulnerable, and it can be tested in future intervention 
studies accordingly.  
Conclusion 
Overall, secondary data analysis has been a widespread method in promoting the 
proficiency of the health research initiative; however there are some advantages and 
disadvantages of analyzing existing secondary data (Cheng & Phillips, 2014). The most valuable 




research approaches when looking at the bigger picture of the readily available collected data 
rather than collecting primary data (Cheng & Phillips, 2014). This would inspire innovative 
usage of collected variables—for example, the use of symptom clusters analysis as a predictive 
tool for profiling subgroups enduring behavioral symptoms post-MTBI. Thus, this approach can 
bridge the gap between research and bedside nursing by addressing symptoms (as a cluster), 
which is the most common reason that individuals seek healthcare (Dodd et al., 2001). This 
paradigm shift might help better manage symptoms, ultimately reducing symptom burden (Aktas 
et al., 2010). 
The second innovative aspect are the chosen frameworks (the psycho-neuro-immunology 
(PNI) framework, the Theory of Unpleasant Symptoms (TOUS), and the genetics field) that 
guide this investigation. These frameworks can potentially lead to remarkable advancement in 
the knowledge regarding improvement of quality of life and cognitive and functional recovery 
post-MTBI and will provide insight into the role of psycho-neuro-immunological processes in 
MTBI patients. Overall, the innovative conceptualized framework creatively addresses the depth 
of the interaction between symptoms experienced and their impact on recovery outcome, and 
explains the variations seen in MTBI patients.         
 The availability of the Track-TBI Pilot database, which provided a real-life data with a 
very un-accessible population and helped in accomplishing this secondary study, will eventually 
aid in identifying new treatment modalities to improve outcome of MTBI patients that can tested 
in future intervention studies (Cheng & Phillips, 2014). 
 This secondary data analysis represents a fortunate example of clinical research 




with increased data availability, scientists from multiple fields can enjoy greater opportunity for 
novel discoveries about the brain in health and disease.” Sorani et al. (2015) add that “The ability 
to integrate clinical, genetic, imaging, and other types of biomedical data will be of tremendous 








  This chapter describes the findings from the study in the following manner.  First, the 
descriptive characteristics of the sample and all study variables are summarized.  Second, the 
results of the study aims are delineated.  As previously stated, there were three aims to this study.  
The first aim was to identify different profiles of MTBI patients based on the intensity of 
depressive mood, fatigue, and poor sleep. The second aim was to determine whether there are 
differences in cognitive and functional outcomes at six months post-MTBI among the identified 
behavioral cluster profiles. The third aim was to explore differences in the intensity of behavioral 
symptoms at six months post-MTBI based on SNP genotype.  
Data Analysis: Aim 1 
Results Summary of Sample Characteristics/Demographic Statistics 
Data for 340 MTBI patients extracted from the TRACK-TBI pilot database. Of the 
340 MTBI patients, 202 patients were included in the Latent Class Analysis (LCA) due to 
missing data. The sample characteristics of the 202 patients are described below and in Table 4.  
The majority of the sample were males (67.3%), white (99.5%) and single (50.5%), with a mean 
age of 45±18 years.  Nearly half (44.6%) of the sample worked full time (35 hours or more per 
week) and had either a High school diploma (34.7%) or Bachelor’s degree (25.7%).  Nearly 20% 
of the sample had a previous TBI (With and Without Hospital Admission).  Past history of 




respectively. Use of tobacco, alcohol, and drugs was reported by 31.7%, 51.5%, and 18.8% of 
the sample, respectively.   
Upon arrival to the ED, the majority of patients (77.7%) had a GCS of 15 and 71% 
reported LOC with varied duration (i.e., 11.4% <1 minute,35.1% 1-29 minutes, 5% 30-59 
minutes, and 20.3% unknown LOC duration). While the majority (62.4%) reported no Post 
Traumatic Amnesia (PTA), of those reporting PTA the duration was: 5.9% <1 minute, 23.8% 1-
29 minutes, 6.9% 30-59 minutes, 7.9% 1-24 hours, and 17.3% unknown PTA duration.  Data on 
injury severity, using the Injury Severity Score (ISS), was available for 88.1% of the sample.  
The ISS rates traumatic injury based on worst injury of 6 body systems, and ranges from 1 to75; 
1-9 Minor, 10-15 Moderate, 16- 24 Moderate/Severe, and ISS > 25 Severe/Critical (Baker, 
O'Neill, Haddon, & Long, 1974).  The majority (56.9%) of the sample had ISS scores ≥ 16, 
placing them in the moderate to severe range.  Nearly all injuries (99.5%) were closed head 
injuries; roughly half (47.5%) were motor vehicle accidents (MVA).  Accidental falls accounted 
for 36.6% of the injuries and 0.5% were due to explosive injury. Please refer to Table 5. 
Descriptive statistics for key study outcome variables.  Fatigue, sleep disturbance and 
depression were assessed by the items from the Rivermead Post-Concussive Questionnaire 
(RPQ).  The items were measured on a Likert scale in which respondents rated items from a 
minimum score of 0 (not experienced at all) to a maximum score of 4 (severe problem). Means 











Deviation Skewness Kurtosis 





RPQ Fatigue  202 1.27 1.233 .475 .171 -.972 .341 
RPQ Sleep 
Disturbance 




202 .75 1.050 1.162 .171 .280 .341 
Note: RPQ = Rivermead post-concussive symptoms questionnaire (each question ranges from 0- 
not experienced to 4-severe problem). STD = Standard 
 
Aim 1 Data Analysis and Results 
Latent Class Analysis of Behavioral Symptoms at six-month post MTBI 
Latent Class Analysis (LCA) was performed to identify profiles of MTBI patients based 
on the intensity of depressive symptoms, fatigue, and poor sleep. The items that address these 
factors were taken from the Rivermead Post-Concussion Questionnaire that was administered at 
the six-month follow-up.  Mplus 7.4 (Muthén & Muthén, 1998-2011) was used to conduct the 
LCA. The analysis was performed by fitting a two-class model, and gradually increasing the 
number of classes one at a time for model comparison, setting a random starting value arbitrarily 
from 500 to 100. A range of random start values was used to confirm that the true minimum was 
reached.   
Several criteria were used to guide the decision on the number of classes in mixture 
modeling, including the Akaike Information Criterion (AIC), the Bayesian Information Criterion 
(BIC (Schwarz, 1978), the sample-size-adjusted aBIC, the Vuong-Lo-Mendell-Rubin (VLMR) 
test (requested using TECH 11 in Mplus) and the bootstrapped parametric likelihood ratio test 




chosen number of classes (K) to a model of K−1 classes. For AIC, BIC, and aBIC, lower 
observed values indicate better model fit. In case of entropy, values closer to 1.00 suggest a 
better fit.  In addition, a nonsignificant p value for the BLMR LR test indicates that the model 
with the K-1 class is preferred to the model with K classes. The final classes were determined by 
small AIC, BIC, and aBIC values comparing each class (K) with each K-1 classes, as well as 
nonsignificant BLMR LR and strong entropy values.   
The four-class model suggested the best fit to the data with the lowest observed AIC, BIC 
and the sample-size-adjusted BIC. Entropy value was the highest also for the four-class model. 
Also, when the number of latent classes was increased from four to five classes, the p value of 
the VLMR test was not statistically significant (p= .5754), indicating that the addition of a fifth 
class did not significantly improve the fit of the model. However, BLMR LR remained 
significant for the five-class model (see Table 2). 
Research suggests that BLMR LR is in general a more accurate indicator of the classes 
than the VLMR test (Nylund, Asparouhov, & Muthén, 2007).  For this reason, the discrepancy 
between these two indices was further investigated by examining which model has most 
conceptual as well as empirical value.  The examination of the three-, four-, and five-class 
solutions revealed that the four-class solution had the clearest interpretation. The three-class 
solution largely combined Classes 3 and 4, which masked the important distinction in the levels 
of depression between these two classes, whereas the five-class solution essentially divided Class 
1 into two subclasses that differed in what appeared to be substantively unimportant ways.  The 





The means of the three variables used to generate the latent classes are shown in Table 3. 
The first column shows the overall means for the full sample, and subsequent columns show the 
means for the four latent classes. Class 1 was the largest class, constituting 67.7% of the cases, 
and was characterized by low endorsement of depression, fatigue, and  sleep disturbance. Class 4 
accounted for 15.9% and had the highest ratings of depression, fatigue, and  sleep disturbance.  
Class 3 (9.5%) was characterized by low depression and high fatigue, whereas Class 2 (7%) was 
characterized by low fatigue and high depression; both classes had the same ratings of sleep 
disturbance. The difference between latent class on demographic and injury-related 
characteristics are addressed in the following section (AIM 2). 
Table 2. Information Criteria and Entropy for Different Class Solutions 
Model AIC BIC aBIC Entropy VLMR BLMR LR 
2 class 1545.078 1578.210 1546.528 0.945 >.001 >.001 
3 class 1518.639 1565.024 1520.669 0.943 .1534 >.001 
4 class 1454.946 1514.584 1446.556 0.951 >.03 >.001 
5 class 1443.224 1516.115 1459.413 0.932 0.5754 >.001 
Table 3. Means and Standard Errors of the Fatigue, Depression and Sleep Disturbance by Latent 
Class Membership 
Variable Full Sample Class 1 Class 2 Class 3 Class 4 
Fatigue      
Mean 1.27 0.165 0.431 1.953 2.538 
SE .087 0.034 0.142   0.166 0.127 




Depression      
Mean 0.75 0.184 2.569 0.605 2.536 
SE .074 0.039 0.221 0.162 0.122 
Sleep 
Disturbance 
     
Mean 1.00 0.394 1.373 1.062 1.837 
SE .094 0.065 0.318 0.202 0.238 
 
Figure 1. Mplus profile plot based on estimated means.    
 
Figure 1. The means of the three variables used to generate the latent classes are shown in Table 
X. Class 1 was the largest class, constituting 67.7% of the cases, and was characterized by low 
endorsement of depression, fatigue, and  sleep disturbance. Class 4 accounted for 15.9% and had 
the highest ratings of depression, fatigue, and  sleep disturbance.  Class 3 (9.5%) was 
characterized by low depression and high fatigue, whereas Class 2 (7%) was characterized by 
low fatigue and high depression; both classes had the same ratings of sleep disturbance. The 
items that address these factors were taken from the Rivermead Post-Concussion Questionnaire 


















Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful). It is a 5-point Likert scale 
that ranges from 0 to 4, ranging from ‘‘not experienced at all’’ to ‘‘a severe problem’’.   
 
Data Analysis: Aim 2  
Sample Exclusion and Inclusion Criteria 
Six hundred TBI patients were enrolled in the TRACK-TBI Pilot study (See Figure X for 
enrollment diagram); however, 68 cases were excluded because of Glasgow Coma Scale < 13 
upon arrival to the ED, 17 cases were excluded because of reported LOC > 30 minutes, 13 cases 
were excluded because of reported PTA > 24 hours, 76 cases were excluded because their injury 
was a result of assault by others or a result of domestic violence. Additionally, 31 cases were 
excluded because of serious psychiatric disorders that would interfere with outcome measures. 
Of the sample that met the inclusion criteria (n=340), 139 MTBI patients had missing data and 
uncompleted biological data as shown in Figure 2.  The final sample consisted of 201 patients 





Figure 2: Enrollment flow diagram 
 
 
Inclusion criteria were both males and females (ages >18years) who suffered external 
force trauma to the head, an emergency department arrival GCS score between 13 and 15 (mild) 
and who have completed the three- and six-month follow-up. Concussion/MTBI patients who 
suffered minor injuries, who were alert, oriented, and who could read, write and speak English 
were included.  Mechanisms of injury included were motor vehicle accident, motorcycle/bicycle 
accident, pedestrian struck by vehicle, struck by/against object, falls, and other accidental causes 
of injury.  
Sample Characteristics/Demographic Statistics  
The sample characteristics by LCA class as describe in Aim 1 are presented below (see 
Table 4).  The demographic and health characteristics of the individuals grouped into the four 




differences (i.e., employment status and GCS score). Among the trending differences were those 
in social behaviors and history of behavioral symptoms (i.e., anxiety, depression, sleep 
disturbance), and causes of injury.   
For social behaviors, Class 4 (high symptoms) reported more alcohol consumption 
(65.6%) compared to other Classes; yet, it is not clear if this was a pre-existing behavior or if it 
developed in association with the post-MTBI symptoms. We attempted to conduct a chi-square 
test of independence between LCA groups and social behaviors; however, all expected cell 
frequencies were below five, and therefore we did not have an adequate sample size to run the 
chi-square test of independence.  
As for history of behavioral symptoms (i.e., anxiety, depression, sleep disturbance), 
Class1 had the least reported history of behavioral symptoms—anxiety (9.5%), depression 
(15.4%), and sleep disorder (3.6%). A comparison of the history of behavioral symptoms (i.e., 
anxiety, depression, poor sleep) between Class 2 and Class 3 revealed that Class 2 reported a 
lower percentage of history of behavioral symptoms (i.e., anxiety (21.4%), depression (28.5%), 
sleep disorder (7.1%)); whereas Class 3 reported a higher percentage of history of behavioral 
symptoms prior to MTBI (i.e., anxiety (26.3%), depression (36.8%), sleep disorder (15.8%)). 
These findings suggest that history of behavioral symptoms does not necessarily predict the 
intensity of symptoms post-TBI. Along the same lines, another interesting finding is that only 
9.4% of those in Class 4 reported some history of a sleep disorder, while a low percentage 
reported history of anxiety (25%) and history of depression (31.3%). Although it is valuable to 
asses for history of behavioral symptoms that could relate to susceptibility of poor long-term 
outcome recovery, no such relationship was found in this sample. We attempted to conduct a chi-




cell frequencies were below five, and therefore, we did not have an adequate sample size to run 
the chi-square test of independence. 
With respect to the causes of injury, the majority of patients in Class 2 were involved in 
accidental falls (43%), while the remainder presented with a mix of MVA, accidental fall, or 
other injury. However, the present findings revealed that the symptom cluster intensity post-
MTBI was not associated with severity of injury, as the ISS Score was ≥ 16 for similar across 
Classes (i.e., 56 % for Class 1, 43% for Class 2, 58 % for Class 3, and 65.6% for Class 4).  A 
chi-square test of independence was conducted, there were no statistically significant differences 
between the LCA groups and causes of injury. 
Lastly, the findings revealed few significant demographic differences across LCA 
groups; that is, differences were observed in employment status and arrival GCS score. A chi-
square test of independence was conducted between LCA groups and Employment status. All 
expected cell frequencies were greater than five. There were statistically significant differences 
between LCA groups and Employment status χ2(21) = 38.364, p < .012. The association was 
moderately strong (Cohen, 1988), Cramer's V = .254. Additionally, a chi-square test of 
independence was conducted between LCA groups and arrival GCS score. All expected cell 
frequencies were greater than five. There were statistically significant differences between LCA 
groups and arrival GCS χ2(6) = 14.094, p < .029. The association was small (Cohen, 1988): 
Cramer's V = .188.   
Overall, the findings revealed no major demographic differences across LCA groups; that 
is, no differences were observed in age, gender, and marital status. An ANOVA was conducted 
between LCA groups and age; however, there were no statistically significant differences.  A 




status; however, there were no statistically significant differences. Also, the findings revealed no 
major injury-related characteristics differences across LCA groups. A chi-square test of 
independence was conducted between LCA groups and injury-related characteristics; however, 
there were no statistically significant differences. 
Descriptive Statistics of Outcome Variables 
For Aim II, differences in the functional and cognitive abilities as well as the quality of 
life factors were investigated as a function of the class membership that was identified in Aim 1.  
The functional outcomes were assessed by the Glasgow Outcome Scale Extended (GOSE); 
Cognitive outcomes were assessed by the Trial Making Test (Part B-Part A Difference and Part 
B/Part A ratio), California Verbal Learning Test-II (CVLT-II; Trials 1-5 Free Recall), Wechsler 
Adult Intelligence Scale-IV (WAIS-IV; Coding Subset Total Raw Score, Symbol Search 
Subset). Quality of life outcomes were assessed by the Satisfaction with Life Scale (SWLS). For 
means and standard deviations of main outcome variables, see Table 6. All variables were 
normally distributed; see Table 6 for Skewness and Kurtosis values.  
For functional outcomes, MTBI patients had a GOSE mean of 6.96 (SD= 1.108) for 
functional level.  More specifically, low symptoms (M=7.37, SD=.933) performed better than all 
other groups: high depression/low fatigue symptoms group (M=6.29, SD=1.204), low 
depression/high fatigue symptoms group (M=6.11, SD=.875), as well as high symptoms group 
(M=6.03, SD=.897). 
When comparing satisfaction with life results to the norms, overall MTBI patients 
(M=22. 30, SD=7.645) reported greater level of satisfaction when compared to TBI patients 
(Corrigan et al., 1998) and university students, but a lower level of satisfaction when compared 




specifically, the low symptoms group (M=25.22, SD=6.590) reported greater level of satisfaction 
when compared to TBI patients (Corrigan et al., 1998), undergraduate students (Diener et al., 
1985), university students, correctional officers and elderly adults (Durak et al., 2010).  While 
both high depression/low fatigue (M=18.71, SD=5.717) symptoms and low depression/high 
fatigue symptoms group (M=16.89, SD=7.203) had lower level of satisfactions when compared 
to all above mentioned groups they had a greater level of satisfaction than correctional officers 
(Durak et al., 2010). Also, high symptoms group (M=14.81, SD=4.967) had the lowest level of 
satisfaction when compared to TBI patients (Corrigan et al, 1998), undergraduate students 
(Diener et al., 1985), university students and correctional officers (Durak et al, 2010). 
When comparing non-verbal learning results, MTBI patients (M=102.55, SD=15.543) 
performed better in WAIS-IV Processing Speed Index Composite Score when compared to all 
the lowest and highest index except for the intellectually gifted (Wechsler, 2008).  More 
specifically, three classes—low symptoms group (M= 105.211, SD=14.773), low 
depression/high fatigue symptoms group (M= 99.611, SD=14.034), and high symptoms group 
(M= 97.143, SD=16.788)—performed better than all the highest and lowest score index clinical 
population except for the intellectually gifted (Wechsler, 2008). Meanwhile, the high 
depression/low fatigue symptoms group (M= 93.154, SD=16.201) performed better than some of 
the highest and lowest except for major depressive disorder, ADHD, intellectually gifted, and 
reading disorder (Wechsler, 2008). 
When comparing mental flexibility results, overall TMT B-A performance was poorer in 
MTBI patients (M=49.070, SD=45.40) as compared to healthy control (young group 16 to 24 
and middle aged 25-54) (Perianez et al., 2007), but better than TBI patients and elderly healthy 




(M=42.58, SD=35.26) and both high depression/low fatigue symptoms group (M=61.96, 
SD=46.31) symptoms and low depression/high fatigue symptoms group (M=56.58, SD=36.61) 
symptoms, as well as high symptoms group (M=66.54, SD=75.84) performed better than TBI 
patients and elderly healthy controls but worse when compared with young and middle healthy 
controls (Perianez et al., 2007). 
When comparing verbal learning (CVLT-II Trials 1-5 Free Recall) results to the norms, 
researchers provide normative data from large samples of 285 outpatients in a mixed neurologic 
sample with low executive functioning (M=34.86, SD= 16.66), medium executive functioning 
(M= 43.10 SD=17.26), and high executive functioning (M= 45.02, SD=22.72) (Hill et al., 2012). 
In our sample, overall MTBI patients (M=49.08, SD=12.770) performed better in CVLT-II 
Trials 1-5 Free Recall when compared to all levels of executive functioning. More specifically, 
low symptoms group (M= 49.64, SD= 12.736), both high depression/low fatigue symptoms 
group (M= 49.54, SD= 15.125) and low depression/high fatigue symptoms group (M= 47.83, 
SD= 13.840), as well as high symptoms group (M= 47.22, SD= 11.430) had better scores when 
compared to all levels executive functioning. 
 
 
Table 4. Sample Characteristics for Aim 2            
 class 1    class 2    class 3    class 4   
 
 n = 136   n = 14   n = 19   n = 32 
N %   N %   N %   N % 
Male 95 70%  8 57%  10 53%  22 69% 
Ethnicity            
    Hispanic or Latino  13 10%  1 7%  3 16%  10 31% 
    Non-Hispanic or Non-Latino  123 90%  13 93%  16 84%  21 66% 
Race            
   Asian 8 6%  1 7%  0 0%  3 9% 
   Black 5 4%  0 0%  0 0%  2 6% 
   White 114 84%  12 85.7  18 95%  25 78% 
   American Indian or Alaska Native 0 0%  0 0%  1 5%  0 0% 
Native Hawaiian or Other Pacific 
Islander 
5 4%  0 0%  0 0%  
1 
3% 
Other 3 2%  1 7%  0 0%  1 3% 
Employment             
  Working full time with 35 hours or more 
per week and at least minimum wage 
69 
51%  
2 14%  3 
16%  16 50% 
  Working 20-34 hours per week at least 
minimum wage 12 9%  
2 14%  4 
21%  2 6% 
  Working less than 20 hours per week and 
at least minimum wage 5 4%  
0 0%  2 
11%  1 3% 
  Special employment (sheltered workshop, 
supportive employment, job coach) 0 0%  
0 0%  1 
5%  0 0% 
Temporary or odd jobs and less  




0%  1 3% 
  Not in paid workforce  26 19%  4 29%  4 21%  5 16% 




Table 4 (cont.)            
            
Education Highest Level            
High school diploma 42 31%  7 50%  9 47%  12 38% 
Associate degree 12 9%  1 7%  0 0%  2 6% 
    GED 4 3%  2 14%  0 0%  2 6% 
    Bachelor’s degree 39 29%  1 7%  4 21%  8 25% 
    Master’s degree 16 12%  0 0%  1 5%  2 6% 
    Doctoral degree 6 4%  0 0%  1 5%  1 3% 
Marital Status            
    Divorced 4 3%  3 21%  2 11%  5 16% 
    Married or living together  54 40%  2 14%  7 37%  9 28% 
    Separated 1 1%  0 0%  0 0%  0 0% 
    Single 71 52.2%  9 64%  9 47%  13 41% 
    Widowed 2 1%  0 0%  1 5%  3 9% 
     Unknown 3 2%  0 0%  0 0%  0 0% 





Table 5. Sample Characteristics for Study Aim 2: Injury-Related Characteristics  
        class 1    class 2    class 3    cclass 4   
 
 n = 136   n = 14   n = 19   n = 32 
N %   N %   N %   N % 
Arrival GCS            
13 2 1.5%  0 0.0%  1 5.2%  0 0.0% 
14 21 15.7%  1 7.1%  4 21.0%  13 40.6% 
15 111 82.8%  13 92.9%  14 74.0%  19 59.4% 
LOC 84 61.7%  9 64.2%  13 68.0%  23 72.0% 
LOC Duration            
<1 minute 15 11.0%  2 14.3%  2 0.9%  4 13.0% 
1-29 minutes 46 33.8%  5 36.0%  7 36.8%  13 41.0% 
30-59 minutes,  6 4.4%  0 0.0%  2 10.5%  2 6.2% 
Unknown 26 19.0%  3 21.0%  3 16.0%  8 28.0% 
PTA  76 55.8%  6 43.0%  10 53.0%  20 63.0% 
PTA Duration            
<1 minute 12 8.8%  0 0.0%  0 0.0%  0 0.0% 
1-29 minutes 30 22.0%  3 21.0%  5 26.3%  10 31.0% 
30-59 minutes 11 8.0%  0 0.0%  1 5.3%  2 6.2% 
1-24 hours 11 8.0%  1 7.0%  0 0.0%  4 12.5% 
Reported injury severity  120 88.0%  11 79.0%  17 89.0%  29 90.6% 
Poly-trauma with any two body regions, 7 5.1%  1 7.0%  2 10.5%  4 13.8% 
Poly-trauma with Head or neck Injury 7 5.1%  1 7.0%  2 10.5%  3 10.3% 
ISS Score ≤ 16 43 31.6%  5 36.0%  6 31.5%  8 27.6% 
ISS Score ≥ 16. 77 56.0%  6 43.0%  11 58.0%  21 65.6% 
Closed head injuries  135 99.3%  14 100.0%  19 100.0%  32 100.0% 
previous TBI 24 17.6%  2 14.3%  3 15.8%  11 34.4% 
  133 
 
 
Table 5 (cont.)            
            
MVA 54 40.0%  4 28.5%  9 47.0%  14 45.1% 
Accidental Fall 46 34.0%  6 43.0%  9 47.0%  13 40.6% 
Cutting and piercing Object 1 0.7%  0 0.0%  0 0.0%  0 0.0% 
Firearm accident by explosive material 1 0.7%  0 0.0%  0 0.0%  0 0.0% 
Striking Accidents  5 3.6%  0 0.0%  0 0.0%  1 3.1% 
Struck accidentally by falling object 2 1.4%  0 0.0%  0 0.0%  0 0.0% 
Other environmental or accidental causes 0 0.0%  1 7.1%  0 0.0%  0 0.0% 
Other vehicle accident 10 7.3%  2 14.3%  0 0.0%  4 12.5% 
Motor vehicle accident but not traffic 
related 
4 2.9%  0 0.0%  0 0.0%  0 0.0% 
Unknown  14 10.2%  1 7.0%  1 5.2%  0 0.0% 
Note, GCS=Glasgow Coma Scale, PTA= Post Traumatic Amnesia, LOC= Loss of Consciousness, MVA= Motor vehicle 
accident, ISS= Injury Severity Score. 
 
Table 6. Descriptive for Main Study Outcome Variables 
 N Range Mean Std. Dev. Skewness Std. Error Kurtosis Std. Error 
GOSE  201 5 6.96 1.108 .172 -1.034 .341 .749 
SWLS  199 28 22.30 7.645 .172 -.241 .343 -1.045 
TMT \Part A-Part B  181 328.5 49.070 45.40 .181 2.971 .359 12.252 
CVLT-II Trials 1-5 Free Recall  177 63 49.08 12.770 .183 -.275 .363 -.303 
WAIS-IV-PSI Composite Score  182 91 102.55 15.543 .180 .179 .358 .407 
         
Note. GOSE= Glasgow Outcome Scale Extended, WAIS-IV PSI= Wechsler Adult Intelligence Scale-IV Processing Speed Index, 
TMT = Trial Making Test (TMT) CVLT-II trials 1– 5= California Verbal Learning Test-II (five learning trials, an interference trial, an 





Aim 2: Data Analysis and Results  
Statistical strategy. First, the assumption of normality and homogeneity of variances and 
outliers was assessed for all outcome measures.  Normality was assessed by examining 
histogram plots and z scores. Homogeneity of variance was assessed by Levene's test.  All 
variables were checked for skewness and kurtosis (see Table 6). Results indicated that all 
outcome variables were normally distributed and no transformations were necessary. 
The second aim of this study was to determine (after identifying the latent class solution 
that best fit the data) the differences among the predicted classes and outcome variables 
(functional, cognitive, and quality of life) at six-months follow-up. Functional outcomes were 
assessed by Glasgow Outcome Scale Extended (GOSE), cognitive outcome and nonverbal 
processing speed were assessed by Wechsler Adult Intelligence Scale-IV (WAIS-IV; Coding 
Subset Total Raw Score, Symbol Search Subset), mental flexibility was assessed by the 
difference score between the Trial Making Test (TMT) B and TMT A (TMT B-A), verbal 
learning was assessed by the California Verbal Learning Test-II (CVLT-II trials 1–5; five 
learning trials, an interference trial, an immediate recall trial, and a post-20 min recall trial); and 
quality of life outcomes assessed by the Satisfaction with Life Scale (SWLS).  An analysis of 
variance (ANOVA) and analysis of covariance (ANCOVA) were conducted to address this aim.  
For all follow-up post hoc tests the Hochberg’s GT2 was used to correct for the unequal sample 
size (Field, 2009).  
Functional outcome and LCA groups.  A one-way ANOVA was conducted to 
investigate differences in the main functional outcome (Glasgow Outcome Scale Extended 
(GOSE) among the four LCA Groups: low symptoms (n = 136), high depression/low fatigue (n 




sizes were unequal, the Hochberg’s GT2 posthoc test which explicitly allows for unequal sample 
sizes was used (Field, 2009). 
Results revealed significant group differences in the level of functional outcome as 
assessed by GOSE at six months post-injury, (F (3,197) = 26.40, p < .05, partial η2 = .287).  The 
assumption of homogeneity of variances was met, as assessed by Levene's test for equality of 
variances (p = .813). The follow-up Hochberg’s GT2 post-hoc test revealed that group 
differences in GOSE were significant between low symptoms (M=7.37, SD=.933) and high 
depression/low fatigue symptoms (M=6.29, SD=1.204) (95% CI .38 to 1.79, p = .0003), as well 
between low symptoms and low depression/high fatigue (M=6.11, SD=.875) symptoms (95% CI 
.65 to 1.88, p< .05), and between low and high (M=6.03, SD=.897) symptoms (95% CI .84 to 
1.83, p< .05). This indicates that those with low symptoms (M=7.37, SD=.933) had significantly 
greater levels of functional outcomes and good recovery as compared to high depression/low 
fatigue (M=6.29, SD=1.204) symptoms and, with low symptoms, had significantly greater levels 
as compared low depression/high fatigue symptoms, and high symptoms. See Tables 7 and 8.  
Table 7. Tests of ____________ Between-Subjects Effects 
 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 70.449a 3 23.483 26.400 .000 
Intercept 4088.928 1 4088.928 4596.844 .000 
LCAclass 70.449 3 23.483 26.400 .000 
Error 175.233 197 .890   
Total 9983.000 201    
Corrected Total 245.682 200    
a. R Squared = .287 (Adjusted R Squared = .276) 
b. Computed using alpha = .05 
Note.  The Glasgow Outcome Scale Extended provides eight categories of outcome, ranges from 






Table 8. LCA Class 
 
Dependent Variable:   Glasgow Outcome Scale Extended (6 Month)   
LCAclass Mean Std. Deviation  
95% Confidence Interval 
Lower Bound Upper Bound 
low symptoms 7.368 .933 7.208 7.527 
high depression/low fatigue 6.286 1.204 5.789 6.783 
low depression/high fatigue 6.105 .875 5.679 6.532 
high symptoms 6.031 .897 5.702 6.360 
Note.  The Glasgow Outcome Scale Extended provides eight categories of outcome, ranges from 
(1) Dead to (8) Upper Good Recovery. 
 
Figure 3. Glasgow Outcome Scale Extended (6-month).   
  
Note. Patients (n=201) were classified into 4 groups: low symptoms (n = 136), high 
depression/low fatigue (n = 14), low depression\ high fatigue (n = 19), and high symptoms (n = 
32), The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in GOSE were 
significant between low symptoms (M=7.37, SD=.933) and high depression/low fatigue 
symptoms (M=6.29, SD=1.204) (95% CI .38 to 1.79, p = .0003), as well between low symptoms 
and low depression/high fatigue (M=6.11, SD=.875) symptoms (95% CI .65 to 1.88, p< .05), and 
between low and high (M=6.03, SD=.897) symptoms (95% CI .84 to 1.83, p< .05). The Glasgow 
Outcome Scale Extended provides eight categories of outcome, ranges from (1) Dead to (8) 
Upper Good Recovery. 
 
Satisfaction with life and LCA groups. A one-way ANOVA was conducted to 




with Life Scale (SWLS) among patients (n=201) in the four LCA groups: low symptoms (n = 
134), high depression/low fatigue (n = 14), low depression\high fatigue (n = 19), and high 
symptoms (n = 32).  Since the subgroup sizes were unequal, the Hochberg’s GT2 post hoc test, 
which explicitly allows for unequal sample sizes was used (Field, 2009). 
Results revealed significant group differences in the level of Satisfaction with Life at six-
months follow-up, (F (3, 195) = 30.239, p < .0005, partial η2 = .318).  The assumption of 
homogeneity of variances was met, (p = .270). The follow-up Hochberg’s GT2 post hoc test 
revealed that group differences in Satisfaction with Life were significant between low (M=25.22, 
SD=6.590) and high depression/low fatigue (M=18.71, SD=5.717) symptoms (95% CI 1.76 to 
11.26, p = .002), as well as the between low symptoms and low depression/high fatigue 
(M=16.89, SD=7.203) symptoms (95% CI 4.18 to 12.47, p< .05), and between low and high 
(M=14.81, SD=4.967) symptoms (95% CI 7.08 to 13.74, p< .05). This indicates that those with 
low symptoms (M=25.22, SD=6.590) had significantly greater levels of satisfaction with life as 
compared to high depression/low fatigue symptoms (M=18.71, SD=5.717) and low 
depression/high fatigue symptoms (M=16.89, SD=7.203); both groups are considered slightly 
below average in life satisfaction. Also, low symptoms (M=25.22, SD=6.590) had a significantly 
greater level of satisfaction with life as compared to high symptoms (M=14.81, SD=4.967), 





Table 9. Tests of Between-Subjects Effects 
 
Dependent Variable: SWLS Total Score (6 Month)   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 3674.702a 3 1224.901 30.239 .000 
Intercept 35154.680 1 35154.680 867.873 .000 
LCA class 3674.702 3 1224.901 30.239 .000 
Error 7898.805 195 40.507   
Total 110503.000 199    
Corrected Total 11573.508 198    
a. R Squared = .318 (Adjusted R Squared = .307) 
Note. SWLS- Satisfaction with Life scale. The SWLS is a series of five statements ranges from 1 
(‘‘strongly disagree’’) to 7 (‘‘strongly agree’’). The total score ranges from a maximum very 
high score between 30 – 35 indicating ‘‘highly satisfied’’, high score 25- 29, “slightly below 
average in life satisfaction” score between 15 – 19, “dissatisfied’ score between 10 – 14, and 
“extremely dissatisfied” score between 5 – 9 
 
Table 10. Descriptive Statistics: SWLS 
 
Dependent Variable:   SWLS Total Score (6 Month)   
LCA class Mean 
Std. 
Deviation  
95% Confidence Interval 
Lower Bound Upper Bound 
low symptoms 25.224 6.590 24.140 26.308 
high depression/low fatigue 18.714 5.717 15.360 22.069 
low depression/high fatigue 16.895 7.203 14.015 19.774 
high symptoms 14.813 4.967 12.594 17.031 
     






Figure 4. Satisfaction with Life Scale. 
 
Note. Patients (n=201) were classified into 4 groups: Low symptoms (n = 134), high 
depression/low fatigue (n = 14), low depression\ high fatigue (n = 19), and high symptoms (n = 
32). The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in Satisfaction 
with Life were significant between low (M=25.22, SD=6.590) and high depression/low fatigue 
(M=18.71, SD=5.717) symptoms (95% CI 1.76 to 11.26, p = .002), as well as the between low 
symptoms and low depression/high fatigue (M=16.89, SD=7.203) symptoms (95% CI 4.18 to 
12.47, p< .05), and between low and high (M=14.81, SD=4.967) symptoms (95% CI 7.08 to 
13.74, p< .05). Note. SWLS- Satisfaction with Life scale. The SWLS is a series of five 
statements ranges from 1 (‘‘strongly disagree’’) to 7 (‘‘strongly agree’’). The total score ranges 
from a maximum very high score between 30 – 35 indicating ‘‘highly satisfied’’, high score 25- 
29, “slightly below average in life satisfaction” score between 15 – 19, “dissatisfied’ score 
between 10 – 14, and “extremely dissatisfied” score between 5 – 9 
 
Cognitive abilities and LCA groups.  A one-way ANOVA was conducted to investigate 
differences in cognitive abilities among patients (n=201) who are classified into four LCA 
groups: low symptoms (n = 136), high depression/low fatigue (n = 14), low depression/high 
fatigue (n = 19), and high symptoms (n = 32). Cognitive measures evaluated were: nonverbal 
processing speed assessed by Wechsler Adult Intelligence Scale-IV (WAIS-IV; Coding Subset 




between the TMT B and TMTA (TMT B-A); and verbal learning assessed by California Verbal 
Learning Test-II (CVLT-II trials 1– 5; five learning trials, an interference trial, an immediate 
recall trial, and a post-20 min recall trial). Since the subgroup sizes were unequal, the 
Hochberg’s GT2 post hoc test, which explicitly allow for unequal sample sizes, was used (Field, 
2009). 
Nonverbal processing speed. Results revealed significant group differences in the level 
of nonverbal processing speed as assessed by WAIS-IV Processing Speed Index Composite 
Score at the six-month follow-up, F (3, 178) = 4.360, p =.005, partial η2 = .068.  The assumption 
of homogeneity of variances was met (p = .905). The Hochberg’s GT2 post hoc test revealed 
significant group differences in nonverbal processing speed between low (M= 105.21, SD= 
14.733) and high depression/low fatigue (M= 93.15, SD= 16.201) symptoms (95% CI .33 to 
23.97, p = .041). This indicated that those with low symptoms (M= 105.21, SD= 14.733) had 
significantly greater level of nonverbal processing speed corresponding to the 50th percentile of 
performance across age groups as compared to high depression/low fatigue (M= 93.15, SD= 
16.201) symptoms corresponding to 25th percentile of performance across age groups.  There are 
no group differences in nonverbal processing speed between individuals with low 





Table 11. Tests of Between-Subjects Effects 
 
Dependent Variable:   Wechsler Adult Intelligence Scale-IV\Processing Speed 
Index Composite Score (6 Month)   
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 2993.048a 3 997.683 4.360 .005 
Intercept 885415.856 1 885415.856 3869.302 .000 
LCA class 2993.048 3 997.683 4.360 .005 
Error 40731.903 178 228.831   
Total 1957913.000 182    
Corrected Total 43724.951 181    
a. R Squared = .068 (Adjusted R Squared = .053) 
Note. The Wechsler Adult Intelligence Scale-IV-Processing Speed Index Composite Score 
ranges from 50 to 150 to resemble a certain percentile (0.1st to 99.9th percentile) of performance 
across different age groups. For example, the 25th percentile represent score of ∼90, the 50th 
represent a score of 100, and 75th percentiles represent a score of ∼110. 
 
Table 12. Descriptive statistics: Wechsler Adult Intelligence Scale-IV Processing Speed Index 
Composite Score  
 
LCA class 
Dependent Variable: Wechsler Adult Intelligence Scale-IV Processing Speed Index Composite Score (6 
Month)   
LCA class Mean 
Std. 
Deviation 
95% Confidence Interval 
Lower Bound Upper Bound 
low symptoms 105.211 14.773 102.520  107.903 
high depression/low fatigue 93.154 16.201 84.874 101.433 
low depression/high fatigue 99.611 14.034 92.575 106.647 
high symptoms 97.143 16.788 91.501 102.784 
 
Mental flexibility. TMT-A assesses visual processing, and TMT-B assesses mental 
flexibility and processing speed, and therefore the difference between TMT-B and TMT-A 
provides an index of executive control and mental flexibility separate from visual processing and 
motor speed (Sanchez-Cubillo et al., 2009; Tombaugh, 2004).  Results revealed significant group 
differences in the level of Mental Flexibility at six-months follow-up, (F (3, 177) = 2.806, p < 




The follow-up Games-Howell post hoc procedure, was chosen to correct for the unequal 
variances. Results revealed that the differences between these LCA groups were not statistically 
significant, Welch's F (3, 31.968) = 1.997, p = .134. 
In an exploratory analysis, results revealed that mental flexibility was positively 
correlated with age (r (181) = .405, p < .01) and negatively with number of years of education 
completed (r (168) = -.270, p < .01); thus these variables were controlled for in the subsequent 
ANOVA.  However, there were no statistical significant group differences in the level of mental 
flexibility as assessed by TMT B-A between LCA Groups at six-months follow- (F (3, 94) = 
1.163, p < .328, partial η2 = .036).   
Table 13. Tests of Between-Subjects Effects 
 
Dependent Variable:   TMT\Part B-Part A (6 Month)   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 16848.534a 3 5616.178 2.806 .041 
Intercept 293793.302 1 293793.302 146.788 .000 
LCA class 16848.534 3 5616.178 2.806 .041 
Error 354262.502 177 2001.483   
Total 806940.471 181    
Corrected Total 371111.036 180    
a. R Squared = .045 (Adjusted R Squared = .029) 
Note. The Trail-Making Test (TMT), the difference score between the Trial B and Trial A (TMT 
B-A) A lower is a two-part timed test (TMT-A and TMT-B), and both scores are measured in 
number of seconds needed for the patient to complete the task.  In this test, a lower score 






Figure 5. Wechsler Adult Intelligence Scale-IV processing speed index composite score.  
 
Note. Patients (n=201) were classified into 4 groups: Low symptoms (n = 136), high 
depression/low fatigue (n = 14), low depression\ high fatigue (n = 19), and high symptoms (n = 
32).  The follow-up Games-Howell post-hoc procedure, was chosen to correct for the unequal 
variances. Results revealed that the differences between these LCA groups were not statistically 
significant, Welch's F (3, 31.968) = 1.997, p = .134. In this test, a lower score suggests improved 
performance, and results were trending toward indicating that the Low symptoms group appears 
to have more improved performance compared to other groups; however, results revealed that 
the differences between these LCA groups were not statistically significant. Note. The Trail-
Making Test (TMT), the difference score between the Trial B and Trial A (TMT B-A) A lower is 
a two-part timed test (TMT-A and TMT-B), and both scores are measured in number of seconds 






Verbal learning. Results of the ANOVA revealed no significant differences in the level 
of verbal learning as assessed by (i.e., CVLT-II trials 1– 5; five learning trials, an interference 
trial, an immediate recall trial, and a post-20 min recall trial) among LCA Groups.  
In an exploratory analysis, results revealed that verbal learning was positively correlated 
with injury severity as assessed by ISS (r (153) = .215, p < .01), thus this variable was controlled 
for in the subsequent ANOVA; however, there were no statistical significant group differences in 
the level of Verbal Learning as assessed by (i.e., CVLT-II trials 1– 5) between LCA Groups at 
six-months follow-up (F (3, 48) = .180, p < .910, partial η2 = .004).   
Summary of Aim 2 
First, there was a significant difference among predicted LCA Groups and functional 
outcomes.  Results revealed significant group differences in the level of functional outcomes as 
assessed by GOSE, indicating that those with low symptoms had significantly greater levels of 
functional outcomes and good recovery as compared to those reporting high depression/low 
fatigue symptoms.  Also, those with low symptoms had significantly greater levels of functional 
outcomes and good recovery as compared to individuals who reported low depression/high 
fatigue symptoms, and high symptoms.  
Second, there were significant differences among predicted LCA Groups and quality of 
life. Results revealed significant group differences in the level of Satisfaction with Life, 
indicating that those reporting low symptoms had significantly greater levels of satisfaction with 
life as compared to individuals reporting high depression/low fatigue symptoms and low 
depression/high fatigue symptoms; the reported life satisfaction scores reported are considered 
slightly below average. Also, individuals with low symptoms had a significantly greater level of 




satisfaction scores of that group is considered “dissatisfied with their life” according to the 
SWLS scoring.   
Third, for cognitive outcomes, there were significant differences among  LCA Groups 
and the level of nonverbal processing speed as assessed at the six-month follow-up, indicating 
that those with low symptoms had levels of nonverbal processing speed/that processing speed 
corresponded to the 50th percentile of performance across age groups, which were significantly 
greater  as compared to individuals reporting high depression/low fatigue symptoms, whose 
processing speed corresponded to the 25th percentile of performance across age groups.  There 
were no group differences in nonverbal processing speed between individuals with low 
depression/high fatigue symptoms and those with high symptoms.  Additionally, there was a 
significant difference between predicted LCA Groups and the level of mental flexibility as 
assessed by the difference between TMT-B and TMT-A at the six-month follow-up.  In this test, 
a lower score suggests improved performance, and results were trending toward indicating that 
the low symptoms group appears to have more improved performance compared to other groups. 
However, there were no group differences among the predicted LCA Group and the level of 
mental flexibility. Lastly, there was no significant relationship between predicted LCA Groups 
and verbal learning as assessed by CVLT-II trials 1– 5.  
Data Analysis: Aim 3—Exploratory Aim  
Sample Exclusion and Inclusion Criteria 
Of the sample that met the inclusion criteria (n=340), 187 MTBI patients had missing 
data and uncompleted biological data (i.e., genetic) as shown in Figure 6.  The final sample 





Figure 6: Enrollment flow diagram. 
Inclusion criteria were the following: males and females (ages >18years) who suffered external 
force trauma to the head, an emergency department arrival GCS score between 13 and 15 (mild) 
and completion of three- and six-month follow-ups. In addition, only those concussion/MTBI 
patients who suffered minor injuries, and who were alert, oriented, and were able to read, write 
and speak English were eligible. Mechanisms of injury included; motor vehicle accident, 
motorcycle/bicycle accident, pedestrian struck by vehicle, struck by/against object, falls, and 




Sample Characteristics/Demographic Statistics  
The majority of the sample was male (66%) and single (52.9%), with a mean age of 18 to 
84 years (M = 44.18, SD = 17.93).  Most were working full time (46.4%) with 35 hours or more 
per week and at least minimum wage. Eighteen percent had a history of anxiety, 24% had a 
history of depression, 7% had some history of sleep disorders. Nearly 23% had a previous TBI 
(with & without hospital admission).  Tobacco use was reported by 31.4% patient, and alcohol 
use was reported by 51.6%, while drug use was reported by 19% patients (see Table 14).  
Injury-related characteristics. Upon arrival to the ED, the majority had a GCS of 15 
(77.1%).  For reference, a GCS score of 8 or less indicates severe injury, GCS of 9-12 moderate 
injury, and a GCS score of 13-15 indicate minor injury. As with mild TBI, 13-15 GCS is one of 
the criteria for MTBI and is indicative of minor injury. Additionally, the majority of the sample 
(76.5%) reported LOC of varied duration; of these 13% had LOC of less than 1 minute, 37.9% 
had LOC between 1-29 minutes, 5.2% between 30-59 minutes, and 20.3% participants had 
unknown LOC duration. PTA was reported by 61.4% patients with varied duration; of these 
0.6% patients had PTA for less than1 minute, 26.7% had PTA between 1-29 minutes, 5.8% had 
PTA between 30-59 minutes, 8.4% had PTA between 1-24 hours, and 16.3% had unknown PTA 
duration. Injury severity scores (ISS) was reported for 87.6% patients. Fourteen suffered poly-
trauma involving two body regions, and 13 suffered poly-trauma with head or neck injury. The 
majority had an ISS Score ≥ 16 (53.5%).  All injuries were closed head injuries. The majority of 
patients were involved in a MVA and accidental falls (see Table 15). 
Descriptive Statistics for Main Study Outcome Variables  
The three main measures were the following: Brief Symptom Inventory 18 (the BSI-18 is 




subscales: BSI-somatization, BSI-anxiety, and BSI-depression), PTSD-PCL (3 subscales—
hypervigilance, avoidance, re-experiencing), and the Rivermead Post Concussion Symptoms 
Questionnaire 13 (RPQ-13). Table 16? lists mean and standard deviations for main study 
outcome variables. All variables were normally distributed.  





MTBI n = 153 
N %    
Male 101 66.0%   
Ethnicity     
    Hispanic or Latino  129 84.3%   
    Non-Hispanic or Latino  23 15.0%   
Race     
   Asian 10 6.5%   
   Black 7 4.6%   
   White 126 82.4%   
   American Indian or Alaska Native 1 0.7%   
Native Hawaiian or other Pacific Islander 5 3.3%   
Other 3 2.0%   
Employment      
  Working full time with 35 hours or more per week and at least 
minimum wage 
71 46.4%  
 
  Working 20-34 hours per week at least minimum wage 16 10.5%   
  Working less than 20 hours per week and at least minimum wage 4 2.6%   
  Special employment (sheltered workshop, supportive employment, 
job coach) 
1 0.7%  
 
  Temporary or odd jobs and less than minimum wage jobs 2 1.3%   
  Not in paid workforce (including child, retired, student, homemaker, 
disabled pre-injury) 
29 19.0%  
 
  Unemployed 25 16.3%   
  Unable to obtain information 3 2.0%   
Education Highest Level     
    None, not currently in school 5 3.3%   





Table 14 (cont.)     
     
    Vocational training (no high school diploma or GED) 1 0.7%   
Table 14 (cont.)     
     
    Vocational training (post high school) 6 3.9%   
    GED, 53 (34.6%) High school diploma 8 5.2%   
     Bachelor’s degree 39 25.5%   
     Master’s degree 15 9.8%   
     Doctoral degree  5 3.3%   
     Unable to obtain information  2 1.3%   
     Unknown 4 2.6%   
Marital Status     
    Divorced 12 7.8%   
    Married or living together or common law 50 32.7 %   
    Separated 3 2.0%   
    Single 81 52.9%   
    Widowed 5 3.3%   
     Unknown 2 1.3%   
 
Table 15. Sample Characteristics for Study Aim 3: Injury-Related Characteristics 
 
Characteristic 
Actual Sample Analyzed  
MTBI n = 153   
N %    
Arrival GCS     
13 2 1.3%   
14 31 20.3%   
15 118 77.6%   
LOC 117 76.9%   
LOC Duration     
     <1 minute 20 13.1%   
     1-29 minutes 58 38.8%   
     30-59 minutes,  8 5.2%   
   Unknown 31 20.3%   
PTA  94 61.8%   
     




Table 15 (cont.)     
     
PTA Duration     
     <1 minute 6 3.9%   
     1-29 minutes 41 26.9%   
     30-59 minutes 9 5.9%   
      1-24 hours 13 8.5%   
   Unknown 25 16.4%   
Reported injury severity  134 88.1%   
Poly-trauma with any two body regions, 14 9.2%   
Poly-trauma with Head or neck Injury 13 8.5%   
ISS Score ≤ 16 52 34.2%   
ISS Score ≥ 16. 82 53.9%   
Closed head injuries  151 99.3%   
MVA 61 39.9%   
  Accidental Fall 61 39.9%   
  Firearm accident by explosive material 1 0.7%   
Striking Accidents  3 2.0%   
  Struck accidentally by falling object 1 0.7%   
   Other environmental or accidental causes 1 0.7%   
Other vehicle accident,  11 7.2%   
   Motor vehicle accident but not traffic-related 2 1.3%   
   Unknown  12 7.8%   
LOC= Loss of Consciousness, PTA= Post Traumatic Amnesia, ISS= Injury severity 
score.  
 
Table 16. Descriptive Statistics 
 
 
N Range Mean 
Std. 
Deviation Skewness Kurtosis 







153 60 11.18 11.291 1.356 .196 2.037 .390 
BSI-Depression 
(6 Month) 
153 20 3.75 4.493 1.274 .196 .947 .390 
BSI-Somatization 
(6 Month) 
153 18 3.66 4.005 1.311 .196 1.297 .390 
BSI-Anxiety (6 
Month) 
153 22 3.77 4.201 1.456 .196 2.232 .390 




Table 16 (cont.)         












152 24 12.78 5.755 1.125 .197 .660 .391 
PTSD PCL-C 
Total Score (6 
Month) 
152 60 30.89 13.615 1.178 .197 .801 .391 
RPQ-13 Score (6 
Month) 
152 49 11.70 11.356 .942 .197 .267 .391 
         
Aim 3 Data Analysis and Results  
Statistical strategy. First, the assumption of normality and homogeneity of variances 
and outliers was assessed for all outcome measures.  Normality was assessed by examining 
histogram plots and z scores, homogeneity of variances was assessed by Levene's test.  All 
variables were checked for skewness and kurtosis (see Tables 16). Results indicated that all 
outcome variables were normally distributed and no transformations were necessary.  
Differences in behavioral symptoms (somatization, anxiety, depression, PTSD, and post 
concussive syndrome) among the SNPs genotype (rs1800497 (ANKK1), rs1799971 (OPRM1), 
rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT)) were 
determined. Behavioural symptoms were assessed by three main measures: (1) BSI-18 (the BSI-
18 is a brief screen of psychological distress with a Global Severity Index (GSI), and three 
clinical subscales: BSI-somatisation, BSI-anxiety, and BSI-depression); (2) PTSD-PCL (3 
subscales; hyper-vigilance, avoidance, Re-experiencing); and (3) the Rivermead Post 




analysis of covariance (ANCOVA), were conducted to address this aim.  For all follow-up post 
hoc tests the Hochberg’s GT2 was used to correct for the unequal sample size (Field, 2009). 
To identify potential covariates, an independent sample t-test statistical test was 
conducted between medical history of depression, anxiety, and poor sleep, ethnicity, and 
outcome variables (i.e., Somatization, Anxiety, Depression, PTSD, and Post-Concussive 
Syndrome) to determines statistically significant differences between the means. Those variables 
that were significantly different were included as covariates in the subsequent ANOVAs (Table 
17a, 17b, and 17c).  Somatization was associated with history of depression (t (151) = 4.423, p < 
.01) and Ethnicity (t (150) = 3.114, p < .01); thus these variables were controlled for in the 
subsequent ANOVA.  Also, anxiety was associated with history of anxiety (t (151) = 4.572, p < 
.01), Ethnicity (t (150) = 2.760, p < .01). These variables were controlled for in the subsequent 
ANOVA. Refer to Tables 17, 18, and 19.
 
 




for Equality of 
Variances t-test for Equality of Means 























3.584 48.975 .001 8.492 2.369 3.731 13.253 
Brief Symptom 
Inventory 18- 










2.841 48.559 .007 2.752 .968 .805 4.698 
Brief Symptom 
Inventory 18- 










3.959 51.771 .000 3.158 .798 1.557 4.758 






Table 17 (cont.) 
          










































2.123 67.165 .037 1.740 .820 .104 3.376 
PTSD Checklist-
Civilian-Domain Score 









1.781 60.112 .080 1.939 1.088 -.238 4.116 




Table 17 (cont.) 
          
           
PCL-C Total Score (6 Month) Equal 
variances 
assumed 





2.521 60.653 .014 6.391 2.535 1.321 11.460 
RPQ-13 Score (6 Month) Equal 
variances 
assumed 





3.020 53.042 .004 6.893 2.283 2.315 11.471 
RPQ-3 Score (6 Month) Equal 
variances 
assumed 





2.287 49.553 .026 1.136 .497 .138 2.134 
















1.359 -9.199 -3.763 
















Table 18. Intendent Sample T-Test Analysis Between Medical History of Anxiety and Outcome Variables 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 








Interval of the 
Difference 
Lower Upper 
Brief Symptom Inventory 









3.536 31.965 .001 9.897 2.799 4.195 15.599 
Brief Symptom Inventory 









2.747 32.590 .010 3.045 1.108 .789 5.301 











3.109 32.770 .004 3.021 .972 1.044 4.999 




Table 18 (cont.)           
           
Brief Symptom Inventory 



































2.193 38.472 .034 2.108 .961 .163 4.054 
PTSD Checklist-Civilian-










2.200 39.454 .034 2.569 1.168 .207 4.930 
           
           158 
 
 
Table 18 (cont.)           
           










2.814 38.483 .008 7.874 2.798 2.212 13.536 
RPQ-13 Score (6 Month) Equal 
variances 
assumed 





3.170 34.687 .003 8.151 2.572 2.929 13.374 
RPQ-3 Score (6 Month) Equal 
variances 
assumed 





2.406 30.884 .022 1.504 .625 .229 2.780 














43.026 .000 -5.789 1.417 -8.646 -2.932 
           
           159 
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Table 19. Independent Sample T-Test Analysis Between Ethnicity, and Outcome Variables  
 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 













GSI (6 Month) 
Equal variances 
assumed 


































3.396 .067 2.760 150 .006 2.564 .929 .729 4.400 
Equal variances 
not assumed   
2.353 27.184 .026 2.564 1.090 .329 4.799 
           161 
 
 
Table 19 (cont.)           

































2.370 26.751 .025 3.646 1.539 .488 6.805 
PCL-C Total 
Score (6 Month) 
Equal variances 
assumed 




2.740 28.115 .011 9.111 3.325 2.301 15.921 








2.781 27.936 .010 7.748 2.786 2.040 13.455 














Table 19 (cont.) 
          
           
SWLS Total 
































Exploratory analysis of SNP rs1800497 ANKK1 on outcome measures.  There were 
marginal differences at α = 0.05 between SNP rs1800497ANKK1 and outcome variables 
included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSI-
depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 
total score, which warrant further exploration.   To identify potential covariates, independent 
sample t-test analysis was conducted between medical history of depression, medical history of 
depression anxiety, ethnicity, and outcome variables.  Those variables that were significantly 
correlated (p < .01) were included as covariates in the subsequent ANOVAs.   
Then, Analysis of Covariance (ANCOVA) was conducted to investigate differences 
between patients who were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 56), A2/A2 (n 
= 86), with respect to distress, posttraumatic symptoms, and post concussive symptoms.  The 
outcome variables included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, 
and BSI-depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-re-experiencing, and 
RPQ-13 total score.  Since the subgroup sizes are greatly unequal, the Hochberg’s GT2 post hoc 
test explicitly allows for unequal sample sizes (Field, 2009).  
Somatisation and SNP rs1800497ANKK1.  Results revealed that somatization was 
associated with history of depression (t (151) = 4.423, p < .01) and ethnicity (t (150) = 3.114, p < 
.01), thus these variables were controlled for in the subsequent ANOVA.  Significant group 
differences in the level of somatisation were found, (F (2,146) = 3.859, p < .023, partial η2 = 
.050).  The assumption of homogeneity of variances was met, as assessed by Levene's test for 
equality of variances (p = .177).  The follow-up Hochberg’s GT2 post hoc test revealed that 
group differences in somatization were significant between A1/A1 (M=7.416, SD=1.188) and 




differences were observed between A1/A1 and A2/A2 (M=5.651, SD=.537) genotypes, and 
A2/A2 and A1/A2 genotypes.  Please refer to Tables 20 and 21. 
Table 20. Tests of Between-Subjects Effects 
 






Square F Sig. 
Partial Eta 
Squared 
Corrected Model 471.845a 4 117.961 8.851 .000 .195 
Intercept 1557.248 1 1557.248 116.849 .000 .445 
SNP1800497ANKK1 102.863 2 51.432 3.859 .023 .050 
Ethnicity 102.176 1 102.176 7.667 .006 .050 
MHPSYCDEP 268.709 1 268.709 20.163 .000 .121 
Error 1945.745 146 13.327    
Total 4487.000 151     
Corrected Total 2417.589 150     
a. R Squared = .195 (Adjusted R Squared = .173) 
Note. Brief Symptom Inventory 18- somatization subscale consists of 6 question (each question 
ranges from 0 “not at all” to 4 “extremely”), total score for somatization subscale ranges from 0 
to 18, a higher score is indicative of higher level of somatization. 
:  
Table 21. Descriptive statistics: Brief Symptom Inventory 18-Somatization 
 





95% Confidence Interval 
Lower Bound Upper Bound 
A1/A1 (n = 10)  7.416 1.188 5.068 9.763 
A1/A2 (n = 56) 4.366 .571 3.237 5.495 
A2/A2 (n = 86) 5.651 .537 4.589 6.712 
Note. Brief Symptom Inventory 18- somatization subscale consists of 6 question (each question 
ranges from 0 “not at all” to 4 “extremely”), total score for somatization subscale ranges from 0 










Note. Patients were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 56), A2/A2 (n = 86). 
The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in somatization 
were significant between A1/A1 (M=7.416, SD=1.188) and A1/A2 (M=4.366, SD= .571) 
genotypes (95 % CI .03 to 6.09, p = .047).  However, no differences were observed between 
A1/A1 and A2/A2 (M=5.651, SD=.537) genotypes, and A2/A2 and A1/A2 genotypes. Note. 
Brief Symptom Inventory 18- somatization subscale consists of 6 question (each question ranges 
from 0 “not at all” to 4 “extremely”), total score for somatization subscale ranges from 0 to 18, a 
higher score is indicative of higher level of somatization. 
 
Anxiety and SNP rs1800497ANKK1.  Results revealed that also, anxiety was associated 
with history of anxiety (t (151) = 4.572, p < .01), and ethnicity (t (150) = 2.760, p < .01); these 
variables were controlled for in the subsequent ANOVA.  Significant group differences in the 
level of anxiety were found, (F (2,145) = 5.060, p < .008, partial η2 = .065).  The assumption of 
homogeneity of variances was met, as assessed by Levene's test for equality of variances (p = 
.269).  The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in anxiety 
were significant between A1/A1 (M=7.982, SD= 1.264) and A1/A2 (M= 4.266, SD= .604) 




A1/A1 and A2/A2 (M=5.824, SD=.572) genotypes and A2/A2 and A1/A2 genotypes. Please 
refer to Tables 22 and 23. 
Table 22. Tests of Between-Subjects Effects 
 
Dependent Variable:   Brief Symptom Inventory 18- Anxiety (6 Month)   
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 588.101a 4 147.025 10.386 .000 .222 
Intercept 1736.771 1 1736.771 122.685 .000 .457 
SNP1800497ANKK1 143.633 2 71.816 5.073 .007 .065 
MHPSYCANX 345.789 1 345.789 24.426 .000 .143 
Ethnicity 117.038 1 117.038 8.268 .005 .054 
Error 2066.826 146 14.156    
Total 4769.000 151     
Corrected Total 2654.927 150     
a. R Squared = .222 (Adjusted R Squared = .200) 
Note. Brief Symptom Inventory 18- Anxiety subscale consists of 6 question (each question 
ranges from 0 “not at all” to 4 “extremely”), total score for anxiety subscale ranges from 0 to 
18, a higher score is indicative of higher level of anxiety. 
 
 
Table 23. Descriptive Statistics: Brief Symptom Inventory 18-Anxiety 
Dependent Variable: Brief Symptom Inventory 18-Anxiety (6 Month)   
Biomarker Data\SNP\SNP 
Calls\rs1800497 (ANKK1) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
A1/A1 (n = 10)  7.982 1.264 5.485 10.480 
A1/A2 (n = 56) 4.266 .604 3.072 5.459 
A2/A2 (n = 86) 5.824 .572 4.693 6.955 
Note. Brief Symptom Inventory 18- Anxiety subscale consists of 6 question (each question 
ranges from 0 “not at all” to 4 “extremely”), total score for anxiety subscale ranges from 0 to 18, 






Figure 8. Brief symptom inventory 18- Anxiety. 
 
 
Note. Patients were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 56), A2/A2 (n = 86).  
The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in anxiety were 
significant between A1/A1 (M=7.982, SD= 1.264) and A1/A2 (M= 4.266, SD= .604) genotypes 
(95 % CI .27 to 6.67, p = .029); however, no differences were observed between A1/A1 and 
A2/A2 (M=5.824, SD=.572) genotypes and A2/A2 and A1/A2 genotypes. Note. Brief Symptom 
Inventory 18- Anxiety subscale consists of 6 question (each question ranges from 0 “not at all” to 
4 “extremely”), total score for anxiety subscale ranges from 0 to 18, a higher score is indicative 
of higher level of anxiety. 
Post-concussive syndrome and SNP rs1800497ANKK1. Results of the ANOVA revealed 
no significant differences in the level of post-concussive syndrome (i.e., as assessed by RPQ-13) 
between the SNP rs1800497ANKK1 genotypes (F (2,148) = .642, p < .537).   
PTSD symptoms and SNP rs1800497ANKK1.  The ANOVA was performed to assess 
the differences between SNP rs1800497ANKK1 genotype groups, with respect to PTSD-PCL 




Results revealed no significant SNP rs1800497ANKK1 genotype group differences for any of 
the PTSD-PCL subscales (i.e., hypervigilance, avoidance, re-experiencing) 
Exploratory analysis of SNP1799971 OPRM1 on outcome measures.  A one-way 
Analysis of variance (ANOVA) was conducted to investigate differences between patients who 
were classified into 3 groups: A/A (n = 111), A/G (n = 39), G/G (n = 2) with respect to distress, 
posttraumatic symptoms and post concussive symptoms.  The outcome variables included: 
BSI18 Global Severity Index (GSI), BSI-somatization, BSI-anxiety, and BSI-depression, PTSD- 
hypervigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total score.  The 
assumption of homogeneity of variances was met, as assessed by Levene's test for equality of 
variances for all outcome measures.  No differences in any outcome measures were observed 
among SNP1799971 OPRM1 Genotype groups.  
Exploratory analysis of SNP rs279836 (GABRA2) on outcome measures.  A one-way 
analysis of variance (ANOVA) was conducted to investigate differences between patients 
(n=151) who were classified into 3 groups: A/A (n = 30), A/T (n = 70), T/T (n = 51) with respect 
to distress, posttraumatic symptoms and post-concussive symptoms.  The outcome variables 
included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSI-
depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total 
score. The assumption of homogeneity of variances was violated, as assessed by Levene's test for 
equality of variances for all outcome measures.  No differences in any outcome measures were 
found among SNP rs279836 GABRA2 Genotype groups.  
Exploratory analysis of rs279845 (GABRA2) on outcome measures.  A one-way 
analysis of variance (ANOVA) was conducted to investigate differences in distress, 




classified into 3 groups:  A/A (n = 29), A/T (n = 73), T/T (n = 49).  The outcome variables were 
assessed using: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSI-
depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total 
score. Results revealed no differences in these behavioural outcome measures between SNP 
rs279845 GABRA2 Genotype groups. 
Exploratory analysis of rs279871 (GABRA2) on outcome measures.  A one-way 
Analysis of variance (ANOVA) was conducted to investigate differences between patients 
(n=152) who were classified into 3 groups:  C/C (n = 29), C/T (n = 70), T/T (n = 53), with 
respect to distress, posttraumatic symptoms and post concussive symptoms.  The outcome 
variables included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSI-
depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total 
score.  No differences in any outcome measures among SNP rs279871 GABRA2 Genotype 
groups were found.        
Exploratory analysis of rs4680 (COMT) on outcome measures.  A one-way Analysis 
of variance (ANOVA) was conducted to investigate differences between patients (n=153) who 
were classified into 3 groups: Met/Met (n = 40), Met/Val (n = 74), Val/Val (n = 39), with respect 
to distress, posttraumatic symptoms and post concussive symptoms.  The outcome variables were 
assessed using the following measures: BSI18 Global Severity Index (GSI), BSI-somatisation, 
BSI-anxiety, and BSI-depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-
experiencing, and RPQ-13 total score.  No differences in any outcome variables were found 
among the SNP rs4680 (COMT) Genotype groups.   
Additional exploratory analysis.  Additional exploratory analysis was conducted to 




fatigue, depression, and sleep disturbance.  The three RPQ-13 questions used for Aim 1 (LCA) 
that addressed fatigue, depression, and sleep were used to measure the dependent variables.  To 
identify potential covariates, an independent sample t-test statistical test was conducted between 
medical history of depression, anxiety, ethnicity, and outcome variables (i.e., RPQ-13 questions; 
RPQ Fatigue: Tiring More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful) 
to determine statistically significant differences between the means. Those variables that were 
significantly different were included as covariates in the subsequent ANOVAs (See Tables 24, 
25, and 26). For all follow-up post hoc tests the Hochberg’s GT2 was used to correct for the 
unequal sample size (Field, 2009).
 
 
Table 24. Independent Sample T-Test Analysis Between Medical History of Anxiety and Outcome Variables (RPQ-13 questions; 
RPQ Fatigue: Tiring More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful) 
 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 








Interval of the 
Difference 
Lower Upper 
RPQ Fatigue, Tiring 
More Easily 









3.448 33.787 .002 .962 .279 .395 1.529 
RPQ Feeling 
Depressed or Tearful 









3.145 33.754 .003 .809 .257 .286 1.333 
RPQ Sleep 
Disturbance 













Table 25. Independent Sample T-Test Analysis Between Medical History of Depression and Outcome Variables (RPQ-13 Questions; 
RPQ Fatigue: Tiring More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful) 
 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 








Interval of the 
Difference 
Lower Upper 
RPQ Fatigue, Tiring 
More Easily 









2.723 53.168 .009 .662 .243 .174 1.150 
RPQ Feeling 
Depressed or Tearful 









3.179 52.261 .002 .708 .223 .261 1.155 
RPQ Sleep 
Disturbance 













Table 26. Independent Sample T-Test Analysis Between Ethnicity and Outcome Variables (RPQ-13 questions; RPQ Fatigue: Tiring 
More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful) 
 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 


















.959 .329 1.624 149 .107 .441 .272 -.096 .978 
Equal variances 
not assumed   








5.839 .017 3.050 149 .003 .739 .242 .260 1.219 
Equal variances 
not assumed   

















Fatigue and SNP rs1800497ANKK1.  Results revealed that fatigue was associated with 
history of anxiety (t (150) = 3.943, p < .01); thus, this variable was controlled for in the 
subsequent ANOVA.  Significant group differences in the level of fatigue were found, (F (2,147) 
= 3.057, p = .050 partial η2 = .040).  The assumption of homogeneity of variances was violated, 
as assessed by Levene's test for equality of variances (p = .008).  The follow-up Hochberg’s GT2 
post-hoc test revealed that there were no differences in fatigue between A1/A1 (M=2.200, SD= 
.366) and A1/A2 (M= 1.354, SD= .166) genotypes.  Also, no differences in fatigue were 
observed between A1/A1 and A2/A2 (M=1.709, SD=.150) genotypes and A2/A2 and A1/A2 
genotypes (see Table 27 and Figure 9).  
Table 27. Descriptive Statistics: RPQ Fatigue, Tiring More Easily 
 Dependent Variable:   RPQ Fatigue, Tiring More Easily (6 Month)   
SNP \rs1800497 (ANKK1) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
A1/A1 2.200 .366 1.476 2.923 
A1/A2 1.354 .166 1.027 1.682 
A2/A2 1.709 .150 1.412 2.006 
Note. RPQ = Rivermead post-concussive symptoms questioner (each questions ranges from 0-






Figure 9. RPQ-Fatigue, tiring more easily. 
 
 
Note.  Patients were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 55), A2/A2 (n = 86).  
The follow-up Hochberg’s GT2 post-hoc test revealed that there were no differences in fatigue 
between A1/A1 (M=2.200, SD= .366), A1/A2 (M= 1.354, SD= .166) genotypes, no differences 
were observed between A1/A1 and A2/A2 (M=1.709, SD=.150) genotypes and A2/A2 and 
A1/A2 genotypes (See Table x, and Figure X). Note: RPQ = Rivermead post-concussive 
symptoms questioner (each question ranges from 0- not experienced to 4-severe problem). 
 
Depression, sleep disturbance and SNP rs1800497ANKK1.No significant differences in 






Summary of Exploratory Aim 
The results of this aim indicated that there are no differences in behavioural symptoms 
outcomes on the three main measures—BSI-GSI, BSI-somatisation, BSI-anxiety, and BSI-
depression, PTSD-PCL (hyper-vigilance, avoidance, re-experiencing), and RPQ-13—among the 
five SNP genotypes—(rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), 
SNP1799971 (OPRM1), and rs4680 (COMT)).  However, differences were found for patients 
with different SNP rs1800497 ANKK1 genotype and their level of BSI-somatisation and BSI-
anxiety.  
First there was a significant difference in somatisation among SNP rs1800497 ANKK1 
genotype groups while controlling for history of depression and ethnicity.   Results revealed 
significant group differences in the level of somatisation, (F (2,146) = 3.859, p < .023, partial η2 
= .050), indicating that those with A1/A1 (M=7.416, SD=1.188) had significantly greater levels 
of somatisation as compared to A1/A2 (M=4.366, SD= .571) genotype.  However, no differences 
were observed between A1/A1 and A2/A2 (M=5.651, SD= .537) genotypes, and A2/A2 and 
A1/A2 genotypes.   
Second, there was a significant difference in anxiety among SNP rs1800497 ANKK1 
genotype groups while controlling for history of anxiety and ethnicity.  Results revealed 
significant group differences in the level of anxiety (F (2,145) = 5.060, p < .008, partial η2 = 
.065).  Specifically, those with A1/A1 (M=7.982, SD= 1.264) reported significantly greater 
levels of anxiety than patients with A1/A2 (M= 4.266, SD= .604) genotype.  However, no 





In conclusion, it is important to note that although the differences observed were 
significant, there was very little difference among the means, which warrants replication with a 
larger sample. Also, perhaps a larger sample size may produce different findings regarding 
differences between groups with different six types of SNPs genotype (rs1800497 (ANKK1), 
rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and 
rs4680 (COMT). 
Schematic of the Variables 
The primary aim of this investigation was to use latent class cluster analysis to identify 
behavioral symptom clusters in MTBI patients; and to then determine whether there were 
differences in quality of life, and in cognitive and functional outcomes among the symptom 
groups. An exploratory aim assessed whether there were differences in the intensity of 




Figure 10. Diagram of the final study variables. 
 
Note. Aim 1: to identify different profiles of MTBI patients based on the intensity of 
depressive mood, fatigue, and poor sleep. Aim 2: to determine whether there are differences 
in cognitive and functional outcomes at six months post-MTBI among the identified 
behavioral cluster profiles. Aim 3:  to explore differences in the intensity of behavioral 
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This chapter summarizes and integrates results for each research question, aim and 
hypothesis; derives conclusions and provide explanations for findings; integrates findings with 
extant literature and discusses areas of convergence and divergence; discusses how findings 
address knowledge gaps; identifies and discusses realistic implications of the findings for 
nursing; addresses strengths and limitations of the study; and identifies directions for further 
study. 
Overview of Findings 
For Aim 1, Latent Class Analysis (LCA) was performed to identify profiles of MTBI 
patients based on the intensity of depressive symptoms, fatigue, and poor sleep. The 
measurements for these variables were derived from the Rivermead Post-Concussion 
Questionnaire, which was administered six months post-MTBI.  Mplus 7.4 (Muthén & Muthén, 
1998-2011) was used to conduct the LCA. The means of the three variables (depressive 
symptoms, fatigue, and poor sleep) were used to generate the latent classes. Results for Aim 1 
revealed four predicted LCA Groups with different symptom intensity that were classified into 
four groups (Class 1—low symptoms, Class 2—high depression/low fatigue, Class 3—low 
depression/high fatigue, and Class 4—high symptoms). Class 1 was the largest class, 
constituting 67.7 % of the sample, and was characterized by low endorsement of depression, 
fatigue, and sleep disturbance. Class 4 accounted for 15.9% of the sample and had the highest 




high fatigue and accounted for 9.5 % of the sample, whereas Class 2 was characterized by low 
fatigue and high depression and accounted for 7 % of the sample; both Class 2 and 3 had the 
same ratings of sleep disturbance. 
After identifying the LCA groups, the second aim of this study was to determine whether 
there were differences among outcome variables (functional, cognitive, and quality with life) 
among the predicted LCA groups.  An analysis of variance (ANOVA) and analysis of covariance 
were conducted to address this aim.  The results for Aim 2 indicated that there were group 
differences in functional and quality of life outcomes among the four predicted LCA Groups.  
First, findings revealed significant group differences in the level of functional outcomes as 
assessed by GOSE, indicating that those with low symptoms had significantly greater levels of 
functional outcomes and good recovery as compared to those reporting high depression/low 
fatigue symptoms, low depression/high fatigue symptoms, and high symptoms. Second, results 
revealed significant group differences in the level of Satisfaction with Life, indicating that those 
reporting low symptoms had significantly greater levels of satisfaction with life as compared to 
individuals reporting high depression/low fatigue symptoms and low depression/high fatigue 
symptoms; the reported life satisfaction scores reported are considered slightly below average. 
Also, individuals with low symptoms had a significantly greater level of satisfaction with life as 
compared to individuals who reported high symptoms; the life satisfaction scores of that group is 
considered “dissatisfied with their life” according to the SWLS scoring.  Third, group 
differences were found in both nonverbal processing speed and mental flexibility; findings 
revealed that those with low symptoms had levels of nonverbal processing speed, which 
corresponded to the 50th percentile of performance across age groups. This level was 




whose processing speed corresponded to the 25th percentile of performance across age groups. 
Additionally, there was a significant difference between predicted LCA Groups and the level of 
mental flexibility as assessed by the difference between TMT-B and TMT-A at the six-month 
follow-up.  In this test, a lower score suggests improved performance. Results revealed a trend, 
such that the low symptoms group had better performance (approaching significance) compared 
to other groups.  No differences in verbal learning were found among the LCA groups. 
For the third exploratory aim, differences in intensity of behaviour symptoms 
(Somatisation, Anxiety, Depression, PTSD, and Post-Concussive Syndrome) among SNP 
genotypes (rs1800497 (ANKK1,) rs1799971 (OPRM1), SNPs genotype (rs1800497 (ANKK1), 
rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and 
rs4680 (COMT)) was explored. An analysis of variance (ANOVA) and analysis of covariance 
(ANCOVA) were conducted to address this aim. The results for Aim 3, revealed no differences 
in intensity of behavioural symptoms at six months post-MTBI for the five different SNP 
genotypes (rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), SNP1799971 
(OPRM1), and rs4680 (COMT)).  However, group differences in the level of BSI-somatisation 
and BSI-anxiety were found for patients with different SNP rs1800497 ANKK1 genotypes.  Yet, 
it is important to note that although the differences were statistically significant, the magnitude 
of these differences was small, and warrants replication with a larger sample. Also, it is likely 
that a larger sample size would reveal significant differences for other functional outcomes, 
especially cognitive function (i.e., non-verbal processing speed and mental flexibility).  As well, 
a larger sample may also yield significant differences in functional outcomes among the six 
types of SNPs genotype (rs1800497 (ANKK1), rs1799971 (OPRM1), rs279836 (GABRA2), 




Relevance to Guiding Frameworks/Theories 
This study was guided by a psychoneuroimmunology (PNI) framework.  The field of PNI 
posits bidirectional networks that underlie the manifestation of behaviour; in this case 
inflammatory-related behaviour.  The type and extent of such interaction and a given behavioural 
phenotype is also influenced by an individual’s genetic make-up; and these behavioural 
phenotypes may influence cognitive and functional outcomes post-MTBI.  Thus, consistent with 
this concept, this investigation explored genetic variants as a potential mechanism to explain 
individual differences in cognitive and functional outcomes post-MTBI. Understanding these 
physiological (genetic) factors may lead to tailored strategies to improve outcomes. Furthermore, 
the Theory of Unpleasant Symptoms (TOUS) (Lenz et al., 1997) guided the symptom-clustering 
analysis. The TOUS emphasizes the importance of consideration of symptom experiences as 
clusters.  Incorporating the experience of symptoms “as clusters” (adapted from TOUS) would 
allow researchers to have a broader view of the symptom-related variables that contribute to the 
symptoms clusters, as well the symptoms-related recovery outcomes (e.g., cognitive and 
functional recovery).   
The PNI framework guided the investigation of these relationships, and the results 
revealed that co-occurring symptoms synergize to negatively impact cognitive and functional 
recovery.  Additionally, the findings revealed that genetic variants (i.e., SNP rs1800497 
ANKK1) could predispose MTBI patients to more intense behavioural symptoms post-MTBI, 
which is consistent with the embodiment of mind and body.  That is, a unique genetic phenotype 
may predispose an individual who suffers mild traumatic brain injury to exhibit more intense 
psychological symptoms.  This line of thought is consistent with this study’s finding that patients 




and anxiety.  That is, those with A1/A1 had a significantly greater level of somatisation and 
anxiety as compared to A1/A2 genotype.  Thus, we could perhaps, speculate that different 
genotypes could have a positive relationship with such psychological symptoms post MTBI. 
These preliminary results offer compelling impetus for further exploration of genetic variants 
linked to mental health outcomes in individuals who suffer MTBI.  Such findings are innovative, 
as they may lead to novel genotype-based biomarkers predictive of who is at risk for worse 
outcomes as early as possible.  
Discussion of Study Aims  
Aim 1: Different Profiles of MTBI Patients and Intensity of Behavioral Symptoms 
The first aim of this study was to identify different profiles of MTBI patients based on 
the intensity of depressive mood, fatigue, and poor sleep.  First, symptom clusters analysis was 
used as a predictive tool for profiling subgroups with enduring behavioral symptoms post-MTBI.  
Such an analysis can reveal symptom interrelationships (Aktas et al., 2010) and facilitate 
exploring the influence of symptoms on each other (AIM 1) and on cognitive and functional 
outcomes (AIM 2).  It is well established from previous research that MTBI patients can suffer 
from anxiety, fatigue, poor sleep, and depressive mood for weeks and months after injury 
(Ayalon et al., 2007; Bay, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al., 1996; Chaput 
et al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport et al., 2006).  
However, few studies have identified behavioral symptom clusters in MTBI patients, and no 
prior study has addressed the extent to which clusters of these symptoms influence functional 
and cognitive outcomes over time. 
The results for Aim 1 extend the existing literature regarding persistence of behavioral 




symptoms or the co-occurrence of two symptoms.  For example, it has been shown that MTBI 
patients who experience sleep disturbance are also more likely to suffer depressive symptoms 
(Auxemery, 2012; Bay & Donders, 2008; Bay, 2009; Beaulieu-Bonneau & Morin, 2012; 
Chaput et al., 2009; Guskiewicz et al., 2007; Kristman et al., 2014; Levin et al., 2005; Mooney 
& Speed, 2001; Ponsford et al., 2011; Rapoport et al., 2006).  Prevalence of depression is 15% 
in the first 3 months post-MTBI (Rapoport et al., 2003) and 18% up to a year after MTBI (Rao 
et al., 2010). These prevalence rates are similar to what was observed in the present study, as 
the present findings found that 25.3 % of the sample reported sleep disturbance (17.4 % mild, 
6.5 % moderate, and 1.5% severe) at six-month post-MTBI. Also, the LCA results revealed that 
7 % of cases had high depression symptoms/low fatigue symptoms (Class 2) and 15% of cases 
had high levels of depressive symptoms along with other symptoms (Class 4).  In addition; 
however, the present results also demonstrate that high levels of sleep disturbance and fatigue 
accompanied such high levels of depression.   
Fatigue is a prominent symptom following TBI, with self-report prevalence rates ranging 
from 43%–73% (Belmont et al., 2006). Fatigue can also endure as a predominant symptom 
several years after the TBI (Cantor et al., 2008; Ouellet et al., 2004). In comparison, the present 
findings reveal that 43.3 % of the sample (24.4 % mild, 14.9 % moderate, and 4% severe) report 
fatigue at six-month post-MTBI; while the LCA revealed prevalence of high fatigue in 9.5% of 
the cases (Class 3), and 15.9% of the cases reported high levels of fatigue symptoms along with 
other symptoms (Class 4). Fatigue after TBI has the potential to impact activities of daily 
functioning, occupational and leisure activities, and thus quality of life (Cantor et al., 2008; 
Ouellet et al., 2004). Although cluster analysis has not been conducted, correlational studies 




disturbance, perceived stress, somatic symptoms, anxiety and depression (Bay & Xie, 2009; 
Bushnik et al., 2008; Ponsford et al., 2000), which resonate with the clustering of symptoms (i.e., 
fatigue, depression, and sleep disturbance) in Class 4.  Along the same line, a prospective 
longitudinal study assessed fatigue and associated factors in patients at 6, 12, and 18-24 months 
after TBI (Bushnik et al., 2008). Results of that study revealed self-reported fatigue improved 
during the first year, as did pain, sleep quality, cognitive independence, and involvement in 
productive activity. On the other hand, the subset of individuals who reported significant 
increases in fatigue over the first two years demonstrated poorer outcomes in regard to cognition, 
motor symptoms, and general functioning than those with decreased or stable fatigue (Bushnik et 
al., 2008).   
In comparison, our results revealed significant group differences in the level of 
satisfaction with life. Those results showed that those who reported low symptoms had 
significantly greater levels of functional outcomes and good recovery, and greater levels of 
satisfaction with life as compared to individuals reporting high levels of fatigue. Further, those 
reporting high fatigue symptoms reported a level of satisfaction considered slightly below 
average.  As for cognitive outcomes, there were significant group differences in the level of 
mental flexibility and results were trending toward indicating that the low symptoms group 
appears to have more improved performance compared to individuals reporting high fatigue 
symptoms. 
Although systematic and comparative studies of fatigue after MTBI are limited, severe 
fatigue has been shown to be highly correlated with the experience of acute symptoms 
(Stulemeijer et al., 2006). In a longitudinal prospective study, post-MTBI fatigue was prevalent 




Interestingly, depression and earlier prevalence of fatigue were highly correlated with later 
depression.  Although fatigue was exacerbated by depression, it was not related to increased 
anxiety (Norrie et al., 2010). Post TBI fatigue appears to be persistent after mild-to-moderate 
TBI.  For example, in those who were hospitalized and followed prospectively for symptom 
persistence and disability outcome, fatigue was present in 57% and persisted in 42% of the 
sample at one year (van der Naalt et al., 1999). Collectively, the findings of this secondary 
analysis and that of others highlight the importance of addressing fatigue after MTBI to identify 
biomarkers that can discern which MTBI patients are at risk for more severe symptoms.  Such 
identification will permit the implementation of interventions earlier for better quality of life.  
Sleep disturbance is a common complaint following TBI, and it is more common with 
MTBI (Beetar et al., 1996; Clinchot et al., 1998; Fichtenberg et al., 2000; Mahmood et al., 2004).  
In recent reviews, 30–70% of TBI survivors reported sleep disturbances (Orff et al., 2009). Most 
of the time the sleep disturbances are directly related to the TBI, enduring for months and/or 
years after the injury, consequently hindering the recovery process and return to pre-injury 
function (Orff et al., 2009). In comparison, the present findings are similar to the literature as the 
findings revealed that sleep disturbance was prevalent in 32.2% of the sample (14.4 % mild, 10.9 
% moderate, and 7% severe) at six-month post-MTBI; and the LCA revealed that 15.9% of the 
cases had high levels of sleep disturbance (i.e., Class 4). 
The above described how fatigue, depression, and sleep disturbance are relevant long-
term outcomes in MTBI patients, in approximately 15% of MTBI survivors.  MTBI research has 
primarily focused on studying symptom(s) (single, parried or all symptoms) experienced 3, 6, 12 
months or years post injury. As mentioned earlier, MTBI patients can suffer from depressive 




Bonneau & Morin, 2012; Beetar et al., 1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 
2010; Ponsford et al., 2000; Rapoport et al., 2006). Although there is ample research regarding 
symptoms experienced post-MTBI, to date only six studies used cluster analysis to identify 
symptom profiles related to recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al., 
2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010).  These studies attempted to 
explain the cluster of behavioral symptoms posited to underlie cognitive and functional recovery 
in MTBI survivors, which is a critical first step to improve risk assessment and to better manage 
post-MTBI outcomes (Lingsma et al., 2014).  In contrast, analysis of symptom clusters has been 
a focus of research in oncology, in which a symptom cluster is defined as co-occurring 
symptoms that share a common influence on an outcome (Fox & Lyon, 2007).  That literature 
provides overwhelming evidence that fatigue, depression, and insomnia commonly co-occur and 
exacerbate each other in cancer patients (Donovan & Jacobsen, 2007).  For example, pain, 
fatigue, anxiety, insomnia, and depression are commonly co-occurring symptoms in breast 
cancer (Fiorentino, Rissling, Liu, and Ancoli-Israel, 2011).  These findings suggest potential for 
practitioners to develop customized and comprehensive approaches that target not only one 
symptom but multiple symptoms; thus, breaking the vicious cycle whereby individual symptoms 
exacerbate each other.  
Another closer look at the results of Aim 1 revealed that Class 3 (9.5%) was 
characterized by low depression and high fatigue, whereas Class 2 (7%) was characterized by 
low fatigue and high depression; both classes had the same ratings of low levels of sleep 
disturbance. These results appear contradictory, given the strong relationship between fatigue 
and depression across different healthcare settings and populations, from community samples to 




Mavreas, 2003; Skapinakis, Lewis, & Meltzer, 2003).  However, fatigue has long been a very 
challenging and elusive concept to comprehend by researchers and health care providers. Results 
are unclear, yet interesting, in that they do not co-occur in Class 2 and Class 3 (each are high 
without the other being high). Yet, they co-occur in 15% of cases in Class 4. Nevertheless, there 
are some factors, which may explain why fatigue and depression do not necessarily always co-
occur. First, it is important to acknowledge that they are district concepts and independent of 
each other despite sharing some similarities and connections.  Beyond that acknowledgement, 
there are several differences why fatigue and depression do not always co-occur:  
(1) There are symptom presentation differences (Leone, 2010); that is, feeling depressed and 
tearful is different than feeling fatigued and tiring more easily (King et al., 1995).  Also 
depression is operationally defined as feeling blue, feeling no interest in things, feeling 
lonely, feeling hopeless about future, feeling worthlessness, and/or having auicidal 
thoughts (Meachen et al., 2008). 
(2) There are biological differences in the regulation of the hypothalamic–pituitary–adrenal 
(HPA) axis associated with fatigue and depression. Interestingly, with chronic fatigue 
syndrome a down-regulation of the HPA axis is observed, while with depression an up-
regulation of the HPA axis is observed (Parker, Wessely, & Cleare, 2001).   
(3) There are differences in epidemiology and etiology determinants. For example, one study 
evaluated genetic and environmental antecedents of fatigue, anxiety, depression and 
psychological distress in healthy adult twin pairs (n= 1004; 533 monozygotic and 471 
dizygotic, age >50). Results distinctively reveled the etiological independence of 
prolonged fatigue; both genetic and environmental determinants were independent for 




genetic factor influenced anxiety and depression, while another independent genetic 
factor solely influenced fatigue. Congruently, fatigue was linked to unique particular non-
overlapping independent environmental factors, incomparable to environmental factor 
influencing psychological distress. Others note that despite some overlap, fatigue is 
independent from psychiatric symptoms, specifically depressive symptoms (Hickie, Kirk, 
& Martin, 1999). 
On the other hand, there is growing evidence that supports the association between 
depression and fatigue, where both may predict and influence each other over time, and this may 
be partially explained by similar risk factors (Harvey, Wadsworth, Wessely, & Hotopf, 2008; 
Huibers, Leone, van Amelsvoort, Kant, & Knottnerus, 2007; Skapinakis, Lewis, & Mavreas, 
2004). This notion emphasizes the importance and necessity of prolonged measurement of long 
term outcomes, as MTBI patients can suffer from depressive mood, fatigue, and poor sleep for 
weeks and months after injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & 
Morin, 2012; Beetar et al., 1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010; 
Ponsford et al., 2000; Rapoport et al., 2006).  If untreated, individuals who fall into Class 2 and 
Class 3 may be predisposed to more severe, debilitating long-term outcomes; specifically, those 
in Class 2 may be predisposed to depression, whereas those in Class 2 maybe be predisposed to 
fatigue. 
The demographic and health characteristics of the individuals grouped into the four 
classes were similar; however, there were some minor trending differences and other significant 
differences (i.e., employment status and GCS score). First, there were trending differences in 
social behaviors, history of behavioral symptoms (i.e., anxiety, depression, sleep disturbance), 




consumption (65.6%) compared to other classes; yet, it is not clear if this was a pre-existing 
behavior or if it developed in association with the post-MTBI symptoms. We attempted to 
conduct a chi-square test of independence between LCA groups and social behaviors; however, 
we did not have an adequate sample size to run the chi-square test of independence. As for 
history of behavioral symptoms (i.e., anxiety, depression, and sleep disturbance), Class1 had the 
least reported history of behavioral symptoms (anxiety (9.5%), depression (15.4%), and sleep 
disorder (3.6). A comparison of the history of behavioral symptoms (i.e., anxiety, depression, 
poor sleep) between Class 2 and Class 3 revealed that Class 2 reported a lower percentage of 
history of behavioral symptoms (i.e., anxiety (21.4%), depression (28.5%), sleep disorder 
(7.1%); whereas Class 3 reported a higher percentage of history of behavioral symptoms prior to 
MTBI (i.e., anxiety (26.3%), depression (36.8%), sleep disorder (15.8%). These findings suggest 
that history of behavioral symptoms does not necessarily predict the intensity of symptoms post 
MTBI. Along the same lines, another interesting finding is that only 9.4% of those in Class 4 
reported some history of a sleep disorder, while a low percentage reported history of anxiety 
(25%) and history of depression (31.3%). Although it is valuable to assess for history of 
behavioral symptoms that could relate to susceptibility of poor long-term outcome recovery, no 
such relationship was found in this sample. We attempted to conduct a chi-square test of 
independence between LCA groups and social behaviors; however, we did not have an adequate 
sample size to run the chi-square test of independence.            
Lastly, the findings revealed few significant demographic differences across LCA groups, 
with the only differences observed being differences in employment status and arrival GCS 




(Cohen, 1988). Also, there were statistically significant differences between LCA groups and 
arrival GCS.   
Overall, the findings revealed no major demographic differences across LCA groups; that 
is, no differences were observed in age, gender, and marital status.  It is possible that a larger 
more heterogeneous sample could yield such differences.  If so, this could lead to tailored 
treatment of behavioral symptoms based on age, gender and marital status.  This could also 
provide descriptive insight into the nature of post-injury affective and behavioral symptoms, 
which in turn could lead to establishing a more inclusive conceptualization of needs with 
specifically, customized treatment modalities (Velikonja et al., 2010).  Other studies were able to 
delineate such differences between their predicted profile patterns and associated demographic 
factors (Demakis et al., 2007; Velikonja et al., 2010; Warriner, Rourke, Velikonja, & Metham, 
2003). For example, researchers found cluster membership was associated with education, age 
and employment status, but not with neurological findings (e.g., lesion location) (Goldstein et al., 
2010). It is possible that relationships between demographic factors (i.e., age, gender, marital 
status, education, and employment status) and symptom experience will be found in the 
TRACK-TBI cohort study; thus emphasizing the importance of replicating this analysis with a 
larger sample.  
Taken together, the results demonstrate that LCA can be used to reliably and objectively 
detect subtypes of behavioral symptom clusters post MTBI. These findings go beyond the prior 
research, which primarily focused on single, paired or all symptoms experienced at 3, 6, 12 
months or years post injury. Although there is ample literature describing symptoms experienced 
post-MTBI, to date only six studies used cluster analysis to identify symptom profiles related to 




Snell et al., 2015; Velikonja et al., 2010). The findings from the current study, therefore, 
encourage further studies of the relationship between symptoms experience and evaluation of 
inflammation-related behavioral symptom clusters as a potential predictor of cognitive and 
functional recovery. Thus, there is a critical need to further develop prognostic models of MTBI 
to identify those at greater risk for poorer cognitive and functional recovery and who will most 
benefit from targeted therapy (McMahon et al., 2014).  Explication of the cluster of behavioral 
symptoms (i.e., depressive mood, fatigue, and poor sleep) posited to underlie cognitive and 
functional recovery in MTBI survivors is a critical first step to improve risk assessment and to 
better manage post-MTBI outcomes (Lingsma et al., 2014). 
In addition, an important cluster that emerged from these findings is a group of individuals 
who experience a cluster of high levels of depression, fatigue, and sleep disturbance. It is likely 
that the co-occurrence of these distressing symptoms presents a vicious cycle, in which these 
symptoms reinforce each other making them more difficult to manage. Understanding the 
etiology of this symptom cluster and treatment of these symptoms as a whole may be more 
effective.  However, to accomplish this, mechanistic studies of the linkages among sleep, fatigue, 
pain, and depression are needed to more fully understand the etiology of this symptom cluster, as 
a common biological pathway may underlie this cluster. Such understanding can guide new 
approaches to manage these symptoms as a group. For example, further understanding the 
relationship among symptom clusters could lead to the development of algorithms and decision 
trees for assessment and management. It is important that practitioners comprehensively assess 
symptoms and make informed decisions as to which interventions could target single and 





Aim 2: Latent Cluster Analysis Groups and Cognitive, Functional, and Quality of Life 
Outcomes  
The second aim of this study was to determine (after identifying the latent class that best 
fit the data) if there were any differences among the predicted classes and outcome variables 
(functional, cognitive, and quality with life) at the six-month follow-up. The extent to which 
membership in an identified cluster predicts functional, cognitive, and quality of life outcomes at 
six-months post -MTBI was explored.  Specifically, we assessed the association between the 
four predicted Classes (low symptoms, high depression/low fatigue, low depression\ high 
fatigue, and high symptoms) and three outcomes (functional outcomes assessed by GOSE, 
cognitive outcome: nonverbal processing speed assessed by WAIS-IV Processing Speed Index; 
mental flexibility assessed TMT B-A, and verbal learning assessed by CVLT-II; and quality of 
life outcomes assessed by SWLS.  An analysis of variance (ANOVA) and analysis of covariance 
were conducted to address this aim.  
Depression, fatigue, and poor sleep have been independently associated with impeded 
cognitive recovery from MTBI (Guskiewicz et al., 2007; Mooney & Speed, 2001; Orff et al., 
2009) and the resumption of pre-injury lifestyle and responsibilities (Patterson & Holahan, 2012; 
Silver et al., 2009).  This aim presents a novel approach since predictive power may be gained by 
evaluating clusters of symptoms that co-occur and which may portend slower recovery. 
Determining the existence of symptom clusters is vital in MTBI patients and will lead to further 
crucial investigation into the mechanisms that underlie these clusters, which will advance the 
knowledge regarding cognitive and functional outcomes. Although there is ample literature 




symptom profiles related to recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al., 
2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010). 
The results of Aim 2 identified group differences in functional outcomes between the 
four LCA symptom cluster groups. Findings revealed that those with low symptoms had 
significantly higher levels of functional outcomes and better recovery as compared to high 
depression/low fatigue symptoms, low depression/high fatigue symptom, and between high 
symptoms. Although, fatigue has been linked to poor recovery post-TBI a recent systematic 
review concluded that the impact of fatigue on patient outcomes is unclear and more intensive 
investigation is essential (Mollayeva et al., 2014).  The prevalence and persistence of fatigue 
after TBI has the potential to impact activities of daily functioning, occupational and leisure 
activities, and thus quality of life (Cantor et al., 2008; Ouellet et al., 2004).  Previous studies 
highlight the importance of fatigue after MTBI and the need for further investigation and 
identification of markers that could possibly identify MTBI patients who are at risk for more 
severe symptoms in order to implement interventions earlier for better quality of life in MTBI 
survivors. Thus, the result of this study revealed the potential importance of evaluating clusters 
of symptoms as an approach to increases predictive power to identify trajectories of recover 
(good versus poor). 
The findings also revealed that six months post-MTBI, those with low symptoms had 
significantly greater levels of satisfaction with life as compared to high depression/low fatigue 
symptoms, and low depression/high fatigue symptoms (M=16.89, SD=7.203).  [Note - both of 
these groups reported slightly below average in life satisfaction based on SWLS scoring]. Also, 
individuals with low symptoms also reported significantly greater levels of satisfaction with life 




the SWLS scoring). In fact, there is some support for this notion, as others have showed that 
post- concussive symptoms associated with MTBI reduce psychological quality of life for 
veterans who experienced deployment-related MTBI (Sofko, Currier, Hill, & Drescher, 2016). 
In regard to cognitive outcomes, the results revealed that there were group differences in 
cognitive outcomes between the four predicted LCA Groups with different symptom intensity.  
Specifically, LCA group differences were found in both nonverbal processing speed and mental 
flexibility (i.e., TMT B-A). This is congruent with previous research that demonstrate that MTBI 
patients also have long-term cognitive impairments related to trauma-induced neuro-
degeneration, and these impairments include impairment of memory, changes in executive 
cognitive function affecting the accomplishment of tasks involving complex cognition, impaired 
attention and concentration, and struggles with speed of information processing (slowed) 
(Binder, Rohling, & Larrabee, 1997; Patterson & Holahan, 2012; Silver et al., 2009).   
Our results indicate that those with low symptoms had significantly greater levels of 
nonverbal processing speed, corresponding to the 50th percentile of performance across age 
groups, as compared to high depression/low fatigue symptoms, whose performance 
corresponded to the 25th percentile of performance across age groups.  Few identified 
differences could explain the difference in nonverbal processing. There were trending 
differences between LCA groups and education background and statistically significant 
differences between LCA groups and employment status.  For example, the majority of Class 1 
(Low symptoms) were working full time and received at least minimum wage (50.7%); also the 
majority had either a Bachelor’s degree (39 %) high school diploma (30.8%), or a master’s 
degree (11.7%); while for Class 2 (high depression/low fatigue), the majority were not in the 




could partially explain the differences in nonverbal processing, perhaps a larger sample could 
explain these differences better. 
As mentioned earlier, there were minor trending differences between LCA groups and 
history of depression, with 15.4% of Class 1 reporting a history of depression, while 28.5% of 
Class 2 reported history of depression (this could also explain how Class 2 patients clustered in 
the Class; high depression/low fatigue). Others have previously reported a relationship between 
level of depression and performance on cognitive tests, with higher levels of depression 
correlating with worse cognitive impairment and poor social functioning (Busch & Alpern, 
1998).  In particular, worse prognosis of depression was highly associated with impaired mental 
flexibility and visio-motor tracking (Veiel, 1997).  This suggests that subgroups of patients with 
MTBI could be identified according to their symptom clusters to delineate those who are at risk 
poor cognitive and functional outcomes. 
Additionally, relevant to this study, Ramati et al. (2009) examined the association 
between psychiatric morbidity and cognitive functioning in 86 electrical injury patients. They 
found that patients with multiple psychiatric morbidities showed worse cognitive impairment 
(verbal memory, executive functioning and attention) when compared to electrical injury patients 
with one or no post-injury psychiatric morbidities. Again, this is consistent with the present 
study results, as they reveal a relationship between psychological symptoms and cognitive and 
functional recovery (Ramati et al., 2009). On the other hand, previous researchers have 
established that MTBI patients with a decreased Glasgow Coma Scale score in the acute phase 
exhibit significantly decreased and disturbed cerebral perfusion in the frontal and occipital grey 
matter as seen on a normal non-contrast CT performed directly after admission. Moreover, these 




Such relationships could not be determined in this study. This is likely because the majority had 
a GCS of 15. Nevertheless, the above-mentioned differences between classes could relate to the 
importance of considering the causes of injuries and cognitive recovery.  
Although the present study revealed a significant difference among LCA Groups and the 
level of Mental Flexibility, as assessed by the difference between TMT-B and TMT-A at six-
months follow-up, unfortunately there were no group differences between the LCA Groups on 
the post hoc test. Perhaps a larger sample size could delineate these differences in the future. 
Also, there were no group differences in verbal learning. This again is likely due to the small 
sample size. However, this finding is important when considered with other research in that only 
10-20% of MTBI patients will experience persistent cognitive impairments beyond the acute 
phase; such cognitive impairment significantly disrupts their capacity to resume many pre-injury 
activities (Patterson & Holahan, 2012; Silver et al., 2009).  Perhaps the small sample size could 
explain these results and a larger sample size could more reflective of the symptom experience of 
the miserable minority (who suffer from a plethora of persistent physical, emotional, and 
cognitive symptoms) (R. Ruff, 2005).  In general, the small sample size hindered finding 
meaningful statistical or clinical differences in verbal learning and mental flexibility for the 
“miserable minority.”  
This study is unique and the first of its kind to link behavioral symptom clusters with 
cognitive outcomes post-MTBI.  In one of the few previous investigations Snell et al. (2015), 
conducted a prospective observational study to examine associations between baseline 
demographic, clinical, psychological variables, and six-months follow-up outcome. Using a two-
step approach for cluster analysis, their findings reveled three clusters of psychological 




2015).  Furthermore, they found that the identified cluster-group membership was significantly 
correlated with outcomes. This study supports the notion that groups could be identified early 
post injury based on psychological factors, and that different group membership is correlated 
with different recovery outcomes. Yet again, low adapters were only 25.3% of the whole sample, 
representing a miserable minority.  This is also comparable to the work by Bailie et al. (2016). 
That study explored the taxonomy of combat-related MTBI (n=1341 military personnel) based 
on symptom patterns within two years of evaluation.  Cluster analysis revealed four subtypes 
(primarily psychiatric PTSD group, a cognitive group, a mixed symptom group, and a good 
recovery group). Once more, the largest cluster had an overall low symptom profile, which was 
the "good recovery" group.  
Overall, previous research was limited to identifying whether the long-term cognitive 
impairments correlate with patho-physiological factors of the injury itself, or if these 
impairments are a result of the influence of other psychological adverse outcomes such as 
fatigue, sleep, and depression (Bigler, 2008; Wood, 2004).  Historically, researchers attempted to 
theorize and explain the development of long-term cognitive impairment post-TBI (Ryan & 
Warden, 2003).  In this secondary analysis, we identified different behavioral profiles of MTBI 
patients based on the intensity of depressive mood, fatigue, and sleep quality, and determined 
differences in quality of life (i.e., satisfaction with life), cognitive (i.e., non-verbal learning and 
mental flexibility), and functional outcomes at six months post-MTBI among the identified 
behavioral cluster profiles.   
It is crucial to advance the knowledge of how symptom clusters can influence cognitive 
and functional outcomes especially in this understudied MTBI population (as opposed to the TBI 




outcomes remain limited.  Further research on such associations can provide insight as to who 
might be at high risk for poor recover.  Thus, it was imperative to attempt to identify subgroups 
within the MTBI patients that may account for the differences in symptom experiences and 
variation in cognitive and functional recovery outcomes over time.  
The results revealed that those with low symptoms had significantly better cognitive and 
functional and quality of life outcomes, concluding that the intensity of experienced symptom 
clusters can influence long term outcomes negatively. Although there is ample literature about 
symptoms experienced post-MTBI, to date only six studies used cluster analysis to identify 
symptom profiles related to recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al., 
2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010). Given this discussion and 
our analysis, one might argue that simply inquiring about symptoms experienced post-MTBI by 
healthcare professionals will improve long term outcomes and predict those who are more at risk 
for poor recovery. Thus, the results of this study along with previous cluster analysis studies, 
highlights the importance of evaluating symptom clusters to critically provide treatment or 
prevention of long-term complications.  Further, these findings highlight the need for unique 
tailored treatment resources and programs (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom 
et al., 2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010). 
Aim 3: SNPs and Behavioural Symptoms 
The third aim of this study was to explore whether the intensity of behavioral symptoms 
differed with respect to SNPs (rs1800497 (ANKK1,) rs1799971 (OPRM1), SNPs genotype 
(rs1800497 (ANKK1), rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), 
rs279871 (GABRA2), and rs4680 (COMT)). We assessed the differences among SNPs 




with a Global Severity Index (GSI), and 3 clinical subscales: BSI-somatization, BSI-anxiety, and 
BSI-depression), PTSD-PCL (3 subscales; hypervigilance, avoidance, Re-experiencing), and 
RPQ-13, and Rivermead Post Concussion Symptoms Questionnaire 13 (RPQ-13). An analysis of 
variance (ANOVA) and analysis of covariance (ANCOVA) were conducted to address this aim. 
Findings revealed no differences in the intensity of behavioral symptoms, as assessed by 
three main measures (BSI-GSI, BSI-somatization, BSI-anxiety, and BSI-depression, PTSD-PCL 
(hypervigilance, avoidance, Re-experiencing), and RPQ-13) at six months post-MTBI based on t 
five types of SNPs genotype (rs279836 (GABRA2), rs279845 (GABRA2), rs279871 
(GABRA2), SNP1799971 (OPRM1), and rs4680 (COMT)).  However, differences were found 
for patients with different SNP rs1800497 ANKK1 genotype and their level of BSI-somatization 
and BSI-anxiety at six months post-MTBI. Specifically, findings revealed a significant 
difference between SNP rs1800497 ANKK1 and somatization, while controlling for history of 
depression and ethnicity. These findings showed that individuals with A1/A1 had significantly 
greater levels of somatization as compared to A1/A2 genotype.  However, no differences were 
observed between A1/A1 and A2/A2 genotypes, and A2/A2 and A1/A2 genotypes.   
Second, there was a significant difference between SNP rs1800497 ANKK1 and anxiety, 
while controlling for history of anxiety and ethnicity.  Individuals with A1/A1 reported 
significantly greater levels of anxiety than patients with A1/A2 genotype.  However, no 
differences were observed between A1/A1 and A2/A2 genotypes and A2/A2 and A1/A2 
genotypes.  
Ample research has shown that anxiety symptoms are prevalent in the aftermath of a mild 
TBI (Hiott & Labbate, 2002; Koponen et al., 2002; Ma et al., 2014; Mooney & Speed, 2001; 




Stulemeijer et al., 2006; Woodcock & Morganti-Kossmann, 2013).   Our results revealed that 
ANKK1 might predispose individuals to experience persistent symptoms of anxiety and 
somatization) after MTBI, which could impede cognitive recovery. These results are important 
when considered in combination with other research. For example, McAllister et al. showed 
rs1800497 (T allele) to be negatively associated with poorer performance on cognitive outcomes, 
specifically poorer verbal learning, at one-month post mild to moderate TBI (McAllister et al., 
2005; McAllister et al., 2008). Subsequently, others examined the influence of the (C/T) SNP 
rs1800497 on post-TBI outcome using data from two multicenter studies: Citicoline Brain Injury 
Treatment trial and TRACK-TBI Pilot. Findings from that study showed that the ANKK1 T/T 
genotype is related to poorer verbal learning performance at six-months post-TBI (Yue et al., 
2015).  Identification of such associations between ANKK and cognitive outcome, will permit 
earlier intervention for those at risk for behavioral symptoms clusters, since behavioral 
symptoms could impede cognitive outcomes as seen in AIM 2. 
Genetic association analyses suggest certain common single nucleotide polymorphisms 
(SNPs) may negatively influence recovery from MTBI (Feng et al., 2015; Lanctot et al., 2010; 
McAllister et al., 2005; McAllister et al., 2008; Pap et al., 2012; Roetker et al., 2012).  Although 
results from this study did not reveal group differences in behavioral symptoms among five 
SNPs (rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), 
and rs4680 (COMT)), we did observe differences in the levels of BSI-somatization and BSI-
anxiety at six months post-MTBI in those patients with different SNP rs1800497 ANKK1 
genotype.  
This study is unique and the first of few studies to link behavioral symptoms to SNPs 




the “miserable minority.”  Ruff et al. (2005) hypothesized that 10- 20 % of MTBI patients will 
suffer long term symptoms, and defined this subgroup as the "miserable minority." New 
approaches can aid in improving the quality of life of these miserable minority who continue to 
experience high levels of behavioral symptoms long after MTBI.  Also, perhaps the TRACK-
TBI cohort with a larger sample size may produce significant differences in symptoms among 
groups that differ with respect to other SNPs genotypes (rs1800497 (ANKK1), rs1799971 
(OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 
(COMT)). The lack of statistically significant findings may be attributed to the small sample size 
and inadequate power to detect statistically significant findings. However, controlling for 
possible correlated covariates added strength and importance to the analysis and produced 
statistically significant differences among groups. As such, these findings highlight the 
importance of considering other variables that could be cofounders for the miserable minority. 
In conclusion, several SNPs have been proposed to be implicated in outcomes post MTBI 
and TBI.  Yet there is a need for replication or validation of those SNPs that may underlie 
individual differences in behavioral symptoms post-MTBI. Only then can this evidence be 
translated to the clinical setting.  If genetic variants predict risk for more intense and enduring 
behavioral symptoms clusters, this might eventually aid in predicting prognoses and responses to 
treatment. Therefore, investigation of these biomarkers genetic variants (SNPs) may provide a 
valuable means to predict persistent and lingering behavioral symptoms in MTBI patients. This 
investigation is significant because it will fundamentally advance knowledge of behavioral 
symptoms in the at risk subgroup of MTBI patients, as well as provide information as to the role 





Summary of Major Findings 
Results revealed that for a sizeable subgroup of MTBI patients, recovery is protracted, 
and prediction of who will experience protracted functional and cognitive recovery was 
explored. Findings from this secondary analysis study increased knowledge as to whether certain 
behavioral symptoms clusters (i.e., depressive mood, fatigue, and poor sleep), differentiate 
cognitive (i.e., mental flexibility and non-verbal learning) and functional recovery; and quality of 
life. Additionally, the LCA identified 4 classes of symptom clusters profiles: Class 1 was the 
largest class, constituting 67.7% of the cases, and was characterized by low endorsement of 
depression, fatigue, and  sleep disturbance. Class 4 accounted for 15.9% and had the highest 
ratings of depression, fatigue, and  sleep disturbance.  Class 3 (9.5%) was characterized by low 
depression and high fatigue, whereas Class 2 (7%) was characterized by low fatigue and high 
depression; both class2 and 3 had the same ratings of sleep disturbance.  
Based on  LCA symptom clusters profiles (i.e., Class 1, 2, 3 and 4), significant 
differences in functional outcomes, quality of life, and cognitive outcomes (nonverbal processing 
speed and mental flexibility) were found at six-months post-MTBI. These differences were: 
 Individuals with low symptoms (Class 1) had significantly greater levels of functional 
outcomes and good recovery as compared to those reporting high depression/low fatigue 




For both high depression/low fatigue symptoms and low depression/high fatigue 
symptoms the reported life satisfaction scores are considered slightly below 
average. Meanwhile, those with high symptoms the reported life satisfaction 
scores of that group is considered “dissatisfied with their life” according to the 
SWLS scoring.   
 For cognitive outcomes, individuals with low symptoms had levels of nonverbal 
processing speed that corresponded to 50th percentile of performance across age 
groups; this performance level was significantly greater as compared to 
individuals reporting high depression/low fatigue symptoms, whose processing 
speed corresponded to the 25th percentile of performance across age groups.  
There were no group differences in nonverbal processing speed between 
individuals with low depression/high fatigue symptoms and those with high 
symptoms.   
 Results revealed significant group differences in the level of mental flexibility at 
six-months follow-up. Those results showed a trend indicating that the low 
symptoms group appears to have better performance compared to other groups. 
Lastly, for the exploratory aim focused on genetic variants, results revealed that 
the ANKK1 genotype might predispose individuals to experience persistent behavioral 
symptoms (i.e., anxiety and somatization) after MTBI; such symptoms could further 





Study Strength and Limitations 
A primary strength of this investigation is the chosen frameworks; namely, the PNI 
framework and the Theory of Unpleasant Symptoms (TOUS).  In combination, these frameworks 
offered an integrated and holistic perspective to guide discovery, which can lead to remarkable 
advancement in symptom science. It is clear that behavioral symptoms arise from complex 
interactions among biological, psychological and social factors; consistent with a PNI 
framework. Overall, the use of an integrated framework in combination with a theory of 
symptom clusters creatively addresses the depth of the interaction among symptoms experienced, 
their impact on recovery outcomes, and may explain individual variation in symptom intensity 
and duration seen in MTBI patients.          
This study acquired data from an existing database, which has both strengths and 
limitations. Overall, secondary data analysis has been a widespread and useful method in health 
promotion research. Nevertheless, there are clear advantages and disadvantages of analyzing 
existing secondary data (Cheng & Phillips, 2014).  One of the most valuable advantages of 
secondary data analysis is the accessibility and ease of data collection; often from large data sets 
than would be impractical to achieve with primary data collection.  This can speed the 
procurement of findings, saving time for the investigator, and stimulating more rapid translation 
of findings to the targeted population (Cheng & Phillips, 2014).  Secondary data analysis can 
lead to unexpected findings and new insights, which can spur hypothesis generation to guide 
future primary data collection.  From a practical point of view, analyzing an existing data set 
requires few resources and is cost effective.  On the other hand, secondary data analysis has its 




specific hypothesis due to the nature and measures used to obtain the original data set. In 
contrast, with primary data collection an investigator can design the study and choose the 
measures to address a specific question. For the current study, measurement of fatigue, 
depression, and sleep had to be obtained from several measures, which may not have adequately 
captured the variables of interest.  Also, there were no biomarkers of inflammation in the data 
set, and these biomarkers were assumed to underlie the clustering of these symptoms.  
Furthermore, the investigator does not have control of data quality or control of potential 
confounders.  However, given the nature, purpose, and oversight of the TRACK-TBI database, 
the data collected could be assumed to be of good quality.  Further, the overall the purpose of the 
TRACK-TBI initiative is to improve long-term outcomes of TBI patients in general, and this 
purpose is consistent with the objectives of the present study.  Therefore, these limitations are 
minimized. Lastly, the availability of the Track-TBI Pilot database provided real-life data from a 
population that is difficult to access single handedly, and this allowed the accomplishment of the 
objectives of this investigation.  
There were limitations in this study based on threats to internal and external validity. 
First, the threat from confounding variables is one of the most important threats the investigator 
needs to account for.  Therefore, this study did control for several confounding variables. For 
example, to address Aim 3 potential, covariates were controlled (i.e., history of behavioral 
symptoms), and this added strength and validity to the findings. However, it is likely that other 
uncontrolled covariates may confound findings, especially as relates to those suffering more 
intense and persistent behavioral symptoms post-MTBI (i.e., the “miserable minority”).  
Another threat to internal validity was missing data.  For this study, data were missing for 




sample size from n=340 to n= 201 for (AIM 1 AND Aim 2), and further reduced the N to 153 for 
Aim 3.  Also, there were missing data regarding injury severity and acute histories. For example, 
duration of LOC and PTA associated with a MTBI has been shown to contribute to worse 
behavioral avoidance and psychological well-being for veterans who experienced deployment-
related MTBI (Sofko et al., 2016).  Therefore, missing data regarding LOC and PTA duration is 
very crucial.  Since this is a secondary data analysis, the research did not have control over data 
that was missing.   
A third threat is selection bias.  For this study, the sample was a convenient and 
nonrandom sample and subject to selection bias. Convenience sampling is known as one of the 
weakest sampling techniques, as available subjects might be atypical of the population of interest 
with regard to critical variables. Selection bias is the most problematic and frequently occurring 
threat to internal validity of studies not using an experimental design (Polit & Beck, 2008).  For 
example, because of the sampling techniques, the majority of the sample was white (84%) and 
male (67%), which limits generalizability. Also, history of behavioral symptoms was not 
controlled for during enrollment; however, it was accounted for in this analysei to address the 
potential impact of this threat to validity; thus attenuating this limitation.   
A fourth threat to validity is history. History refers to the occurrence of external events 
that take place concurrently with the independent variable and which can affect the dependent 
variable (Polit & Beck, 2008).  A case in point is when something happens to the patient 
between follow-up data collection or even before enrollment that influences depression, fatigue, 
or poor sleep.  Such events might be a death in the family or loss of a job. Pre-injury stress has 
been hypothesized to play a role in long-term maintenance of symptoms (van Veldhoven et al., 




of major life events.  In fact, there is support for this notion, as research shows that incidence of 
stressful life events to be a significant predictor of anxiety, depression, and mental health in 
MTBI patients (van Veldhoven et al., 2011). Thus, the experience of stressful events prior to the 
injury may predispose those with MTBI to suffer from poor long-term outcomes. Assessment of 
stressful life events during acute stages post-MTBI is essential (van Veldhoven et al., 2011). 
Again, since this is a secondary data analysis and the researcher was unable to overcome this 
threat. 
Lastly, the use of self-report questionnaires to measure symptoms is considered a minor 
threat to validity. For this secondary analysis, there were no data available that used specific 
validated measures for each behavioral symptom (i.e., anxiety, depression, fatigue, poor sleep).  
Measures for these variables were obtained from either subscales of the BSI- GSI (i.e., BSI-
Depression, BSI-anxiety, BSI- Somatization), or the Rivermead Post-Concussion Questionnaire.  
Use of validated instruments, containing more items, may have revealed more significant 
differences in outcomes among symptom cluster groups.  Again, this was a secondary analysis 
and the researcher was limited by the measurements used in the original investigation.  Perhaps, 
replication of this study with more comprehensive and specific measures of behavioral 
symptoms could produce more representative and valid results. 
Generalizability is identified as a threat to external validity. According to Polit and Beck 
(2008), generalizability is the criterion used in quantitative research to assess the extent to which 
the findings can be applied to other groups and settings. The target population for this study is 
MTBI patients with a range of ethnic diversity. Due to the study limitations, this study may not 
be generalizable to the general population of MTBI patients. However, the findings could 




ability of clinicians to predict those who are at greater risk for worse cognitive/functional 
outcomes.  Another threat to external validity is the relatively small sample size. The TRACK-
TBI pilot phase recruited subjects from three centers, resulting in data collection from 599 
patients (only 340 MTBI patients; with only 201 eligible for the study due to missing data).  
With regard to this secondary data analysis, the results are not generalizable beyond the 
institutions where data was collected and the demographics of the sample; hence, the findings 
cannot be generalizable to all MTBI patients.  
Nevertheless, despite these limitations, ultimately, the knowledge acquired can be used to 
develop and implement improved risk assessment protocols and targeted interventions to those 
most vulnerable for behavioral symptoms and poor outcomes.  
Nursing Implications   
One of the important contributions of the symptom clusters analysis is that in 
addition to profiling subgroups, it also to a certain extent reveals symptom 
interrelationships (Aktas et al., 2010).  This conceptualization of symptom clusters is 
visualized as a paradigm shift in symptom management research.  The goal of symptom 
cluster research is to address the reality of concurrent symptom experiences in different 
populations and to lead to more promising research that will potentially generate 
knowledge needed to rapidly improve symptom management. Thus, the findings from 
this study can contribute to bridging the gap between research and bedside nursing by 
addressing symptoms (as a cluster), which is the most common reason that individuals 
seek healthcare (Larson et al., 1994).  Furthermore, advancing knowledge of symptom 
interrelationships within a cluster might lead to more efficient approaches that target 




leverage scarce recourses and ultimately reduce the symptom burden (Aktas et al., 2010).  
Consistent with this notion, a recent study demonstrated that military MTBI patients who 
completed multidisciplinary treatment reported a reduction in both persistent post-
concussive and PTSD symptoms (Janak et al., 2015).  Thus, profiling subgroups of MTBI 
patients has potential to improve clinical practice, inform clinical practice guidelines, and 
ultimately provide patients with the most effective and innovative treatment modalities 
(Barsevick et al., 2006; Dodd et al., 2001; Kim & Abraham, 2008). 
Additionally, enhanced understanding of which clusters of symptoms relate to the 
development of specific cognitive profiles of MTBI patients would allow for the 
development of future rehabilitation programs that target specific cognitive deficits. 
Furthermore, clinicians could identify patients at risk for poor cognitive and functional 
outcomes based on post-MTBI symptoms experiences/presentations (perhaps symptom 
clusters). Such identification may facilitate the tailoring of earlier interventions to better 
serve this population and promote better quality of life. 
Collectively, several implications can be derived from the findings of this study. 
Nurses are the first line of contact with MTBI patients at their ER visits post-MTBI. In 
most cases, it is the only time they are seeking medical help. Often a diagnosis of a 
“mild” traumatic brain injury could be misleading. After discharge from the ER, they 
may never return for a follow-up visit at a concussion clinic or even to their primary 
physician.  Although a few, but identifiable, number of MTBI patients will suffer from 
lingering long-term symptoms, it is important for nurses to know and understand the 
prevalence of symptom clusters in MTBI patients and their relationship with long-term 




of MTBI and to teach these patients when to seek help prior to being discharged from the 
ER.  It is imperative that nurses are aware of the long-term cognitive and functional 
outcome that are disabling and hinder MTBI patients from retuning to life before the 
injury.  In follow-up concussion clinics, it may be necessary to include self-reported 
measures of depression, fatigue, and sleep quality along with the usually addressed 
questions about physical symptoms (such as headache). For those who report these 
symptoms, a follow-up teaching session is necessary to address the relationship between 
symptom clusters and cognitive and functional outcomes. Health care providers may 
want to consider earlier screening for history of behavioral symptoms that could be 
aggravated by the injury.    
Also, involved family members or supportive people of MTBI patients should be 
educated on the risks of symptom clusters. MTBI patients will most probably need help 
in recognizing these symptom clusters and guidance to see medical help accordingly. If 
the family and support system of the MTBI patients are educated about symptom clusters, 
and cognitive and functional outcomes, they may be more likely to support and even 
recognize the need for MTBI patients to seek medical treatment. MTBI patients’ need to 
be reassured by nurses (the first line of help) that symptom clusters are common and 
there is treatment designed to help them deal with these symptoms. In order to bridge the 
gap between research and nursing practice, it should a high priority for nurses to provide 
sympathetic and compassionate care for these patients, while emphasizing that although 
some can experience these symptoms clusters, early treatment can lead to better recovery. 
 One interesting contribution of this study is the consideration of predictive 




of genetic markers may lead to new ways to prevent, predict, and treat behavioral 
symptoms, and directly or indirectly improve long-term cognitive and functional 
outcomes. Specifically, the preliminary findings of this study suggest that those with SNP 
rs1800497 ANKK1 who had the A1/A1 allele had significantly greater levels of 
somatization as compared to A1/A2 genotype. Additionally, those with A1/A1 reported 
significantly greater levels of anxiety than patients with A1/A2 genotype.  Confirming 
these genetic findings in larger studies can lead to genetic risk profiling for such 
symptoms. Somatization is a very elusive concept, which has been defined in many ways 
(De Gucht & Fischler, 2002).  For example, somatization has been defined as “the 
tendency to experience and communicate somatic distress and symptoms unaccounted for 
by pathological findings, to attribute them to physical illness, and to seek medical help 
for them” (Lipowski, 1988).  Furthermore, some researchers distinguish between 
presenting and functional somatization, with presenting somatization defined as “the 
predominantly or exclusively somatic presentation of psychiatric disorder, most 
commonly depression and anxiety,” (Kirmayer & Robbins, 1991); and functional 
somatization defined as “high levels of medically unexplained symptom reporting in 
multiple physiological systems” (Kirmayer & Robbins, 1991). This added distinction 
draws attention to hidden psychiatric morbidity, especially anxiety and depressive 
disorders (De Gucht & Fischler, 2002). 
Shifting the paradigm to view symptoms as clusters will potentially assist in 
identifying common underlying mechanisms, which can then lead to single approaches to 
treat multiple symptoms.  For example, this may lead to new discoveries that target 




clusters and cognitive impairment) and/or targeting symptoms at the genetics-epigenetic 
level. Using predictive parameters can help ED personnel identify MTBI patients who are 
at higher risk before discharging them from the ED; allowing the opportunity to make 
appropriate referrals and prevent prolonged suffering from debilitating symptoms. This is 
a clinically relevant and important area for research, as early identification and providing 
more knowledge about risk factors for MTBI behavioral symptoms soon after the injury 
can help initiate preemptive treatment; thus, promoting optimal quality of life in the long 
run.    
Implications for Cytokines-Brain Signaling  
It is well established that one of the causative factors implicated in cognitive impairment 
following MTBI is neuro-inflammation, which is likely related to dysregulation of pro-
inflammatory cytokines (Huang & Sheng, 2010; McAfoose & Baune, 2009; J. A. Smith et al., 
2012).  For example, ample evidence shows that when the microglia are activated post-injury, 
they release pro-inflammatory cytokines (e.g., IL-1, IL-6, and TNF-α), which, in turn, alter 
neuro-cognitive function. Thus, it is possible that cytokine dysregulation could orchestrate the 
long-term development and pathogenesis of neuropsychiatric disorders (McAfoose & Baune, 
2009).  Emerging research suggests that enhancing the environment may improve cognition by 
restoring cytokine balance, as discussed below. 
Interventions to reduce long-term consequences of MTBI.  Environmental 
enhancement (EE) refers to conditions that provide increased social, cognitive, and physical 
stimulation.  Such enhancement could help decrease the negative long-term consequences of 
MTBI subsequent to neuro-inflammation. EE may also decrease the alterations in brain energy 




levels of the pro-inflammatory cytokines IL-1β and TNF-α and enhanced levels of the anti-
inflammatory cytokine IL-10 after MTBI (Briones et al., 2013). Also, there is evidence that EE 
alleviated MTBI-induced cognitive impairment in rodent models (Briones et al., 2013).  Thus, 
these findings demonstrate the potential of EE to attenuate the persistent neuro-inflammatory 
state, which occurs after MTBI (Briones et al., 2013). 
Behavioral therapies implications. Behavioral therapies could be exploited to alleviate 
stress and other adverse environmental factors that may potentially lead to epigenetic 
modification within the brain and restoration of brain function. For example, exercise can result 
in weight loss and help provide resistance to stress-induced chromatin remodeling within the 
brain. It has been shown that rats that were exposed to greater physical activity prior to stress 
exposure exhibited resistance to stress-induced chromatin remodeling within the dentate gyrus 
(Bilang-Bleuel et al., 2005).  These findings demonstrate that stress-related learning results in 
hippocampal chromatin remodeling, which may facilitate behavioral adaptation to environmental 
changes. This presents an opportunity for the exploration of other behavioral life-style changes 
that could aid in the prevention or restoration of epigenetic modification (Mathews & Janusek, 
2011) and may offer potential to prevent and/or restore cognitive function after MTBI. 
Recently, Yehuda et al. (2013) examined the association between methylation of the GR 
and FKBP5 genes, downstream neuroendocrine measures, cortisol, and NPY, and before and 
after prolonged exposure to psychotherapy in combat veterans with PTSD (N=8). The purpose 
was to determine if cytosine methylation in promoter regions of the glucocorticoid-related 
NR3C1 and FKBP51 genes would predict or correlate with treatment (prolonged exposure 
psychotherapy) outcome in these patients. These results denote that specific genes can be 




replication and validation, they support research indicating that some glucocorticoid-related 
genes are subject to environmental regulation throughout lifespan, and also that psychotherapy 
treatment may alter epigenetic state through environmental regulation. This is the first 
longitudinal study of an epigenetic alteration in association with behavioral treatment outcomes. 
This study represents an important initial step in establishing relevant molecular markers for 
PTSD therapies (Yehuda et al., 2013), and perhaps injury-related traumatic events that results in 
MTBI and risk for PTSD post-injury (Yehuda et al., 2013). 
Several symptoms (e.g., pain, sleep disruption, and fatigue) can result from the persistent 
release of cytokines as a response to inflammation; thus specific treatments aimed to block 
cytokine production may have a direct effect on symptoms relief. Furthermore, the model of 
cytokine-induced depression provides valuable insight into the relationship between cytokines 
and depression (Dantzer, 2009).  Clinicians may explore the implications of sickness behavior 
related to depression and specific disease-related symptoms.  For example, nurses could benefit 
from increased awareness and understanding of the relationship between pro-inflammatory 
cytokines and sickness behaviors. Enhanced knowledge in this arena will aid nurses in assessing 
and identifying vulnerable patients at risk for these sickness behavior symptoms.  
Future Research  
  Collectively, the results from this study provide compelling impetus for further 
exploration of behavioral symptom clusters post-MTBI using genetic and PNI paradigms. 
Findings that suggest symptom clusters participate directly or indirectly in the symptomatology 
of functional cognitive impairment in trauma patients is fascinating and worth further 
investigation. Future investigation of genetic variants could provide information for the 




anxiety. As such, this study enhanced the knowledge regarding relationships among genetic 
variants, symptom clusters, and functional outcomes post MTBI.  Yet, given that many of the 
findings in the current study were trending toward significance, a larger study is needed to 
determine if there are additional statistically significant differences in cognitive outcomes, 
specifically, verbal learning.  A well-powered study may reveal significant findings regarding 
differences among groups based on the six different SNP genotypes evaluated in this study (i.e., 
rs1800497 (ANKK1), rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), 
rs279871 (GABRA2), and rs4680 (COMT). Additionally, future studies could benefit from use 
of additional and more comprehensive symptom measurement instruments and a longitudinal 
design which evaluates patients beyond six months. As well, the addition of reliable measures 
for each symptom (fatigue, depression, and poor sleep) could yield more favorable results.  
Second, it has been long emphasized that longitudinal research regarding post-discharge 
cognitive impairment in MTBI patients is needed, as it is possible that persistent intense 
behavioral symptoms sustain cognitive and functional outcomes in the absence of long-term 
structural damage (Bernstein, 1999). These studies will help inform the development of the most 
appropriate treatment approaches for MTBI patients with persistent intense symptoms and poor 
cognitive and functional outcomes.   
Following the aims of the TRACK-TBI initiative, this current secondary analysis 
identified symptom clusters that account for variability in cognitive and functional outcomes 
post-MTBI. The above-mentioned clinical implications are suggestive of the need for more 
future prospective studies of symptom management designed to identify components of specific 
collaborative multidisciplinary innovative-therapeutic interventions that contribute to symptom 




call for further investigation of the prevalence of cognitive impairments after the reduction or 
elimination of symptoms. Also, the results can open the venue for more research in specific 
areas; studies of genetic, epigenetic, neurobiological and inflammatory mechanisms underlying 
MTBI; as well as intervention studies that incorporate PNI (mind-body) framework. 
Future Genetic Studies 
There is increasing knowledge of gene-to-brain communication and the complex ways in 
which genes regulate brain function and behavior.  Yet, there is a need to increase such evidence 
in human paradigms for translation to clinical practice.  Results from this study revealed that the 
symptom experience negatively affects MTBI patients. Further, results suggest specific pre-
existing genetic variants (i.e., ANKK) predispose certain individuals to more persistent 
behavioral symptoms post-injury (i.e., anxiety and somatization).  Determining the extent to 
which genetic variants contribute to the symptomatology of more intense behavioral symptoms 
in MTBI patients can result in novel biomarkers to predict behavioral symptoms as early as 
possible.  The identification of these genetic variants may shed light on viable targets to predict 
distinct sets of behavioral symptoms. Such knowledge may eventually help in genetic-targeted 
intervention tailored for greater treatment response and tolerability, and improvement of 
resiliency against developing inflammatory cytokine-associated behavioral symptoms. 
Future Epigenetic Studies  
Environmental exposures have been shown to affect the activity of the methylation 
machinery, leading to behavioral and mental pathologies. Future epigenetic studies can provide 
key insight into the impact of environment-gene interaction on behavior and vulnerability to 
poor health over the human lifespan (Mathews & Janusek, 2011).  Since evidence shows that 




window for a variety of novel epigenetic-based interventions that could be implemented at 
periods of biological vulnerability (i.e., post-trauma) to prevent the harmful effects of stress and 
reduce incidences of intense behavioral symptoms post MTBI.   
Individuals who suffer traumatic brain injury are at risk for post-traumatic stress disorder 
(PTSD). Recently, traumatic events have been found to induce epigenetic modifications for 
genes that encode immuno-regulatory proteins in individuals with PTSD (Segman et al., 2005).  
Evidence reveals that for PTSD patients, the experience of a traumatic event triggers downstream 
alterations in immune function by decreasing methylation of immune-related genes (Uddin et al., 
2010).  These findings demonstrate the capacity of a traumatic event to trigger long-lasting 
epigenetic-induced alterations (i.e., DNA methylation) in immune function, possibly through 
brain-immune interactions (Uddin et al., 2010).  Although currently there is little evaluation of 
stress-related epigenetic modification in trauma survivors, the findings in individuals with PTSD 
provide preliminary evidence suggesting this possibility (Uddin et al., 2010).  Investigation of 
these biomarkers (DNA methylation and pro-inflammatory cytokines) may provide valuable 
information for understanding the link between behavioral symptoms and cognitive/functional 
outcomes in MTBI patients.  Such understanding is a critical first step that will improve risk 
assessment and ultimately lead to prevention and/or better management of trauma-associated 
behavioral symptoms. Moreover, future studies that enhance the knowledge regarding the role of 
epigenetic modification (i.e., DNA methylation) has potential to lead to predicting at discharge, 
which MTBI patients are at risk for prolonged behavioral symptoms.  These studies can guide 
the future development of personalized epigenetic-based approaches to identify and treat trauma 





Future Neurobiological Mechanisms and Pro-Inflammatory Cytokines Studies 
The results from this secondary analysis study have increased knowledge of the 
importance of body-to-brain communication, but there is a need to further increase such 
evidence in human paradigms for translation to clinical practice. Furthermore, the 
neurobiological mechanisms underlying the behavioral effects of pro-inflammatory cytokines 
have not been investigated in a manner that correlates to a given behavioral effect of a cytokine 
on a well-defined area of the brain. For this reason, micro-pharmacology experiments that target 
inflammatory mediators in specific brain areas must be implemented to define cause-effect 
relationships (Dantzer et al., 2008). The identification of the intracellular association between 
inflammation and behavioral symptoms (i.e., depression) will provide valuable targets for the 
development of new antidepressant drugs, if the activation of brain pro-inflammatory cytokine 
signaling is proven to represent the final common pathway for the various conditions that lead to 
depression (Dantzer et al., 2008). 
With respect to MTBI, low-grade systemic inflammation might contribute to the 
development of psychological long-term morbidities in patients with MTBI. Yet, studies focused 
on the systemic inflammation following MTBI are limited.  Findings from animal models of 
MTBI do show that systemic inflammatory processes are activated post-MTBI; specifically 
circulating IL-6 levels are increased in rodent models of MTBI (Holmin et al., 1997; Shohami et 
al., 1994; S. H. Yang et al., 2013).  Similarly, Yang et al. (2013) found serum cytokines 
interleukin-6 and keratinocyte-derived chemokine to be significantly increased within 90 minutes 
after MTBI in a murine model.  In a rat model of closed head injury, Shohami et al. (1994) found 
elevated levels of IL-6 following injury, and suggested that rapid production of IL-6 following 




Yet, it still remains unknown whether the systemic inflammatory process could be used 
as predictive markers for psychological outcomes after MTBI. Thus, it presents a fruitful area of 
research, in view of the fact that it is well established that systemic inflammatory processes 
activate the neuroendocrine HPA axis (Murray et al., 2013) and were found to result in chronic 
stress linked to anxiety and depression (Mustafa, 2013).  Also, systemic inflammation results in 
an increase in indoleamine 2, 3-dioxy-genase (IDO) expression (Yamada et al., 2009), which 
leads to an overproduction of kynurenic and quinolinic acids, and subsequent reduction of 
serotonin within the brain.  Lower serotonin is established to result in depression and other 
psychological and behavioral problems (Capuron & Miller, 2011; Haroon et al., 2012; A. H. 
Miller et al., 2009). Therefore, investigation of acute circulating inflammatory marker responses 
is a fruitful area which may provide insight into the role of psycho-neuro-immunological 
processes in MTBI patients. Additionally, standardization of appropriate markers of 
inflammation and a systematic approach for investigation of the risk factors will improve 
outcomes and quality of life. Furthermore, it is possible to develop clinical trials aimed at 
blocking cytokine production or action, attenuating the production of second messengers or 
deactivating glial cells and halting excessive quantities of pro-inflammatory cytokines.  More 
research is needed in this area to enhance its innovative potential and avoid the duplication of 
efforts likely to occur because of the diversity of pathological conditions that lead to non-specific 
clinical signs of sickness behavior (Dantzer & Kelley, 2007). 
Taken together, future studies are warranted to illuminate the precise effects of certain 
cytokines and explore targets for interventions and therapies in the MTBI population. For 
example, targeting of inflammatory pathways for depression treatments post-MTBI can provide 




may be most appropriate for immune-targeted therapies.  Such studies can lead to the 
development of feasible and effective interventions to identify patients at risk for sickness 
behaviors; thus, preventing or decreasing the negative effects of cytokine-induced inflammatory 
responses, which reduce quality of life post-MTBI. 
Intervention Studies 
Findings from this secondary data analysis revealed that somatization and anxiety were 
common symptoms after MTBI.  Further, a significant relationship between SNP rs1800497 
ANKK1 and anxiety and somatization was revealed; suggesting that this genetic variant 
predisposed these individuals to these particular behavioral symptoms. Therefore, perhaps 
screening MTBI patients for genetic variants linked to risk of these symptoms could lead to early 
targeting of treatment and improvement in recovery. 
Also, since symptom clusters predicted poor function and cognitive recovery, future 
intervention studies may want to use EE to treat depression, stress, and anxiety at the same time.  
The successful treatment of those symptom clusters may improve cognitive and functional 
outcomes and subsequently quality of life for those most affected (i.e., the “miserable minority”). 
Also, the consideration of controlling for previous history of behavioral symptoms and prior 
stressful life events could yield better results. Early implementation of treatment modalities for 
the “miserable minority” could improve or even prevent long-term cognitive impairment. Future 
studies are needed to evaluate novel interventions that target symptom clusters, so that such 
treatment could be incorporated into cognitive and functional rehabilitation programs for those 
who suffer MTBI.  Promising interventions include cognitive behavioral therapy or mindfulness-






For a sizeable subgroup of MTBI patients, recovery is protracted, and prediction of who 
will experience protracted recovery was explored. Findings from this secondary analysis study 
attempted to increase the understanding of the role of depressive mood, fatigue, and poor sleep 
as a symptom cluster, on cognitive and functional recovery. This enhanced knowledge can guide 
future studies that may pursue the following: (1) evaluate use of behavioral symptom clusters as 
risk factors for poor cognitive/function outcomes and poor quality of life post-MTBI, and (2) 
evaluate the usefulness of biomarkers (genetic variants, epigenetic modifications and pro-
inflammatory cytokines) as predictors for the risk of more intense and enduring behavioral 
symptoms in MTBI patients.  Ultimately, the knowledge from this secondary analysis can be 
used a starting point to build on and develop clinical strategies for earlier identification (i.e., at 
discharge) of MTBI patients who are at risk of such behavioral symptoms. This crucial 
knowledge can positively impact the care of MTBI patients, as it will stimulate the development 
and implementation of specific symptom profiles to be used clinically to stratify risk for poor 
recovery and to identify those who may require earlier and more intense intervention to promote 
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Table 1. Study Variables 
Note: BSI-18= Brief Symptom Inventory=18, PTSD-PCL= The Post-Traumatic Stress Disorder Checklist Civilian Version, RPQ=The Rivermead Post-Concussion 
Symptoms Questionnaire, SNP= single-nucleotide polymorphism, GOSE= Global outcomes Glasgow Outcome Scale-Extended score, WAIS-IV= Wechsler Adult Intelligence 
Scale-IV, CVLT-II= California Verbal Learning Test-II, TMT B-A= the difference score between the Trial Making Test B and TMT A, SWLS= Satisfaction with -Life Scale  
 
  
PRIMARY VARIABLES TO BE USED IN THE ANALYSIS 







and rs4680 (COMT) 
PTSD-PCL Nonverbal Processing 
Speed assessed by 
WAIS-IV  
SWLS GOSE  
RPQ (Sleep Disturbance, Fatigue, 
Depression items) 
Verbal Learning 
assessed by CVLT-II 
BSI-18 (Depression, Anxiety, & 
Somatization subscales) 
Mental Flexibility 




Table 2. Tools and Data Collection Time Points  
  T1: 3-month T2: six-month 
Background information 
Demographic Information & health assessment X  
Age & Gender X  
Biological Variables  
SNPs rs1800497 (ANKK1) rs1799971 (OPRM1), rs279836 (GABRA2), 
rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT) X  
Psychological/Behavioral Variables 
PTSD-PCL X 
RPQ (Sleep Disturbance, Fatigue, Depression items) X 
BSI-18 (Depression, Anxiety, & Somatization subscales) X 
Cognitive outcomes 
Nonverbal Processing Speed assessed by WAIS-IV  X 





Table 2 (cont.)  
Mental Flexibility assessed by TMT B-A X 
Quality of life  
SWLS X 
Functional outcomes 
GOSE  X 
Note: BSI-18= Brief Symptom Inventory=18, PTSD-PCL= The Post-Traumatic Stress Disorder Checklist Civilian Version, 
RPQ=The Rivermead Post-Concussion Symptoms Questionnaire, SNP= single-nucleotide polymorphism, GOSE= Global 
outcomes Glasgow Outcome Scale-Extended score, WAIS-IV= Wechsler Adult Intelligence Scale-IV, CVLT-II= California 
Verbal Learning Test-II, TMT B-A= the difference score between the Trial Making Test B and TMT A, SWLS= Satisfaction 























A frequently studied SNP, known as TaqI polymorphism Dopamine D2 receptor reduction DRD2 gene (rs1800497 allele (T)) 
is associated with neurobiological correlate evidenced by the decreased dopamine binding sites in the brain (Pohjalainen et al., 
1998) 
There is some evidence suggesting that ANKK1 pays a role in comorbid substance use disorder (Blum et al. 1996), 
diminished reaction to negative action consequences, which may explain an increased risk for addictive behaviors in A1-allele 
carrier specifically (Klien et al, 2007), and risk for chronic renal disease and high blood pressure (Jiang et al., 2014).  Also, 
traumatic brain injury patients who are carriers of rs1800497(A) alleles recover slower as assessed by memory and attention 









Carriers of at least one rs1799971(G) allele are more at higher risk for alcoholism than carriers of two A alleles. (van den 
Wildenberg et al., 2007; Bart et al., 2005; Bergen et al., 1997; Crowley et al., 2003; Miranda et al., 2010); however, in 
alcoholics treated with naltrexone, rs1799971(G) carriers had better clinical outcome when compared to rs1799971(A: A) 
carriers (Anton et al., 2008).  In regards to influences of opioids consumption (i.e., heroin, codeine or morphine): 
rs1799971(G) allele carriers consumed more opioids for analgesia but still reported higher pain scores and less nausea and 
vomiting than rs1799971(A: A) allele carriers during the first 24-hour postoperative period (Ren et al., 2015).  A118G 











This SNP in the GABRA2 gene has been linked to Alcoholism (Rangaswamy and Porjesz, 2008; Lind et al, 2008), and has 
been found to be associated with human cocaine addiction (Dixon et al., 2010).  Some research suggests it can be used as a 
marker for alcoholism (Zintzaras, 2012).  Evidence are suggestive that GABRA2 might influence susceptibility to alcohol 
dependence by modulating the level of neural excitations specifically in carriers of these alleles:rs279871(A) + rs279845(T) + 








Table 3 (cont.)   









Associated condition: panic disorder 1 and schizophrenia (Gupta et al., 2009), cocaine dependence (Lohoff at el., 2008), 
breast cancer (Onay et al., 2008), venous thrombosis (Gellekink et al., 2007).  Val alleles have increased COMT activity 
and lower prefrontal extracellular dopamine compared with those with the Met substitution (Stein et al., 2006).  Val158 
alleles may be associated with an advantage in the processing of aversive stimuli (warrior strategy). Under stressful 
situations that cause increased dopamine release, carriers of Val158 alleles may have improved dopaminergic 
transmission and better performance. Some evidence suggests that Val158 alleles are associated with schizophrenia 
(Stein et al., 2006) However, Met158 alleles may be associated with an advantage in memory and attention tasks 
(worrier strategy). Under stressful situations that cause decreased dopamine release, carriers of Met158 alleles may have 
less efficient neurotransmission and worse performance. Some evidence suggests Met158 alleles are associated with 
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